Propanc Biopharma (PPCBD) S-1 13 May 20 IPO registration Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Dec. 31, 2019
Cover [Abstract]
Entity Registrant Name	Propanc Biopharma, Inc.
Entity Central Index Key	0001517681
Document Type	S-1
Amendment Flag	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
CURRENT ASSETS:
Cash	$ 12,022	$ 2,394	$ 19,921
GST tax receivable	2,432	5,439	6,257
Prepaid expenses and other current assets	6,334	83,299	34,712
TOTAL CURRENT ASSETS	20,788	91,132	60,890
Security deposit - related party	2,109	2,103	2,220
Operating lease right-of-use assets, net - related party	35,391
Property and equipment, net	7,137	8,417	8,277
TOTAL ASSETS	65,425	101,652	71,387
CURRENT LIABILITIES:
Accounts payable	826,853	917,337	1,157,369
Accrued expenses and other payables	590,246	723,042	364,404
Convertible notes and related accrued interest, net of discounts and premiums	2,934,340	1,657,377	4,699,299
Operating lease liability - current portion - related party	14,216
Embedded conversion option liabilities	924,744	698,264	371,532
Due to former director - related parties	31,257	31,164	32,898
Loans from directors and officer - related parties	52,022	51,867	54,753
Employee benefit liability	340,637	323,837	143,052
TOTAL CURRENT LIABILITIES	5,714,315	4,402,888	6,823,307
NON-CURRENT LIABILITIES:
Operating lease liability - long-term portion - related party	23,094
TOTAL NON-CURRENT LIABILITIES	23,094
TOTAL LIABILITIES	5,737,409	4,402,888
Commitments and Contingencies (See Note 7)
STOCKHOLDERS' DEFICIT:
Common stock, $0.001 par value; 100,000,000 shares authorized; 2,234,901, 968,042 and 92,859 shares issued; 2,234,852, 967,993 and 92,810 outstanding as of December 31, 2019, June 30, 2019 and 2018, respectively	2,235	968	93
Additional paid-in capital	47,766,162	45,713,322	38,214,213
Accumulated other comprehensive income (loss)	1,001,191	1,066,998	357,929
Accumulated deficit	(54,400,096)	(51,041,047)	(45,282,678)
Treasury stock (49 shares)	(46,477)	(46,477)	(46,477)
TOTAL STOCKHOLDERS' DEFICIT	(5,671,985)	(4,301,236)	(6,751,920)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	65,425	101,652	71,387
Series A Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, 1,500,005 shares authorized, $0.01 par value:	5,000	5,000	5,000
TOTAL STOCKHOLDERS' DEFICIT	5,000	5,000	5,000
Series B Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, 1,500,005 shares authorized, $0.01 par value:
TOTAL STOCKHOLDERS' DEFICIT

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Preferred stock, shares authorized	1,500,005	1,500,005	1,500,005
Preferred stock, par value	$ 0.01	$ 0.01	$ 0.01
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares issued	2,234,901	968,042	92,859
Common stock, shares outstanding	2,234,852	967,993	92,810
Treasury stock, shares	49	49	49
Series A Preferred Stock [Member]
Preferred stock, shares authorized	500,000	500,000	500,000
Preferred stock, par value	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares issued	500,000	500,000	500,000
Preferred stock, shares outstanding	500,000	500,000	500,000
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5	5	5
Preferred stock, par value	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares issued	1	1	1
Preferred stock, shares outstanding	1	1	1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
REVENUE
Revenue
OPERATING EXPENSES
Administration expenses	1,375,971	656,594	2,209,385	1,041,194	2,326,350	2,103,684
Occupancy expenses	7,592	6,449	18,224	14,527	28,062	30,521
Research and development	37	94,777	65,409	150,970	260,335	1,825,728
TOTAL OPERATING EXPENSES	1,383,600	757,820	2,293,018	1,206,691	2,614,747	3,959,933
LOSS FROM OPERATIONS	(1,383,600)	(757,820)	(2,293,018)	(1,206,691)	(2,614,747)	(3,959,933)
OTHER INCOME (EXPENSE)
Interest expense	(446,082)	(494,989)	(1,121,307)	(1,119,527)	(1,314,539)	(2,789,196)
Interest income	3	23	6	27	31	87
Change in fair value of derivative liabilities	(675,024)	39,470	(156,068)	(1,931,646)	(2,472,146)	(7,612)
Gain (loss) on debt settlements, net		(132)		14,289	14,101	(18,585)
Gain (loss) on extinguishment of debt, net	20,176	(20,355)	20,176	1,165,516	1,204,242	251,392
Foreign currency transaction gain (loss)	617,561	(333,205)	82,411	(613,912)	(690,748)	(694,614)
TOTAL OTHER INCOME (EXPENSE)	(483,366)	(809,188)	(1,174,782)	(2,485,253)	(3,259,059)	(3,258,528)
LOSS BEFORE TAXES	(1,866,966)	(1,567,008)	(3,467,800)	(3,691,944)	(5,873,806)	(7,218,461)
TAX (EXPENSE) BENEFIT	(143)	116,970	108,751	116,970	115,437	179,306
NET LOSS	$ (1,867,109)	$ (1,450,038)	$ (3,359,049)	$ (3,574,974)	$ (5,758,369)	$ (7,039,155)
BASIC AND DILUTED NET LOSS PER SHARE	$ (1.25)	$ (41.33)	$ (2.64)	$ (11.57)	$ (10.97)	$ (178.75)
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING	1,492,757	35,081	1,273,029	309,114	524,939	39,381
NET LOSS	$ (1,867,109)	$ (1,450,038)	$ (3,359,049)	$ (3,574,974)	$ (5,758,369)	$ (7,039,155)
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized foreign currency translation gain (loss)	(629,494)	358,279	(65,807)	634,495	709,069	499,678
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	(629,494)	358,279	(65,807)	634,495	709,069	499,678
TOTAL COMPREHENSIVE INCOME (LOSS)	$ (2,496,603)	$ (1,091,759)	$ (3,424,856)	$ (2,940,479)	$ (5,049,300)	$ (6,539,477)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders Deficit (Unaudited) - USD ($)	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
Balance at Jun. 30, 2017	$ 5,000		$ 9	$ 32,984,989	$ (38,243,523)	$ (46,477)	$ (141,749)	$ (5,441,751)
Balance, shares at Jun. 30, 2017	500,000	1	9,156
Issuance of common stock for conversion of convertible debt and accrued interest			$ 82	2,770,106				2,770,188
Issuance of common stock for conversion of convertible debt and accrued interest, shares			81,795
Reclassification of premium upon debt conversion				948,129				948,129
Extinguishment of derivative liability associated with convertible notes				809,642				809,642
Loss on settlement of debt, net				55,201				$ 55,201
Loss on settlement of debt, net, shares			(30)
Issuance of common stock for exercise of warrants, shares
Issuance of common stock for services			$ 2	129,998				$ 130,000
Issuance of common stock for services, shares			1,938
Stock option expense				516,148				516,148
Foreign currency translation gain (loss)							499,678	499,678
Net loss					(7,039,155)			(7,039,155)
Balance at Jun. 30, 2018	$ 5,000		$ 93	38,214,213	(45,282,678)	(46,477)	357,929	(6,751,920)
Balance, shares at Jun. 30, 2018	500,000	1	92,859
Issuance of common stock for conversion of convertible debt and accrued interest			$ 258	1,413,060				1,413,318
Issuance of common stock for conversion of convertible debt and accrued interest, shares			258,285
Reclassification of premium upon debt conversion				600,209				600,209
Extinguishment of derivative liability associated with convertible notes				1,029,039				1,029,039
Exercise of warrants				30				30
Exercise of warrants, shares			24
Foreign currency translation gain (loss)							276,216	276,216
Net loss					(2,124,936)			(2,124,936)
Balance at Sep. 30, 2018	$ 5,000		$ 351	41,256,551	(47,407,614)	(46,477)	634,145	(5,558,044)
Balance, shares at Sep. 30, 2018	500,000	1	351,168
Balance at Jun. 30, 2018	$ 5,000		$ 93	38,214,213	(45,282,678)	(46,477)	357,929	(6,751,920)
Balance, shares at Jun. 30, 2018	500,000	1	92,859
Net loss								(3,574,974)
Balance at Dec. 31, 2018	$ 5,000		$ 547	44,002,122	(48,857,652)	(46,477)	992,424	(3,904,036)
Balance, shares at Dec. 31, 2018	500,000	1	546,555
Balance at Jun. 30, 2018	$ 5,000		$ 93	38,214,213	(45,282,678)	(46,477)	357,929	(6,751,920)
Balance, shares at Jun. 30, 2018	500,000	1	92,859
Issuance of common stock for conversion of convertible debt and accrued interest			$ 704	3,350,079				3,350,783
Issuance of common stock for conversion of convertible debt and accrued interest, shares			704,258
Issuance of common stock under equity purchase agreement			$ 147	1,100,233				1,100,380
Issuance of common stock under equity purchase agreement, shares			147,200
Reclassification of premium upon debt conversion				1,824,317				1,824,317
Extinguishment of derivative liability associated with convertible notes				1,029,039				1,029,039
Issuance of common stock for exercise of warrants				30				$ 30
Issuance of common stock for exercise of warrants, shares			24
Issuance of common stock for offering costs			$ 8	298,914				$ 298,922
Issuance of common stock for offering costs, shares			7,701
Issuance of common stock for services			$ 16	168,984				169,000
Issuance of common stock for services, shares			16,000
Stock based compensation in connection with stock option grants and restricted stock unit grants				41,436				41,436
Amortization of offering costs				(313,923)				(313,923)
Foreign currency translation gain (loss)							709,069	709,069
Net loss					(5,758,369)			(5,758,369)
Balance at Jun. 30, 2019	$ 5,000		$ 968	45,713,322	(51,041,047)	(46,477)	1,066,998	(4,301,236)
Balance, shares at Jun. 30, 2019	500,000	1	968,042
Balance at Sep. 30, 2018	$ 5,000		$ 351	41,256,551	(47,407,614)	(46,477)	634,145	(5,558,044)
Balance, shares at Sep. 30, 2018	500,000	1	351,168
Issuance of common stock for conversion of convertible debt and accrued interest			$ 128	1,094,972				1,095,100
Issuance of common stock for conversion of convertible debt and accrued interest, shares			127,685
Reclassification of premium upon debt conversion				708,184				708,184
Issuance of common stock under put premium			$ 54	574,506				574,560
Issuance of common stock under put premium, shares			54,000
Issuance of common stock for offering costs			$ 8	298,915				298,923
Issuance of common stock for offering costs, shares			7,702
Issuance of common stock for services			$ 6	68,994				69,000
Issuance of common stock for services, shares			6,000
Foreign currency translation gain (loss)							358,279	358,279
Net loss					(1,450,038)			(1,450,038)
Balance at Dec. 31, 2018	$ 5,000		$ 547	44,002,122	(48,857,652)	(46,477)	992,424	(3,904,036)
Balance, shares at Dec. 31, 2018	500,000	1	546,555
Balance at Jun. 30, 2019	$ 5,000		$ 968	45,713,322	(51,041,047)	(46,477)	1,066,998	(4,301,236)
Balance, shares at Jun. 30, 2019	500,000	1	968,042
Issuance of common stock for conversion of convertible debt and accrued interest			$ 182	123,531				123,713
Issuance of common stock for conversion of convertible debt and accrued interest, shares			181,939
Reclassification of premium upon debt conversion				73,235				73,235
Relative fair value of warrants issued with convertible debt				375,905				375,905
Issuance of common stock for services			$ 20	39,780				39,800
Issuance of common stock for services, shares			20,000
Stock based compensation in connection with stock option grants and restricted stock unit grants				75,104				75,104
Foreign currency translation gain (loss)							563,687	563,687
Net loss					(1,491,940)			(1,491,940)
Balance at Sep. 30, 2019	$ 5,000		$ 1,170	46,400,877	(52,532,987)	(46,477)	1,630,685	(4,541,732)
Balance, shares at Sep. 30, 2019	500,000	1	1,169,981
Balance at Jun. 30, 2019	$ 5,000		$ 968	45,713,322	(51,041,047)	(46,477)	1,066,998	(4,301,236)
Balance, shares at Jun. 30, 2019	500,000	1	968,042
Net loss								(3,359,049)
Balance at Dec. 31, 2019	$ 5,000		$ 2,235	47,766,162	(54,400,096)	(46,477)	1,001,191	(5,671,985)
Balance, shares at Dec. 31, 2019	500,000	1	2,234,901
Balance at Sep. 30, 2019	$ 5,000		$ 1,170	46,400,877	(52,532,987)	(46,477)	1,630,685	(4,541,732)
Balance, shares at Sep. 30, 2019	500,000	1	1,169,981
Issuance of common stock for conversion of convertible debt and accrued interest			$ 1,065	218,401				219,466
Issuance of common stock for conversion of convertible debt and accrued interest, shares			1,064,920
Reclassification of premium upon debt conversion				86,970				86,970
Stock based compensation in connection with stock option grants and restricted stock unit grants				75,104				75,104
Stock based compensation in connection with fair value of warrants issued for services				984,810				984,810
Foreign currency translation gain (loss)							(629,494)	(629,494)
Net loss					(1,867,109)			(1,867,109)
Balance at Dec. 31, 2019	$ 5,000		$ 2,235	$ 47,766,162	$ (54,400,096)	$ (46,477)	$ 1,001,191	$ (5,671,985)
Balance, shares at Dec. 31, 2019	500,000	1	2,234,901

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,359,049)	$ (3,574,974)	$ (5,758,369)	$ (7,039,155)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Issuance and amortization of common stock and warrants for services	1,024,610	69,000	245,145	130,000
Issuance of convertible promissory notes for services				310,000
(Gain) loss on settlements, net		(14,289)	(14,101)	18,585
Foreign currency transaction loss (gain)	(82,411)	613,912	690,748	694,614
Depreciation expense	1,270	1,068	2,306	2,225
Amortization of debt discounts	307,085	303,813	389,673	853,459
Change in fair value of derivative liabilities	156,068	1,931,646	2,472,146	7,612
Gain on extinguishment of debt	(20,176)	(1,165,516)	(1,204,242)	(251,392)
Stock option expense				516,148
Reduction of put premium due to payment of debt				(80,769)
Stock option and restricted stock expense	150,208
Accretion of put premium	698,307	699,230	706,154	1,784,231
Changes in Assets and Liabilities:
GST receivable	3,024	(2,757)	489	1,636
Prepaid expenses and other assets	76,990	(53,104)	(83,296)	(29,842)
Accounts payable	(93,233)	(26,388)	(164,926)	732,794
Deferred rent	1,921
Employee benefit liability	15,829	177,232	188,326	28,052
Accrued expenses	(134,768)	(51,533)	377,846	(70,537)
Accrued interest	111,448	107,643	184,198	214,694
NET CASH USED IN OPERATING ACTIVITIES	(1,142,877)	(1,056,786)	(2,060,037)	(2,177,645)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment			(2,874)
NET CASH USED IN INVESTING ACTIVITIES			(2,874)
CASH FLOWS FROM FINANCING ACTIVITIES:
Loan repayments				(2,326)
Proceeds from convertible promissory notes, net of original issue discounts and issue costs	1,130,000	1,054,089	1,369,000	2,890,080
Repayments of convertible promissory notes		(219,000)	(272,000)	(490,181)
Proceeds from the issuance of common stock		405,773	1,100,380
Fees associated with offering costs		(15,000)	(15,000)
Debt issuance cost			(63,850)
Proceeds from the exercise of warrants		30	30
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,130,000	1,225,892	2,118,560	2,396,488
Effect of exchange rate changes on cash	22,505	(62,827)	(73,175)	(267,965)
NET INCREASE IN CASH	9,628	104,617	(17,527)	(49,122)
CASH AT BEGINNING OF PERIOD	2,394	19,921	19,921	69,043
CASH AT END OF PERIOD	12,022	124,538	2,394	19,921
Cash paid during the year:
Interest	4,467	8,585	100,719	16,899
Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Reduction of put premium related to conversions of convertible notes	160,205	1,308,393	1,824,317	948,129
Conversion of convertible notes and accrued interest to common stock	318,768	2,508,421	3,350,783	2,770,187
Proceeds receivable from the issuance of common stock		168,787
Discounts related to warrants issued with convertible notes	375,904
Deferred financing costs associated with equity purchase agreement		298,923	318,059
Discounts related to derivative liability	115,000	50,000	180,000	543,744
Settlement of accounts payable for shares of common stock
Issue and amortization of common stock and warrants for services	1,024,610	69,000
Operating lease right-of-use asset and operating lease liability recorded on adoption of ASC 842	$ 46,696

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting and Reporting Policies	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Accounting Policies [Abstract]
Nature of Operations and Summary of Significant Accounting and Reporting Policies	NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated in Melbourne, Victoria Australia on October 15, 2007 as Propanc PTY LTD, and continues to be based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. On November 23, 2010, the Company was incorporated in the state of Delaware as Propanc Health Group Corporation. In January 2011, to reorganize the Company, we acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of December 31, 2019, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to better reflect the Company’s stage of operations and development. The Company has filed multiple patent applications relating to its lead product, PRP. The first application was filed in October 2010 in each of the countries listed in the table below. This application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Hong Kong, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Mexico, Republic of Korea and India. In Brazil and Canada, the patent application remains under examination. In 2016 and 2017 we filed other patent applications, as indicated below. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, which allows the applicants to seek protection for an invention in over 150 countries. Once national or regional applications are filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national or regional phase. One PCT application, filed in November 2016, entered the national phase in July 2018 in each of the countries listed in the table below. A second application filed in January 2017 entered the national phase commencing July 2018. A third application entered the national phase in October 2018. No. Title Country Case Status Date Filed 1. A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic reduction agent. USA, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Hong Kong, Japan, Indonesia, Israel, New Zealand, Malaysia, Singapore, Malaysia South Africa, Mexico, Republic of Korea and India Granted Oct-22-2010 Brazil and Canada Under Examination Divisional applications filed and under examination in Mexico and China USA Divisional application granted 2. Proenzyme composition Australia, Canada, China, Europe, Hong Kong, India, Indonesia, Israel, Japan, Malaysia, New Zealand, Singapore, South Africa and USA Application filed and pending Nov-11-2016 3. Cancer Treatment Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Malaysia, New Zealand, Singapore and USA Application filed and pending Jan-27-2017 4. Composition of proenzymes for cancer treatment Australia, China, Europe, Japan and USA Application filed and pending Apr-12-2017 The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development. Decrease in Authorized Common Stock and Reverse Split On June 24, 2019, the Company effected a one-for-five hundred (1:500) reverse stock split whereby the Company (i) decreased the number of authorized shares of common stock, $0.001 par value per share, to 100,000,000 and (ii) decreased by a ratio of one-for-five hundred (1:500) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts have been retroactively adjusted as of the earliest period presented in the consolidated financial statements to reflect the reverse stock split. On February 4, 2020 the Directors resolved to increase the Common Stock of the Company from 100,000,000 authorized shares to 1,000,000,000 authorized shares and believes that such number of authorized shares of Common Stock will be in the best interests of the Corporation and its stockholders because the Board believes that the availability of more shares of Common Stock for issuance will allow the Corporation greater flexibility in pursuing financing from investors, meeting business needs as they arise, taking advantage of favorable opportunities and responding to a changing corporate environment. The Company filed the necessary documents with the U.S. Securities and Exchange Commission on February 6, 2020 and at the date of this filing the increase in authorized shares to 1,000,000,000 has not yet been effected. Basis of Presentation The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three and six months ended December 31, 2019 and 2018 and cash flows for the six months ended December 31, 2019 and 2018 and our financial position at December 31, 2019 have been made. The Company’s results of operations for the three and six months ended December 31, 2019 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2020. Reference is frequently made herein to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”). This is the source of authoritative US GAAP recognized by the FASB to be applied to non-governmental entities. Each ASC reference in this Quarterly Report is presented with a three-digit number, which represents its Topic. As necessary for explanation and as applicable, an ASC topic may be followed with a two-digit subtopic, a two-digit section or a two-or-three-digit paragraph. Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2019. The June 30, 2019 balance sheet is derived from those statements. Principles of Consolidation The condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive subsidiary at December 31, 2019. Use of Estimates The preparation of financial statements in conformity with the accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying unaudited condensed consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of beneficial conversion features on convertible debt, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar ($) and/or (USD) as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. For the six months ended December 31, 2019, the Company recognized an exchange loss of approximately $575,700 on intercompany loans made by the parent to the subsidiary which have not been repaid as at December 31, 2019. As of December 31, 2019 and June 30, 2019, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: December 31, 2019 June 30, 2019 Exchange rate on balance sheet dates USD : AUD exchange rate 0.7030 0.7153 Average exchange rate for the period USD : AUD exchange rate 0.6847 0.7009 The exchange rates used to translate amounts in AUD into USD for the period ended December 31, 2018 are: 0.7046 as of the balance sheet date and 0.7248 average exchange rate for that period. Change in Accumulated Other Comprehensive Income (Loss) by component during the six months ended December 31, 2019 was as follows: Foreign Beginning balance, June 30, 2019 $ 1,066,998 Foreign currency translation loss (65,807 ) Ending balance, December 31, 2019 $ 1,001,191 Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 10 - Derivative Financial Instruments and Fair Value Measurements. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no cash equivalents as of December 31, 2019 or June 30, 2019. Patents Patents are stated at cost and classified as intangible assets and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any product costs as long as we are in the startup stage. Accordingly, as the Company’s products were and are not currently approved for market, all historical patent costs incurred through December 31, 2019 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency. Impairment of Long-Lived Assets In accordance with ASC 360-10, “ Long-lived assets,” Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of December 31, 2019 and June 30, 2019, the Company was owed $2,432 and $5,439, respectively, from the Australian Taxation Office. These amounts were fully collected subsequent to the balance sheet reporting dates. Derivative Instruments ASC Topic 815, Derivatives and Hedging Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480, “ Distinguishing Liabilities from Equity Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act (“TCJA”) was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for fiscal years beginning after December 31, 2017. On December 22, 2017, the SEC Staff Accounting Bulletin No. 118 (“SAB 118”) was issued, which allows a company to recognize provisional tax amounts when it does not have the necessary information available, prepared or analyzed, including computations, in reasonable detail to complete its accounting for the change in tax law. SAB 118 provides for a measurement of up to one year from the date of enactment. Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as an income tax benefit, in operations, upon receipt. During each of the six months ended December 31, 2019 and 2018, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $108,751 and $116,970, respectively, which is reflected as a tax benefit in the accompanying condensed consolidated statements of operations and comprehensive income (loss). Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption. There was no cumulative effect of adoption on July 1, 2019. Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. As of December 31, 2019, there were 1,975,059 warrants outstanding, 59,644 stock options and 15 convertible notes payable, which notes are convertible into approximately 10,200,000 shares of the Company’s common stock (based on the closing price on the last trading day of the quarter ended December 31, 2019). Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance. Such securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive. Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases On July 1, 2019, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Operating lease ROU assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the condensed consolidated statements of operations. Recent Accounting Pronouncements We have reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management.	NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated in Melbourne, Victoria Australia on October 15, 2007 as Propanc PTY LTD, and continues to be based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. On November 23, 2010, the Company was incorporated in the state of Delaware as Propanc Health Group Corporation. In January 2011, to reorganize the Company, we acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of June 30, 2019, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to better reflect the Company’s stage of operations and development. The Company has filed multiple patent applications relating to its lead product, PRP. The first application was filed in October 2010 in each of the countries listed in the table below. This application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Mexico, Republic of Korea and India. In Brazil and Canada, the patent application remains under examination. In 2016 and 2017 we filed other patent applications, as indicated below. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, which allows the applicants to seek protection for an invention in over 150 countries. Once national or regional applications are filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national or regional phase. One PCT application, filed in November 2016, entered the national phase in July 2018 in each of the countries listed in the table below. A second application filed in January 2017 entered the national phase commencing July 2018. A third application entered the national phase in October 2018. No. Title Country Case Status Date Filed 1. A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic reduction agent. USA, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Malaysia, Singapore, Malaysia, South Africa, Mexico, Republic of Korea and India Granted Oct-22-2010 Brazil and Canada Under Examination Divisional applications filed and under examination in Mexico and China USA Divisional application granted 2. Proenzyme composition Australia, Canada, China, Europe, Hong Kong, India, Indonesia, Israel, Japan, Malaysia, New Zealand, Singapore, South Africa and USA Application filed and pending Nov-11-2016 3. Cancer Treatment Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Malaysia, New Zealand, Singapore and USA Application filed and pending Jan-27-2017 4. Composition of proenzymes for cancer treatment Australia, China, Europe, Japan and USA Application filed and pending Apr-12-2017 The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development. Increase in Authorized Common Stock and Reverse Stock Split On January 23, 2018, Company filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock from 100,000,000 to 400,000,000. On September 21, 2018, the Company filed a Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock from 400,000,000 to 4,000,000,000, which was approved by the Company’s board of directors and holders of a majority of the Company’s voting stock on August 28, 2018. On June 24, 2019, the Company effected a one-for-five hundred (1:500) reverse stock split whereby the Company (i) decreased the number of authorized shares of common stock, $0.001 par value per share, to 100,000,000 and (ii) decreased by a ratio of one-for-five hundred (1:500) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts have been restated as of the earliest period, presented in the consolidated financial statements to reflect the reverse stock split. Principles of Consolidation The consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive subsidiary at June 30, 2019. Use of Estimates The preparation of financial statements in conformity with the accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of derivatives, valuation of beneficial conversion features on convertible debt, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar ($) and/or (USD) as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. As of June 30, 2019 and 2018, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: June 30, 2019 June 30, 2018 Exchange rate on balance sheet dates USD : AUD exchange rate 0.7153 0.7399 Average exchange rate for the period USD : AUD exchange rate 0.7009 0.7753 Change in Accumulated Other Comprehensive Income (Loss) by component during the years ended June 30, 2019 and 2018 was as follows: Foreign Beginning balance, June 30, 2017 $ (141,749 ) Foreign currency translation gain 499,678 Balance, June 30, 2018 357,929 Foreign currency translation gain 709,069 Ending balance, June 30, 2019 $ 1,066,998 Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 12 - Derivative Financial Instruments and Fair Value Measurements. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no cash equivalents as of June 30, 2019 or June 30, 2018. Receivables As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of uncollectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical write-off experience. The Company’s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: Machinery and equipment - 5 years Furniture - 7 years Patents Patents are stated at cost and reclassified to intangible assets and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any product costs as long as we are in the startup stage. Accordingly, as the Company’s products were and are not currently approved for market, all patent costs incurred from 2013 through June 30, 2019 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency. Impairment of Long-Lived Assets In accordance with ASC 360-10, “ Long-lived assets,” Employee Benefit/Liability Liabilities arising in respect of wages and salaries, annual leave, accumulated sick leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured at their nominal amounts based on remuneration rates which are expected to be paid when the liability is settled. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months and therefore, recorded at nominal value. Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of June 30, 2019 and 2018, the Company was owed $5,439 and $6,257, respectively, from the Australian Taxation Office. These amounts were fully collected subsequent to the balance sheet reporting dates. Derivative Instruments ASC Topic 815, Derivatives and Hedging Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480, “ Distinguishing Liabilities from Equity Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act (“TCJA”) was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for fiscal years beginning after December 31, 2017. On December 22, 2017, the SEC Staff Accounting Bulletin No. 118 (“SAB 118”) was issued, which allows a company to recognize provisional tax amounts when it does not have the necessary information available, prepared or analyzed, including computations, in reasonable detail to complete its accounting for the change in tax law. SAB 118 provides for a measurement of up to one year from the date of enactment. Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as an income tax benefit, in operations, upon receipt. During each of the fiscal years ended June 30, 2019 and 2018, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $115,437 and $179,306, respectively, which is reflected as a tax benefit in the accompanying consolidated statements of operations and comprehensive income (loss). Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation Share Based Payment The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 505-50 “ Equity-Based Payments to Non-Employees Revenue Recognition The Company adopted and implemented on July 1, 2018, ASC 606 – Revenue from Contracts with Customers (“ASC 606”). ASC 606 did not have a material impact on the consolidated financial statements. Upon implementation of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun. Legal Expenses All legal costs for litigation are charged to expense as incurred. Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. As of June 30, 2019 and 2018, there were 59 and 291 warrants outstanding, 59,644 and 1,144 stock options and 10 and 20 convertible notes payable, which notes are convertible into approximately 1,810,347 and 207,397 shares of the Company’s common stock respectively. Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance. Such securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive. Recent Accounting Pronouncements Certain FASB Accounting Standard Updates (“ASU”) that are not effective until after June 30, 2019 are not expected to have a significant effect on the Company’s consolidated financial position or results of operations. Future pronouncements are as follows: ASU 2016-02 ASU 2017-11 - ASU 2018-07

Going Concern

Going Concern	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 – GOING CONCERN The accompanying condensed consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the six months ended December 31, 2019, the Company had no revenues, had a net loss of $3,359,049 and had net cash used in operations of $1,142,877. Additionally, as of December 31, 2019, the Company had a working capital deficit, stockholders’ deficit and accumulated deficit of $5,693,527, $5,671,985 and $54,400,096, respectively. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the date of this Quarterly Report. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications, obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company’s cost structure and business plan. The Company’s ability to continue as a going concern is also dependent on its ability to further develop and execute on its business plan. However, there can be no assurances that any or all of these endeavors will be successful.	NOTE 2 – GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the fiscal year ended June 30, 2019, the Company had no revenues, had a net loss of $5,758,369 and had net cash used in operations of $2,060,037. Additionally, as of June 30, 2019, the Company had a working capital deficit, stockholders’ deficit and accumulated deficit of $4,311,756 $4,301,236 and $51,041,047, respectively. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the date of this filing. The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications, obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company’s cost structure and business plan. The Company’s ability to continue as a going concern is also dependent on its ability to further develop and execute on its business plan. However, there can be no assurances that any or all of these endeavors will be successful.

Property and Equipment

Property and Equipment	12 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 3 – PROPERTY AND EQUIPMENT Property and equipment consist of the following as of June 30, 2019 2018 Office equipment at cost $ 26,749 $ 25,244 Less: Accumulated depreciation (18,332 ) (16,967 ) Total property, plant, and equipment $ 8,417 $ 8,277 Depreciation expense for the years ended June 30, 2019 and 2018 were $2,306 and $2,225, respectively

Due to Former Director - Relate

Due to Former Director - Related Party	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Related Party Transactions [Abstract]
Due to Former Director - Related Party	NOTE 3 – DUE TO FORMER DIRECTOR - RELATED PARTY Due to director - related party represents unsecured advances made primarily by a former director for operating expenses on behalf of the Company such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amount owed the former director at December 31, 2019 and June 30, 2019 is $31,257 and $31,164, respectively. The Company plans to repay the notes as its cash resources allow.	NOTE 4 – DUE TO FORMER DIRECTOR - RELATED PARTY Due to director - related party represents unsecured advances made primarily by a former director for operating expenses on behalf of the Company such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amount owed the former director at June 30, 2019 and 2018 is $31,164 and $32,898, respectively. The Company plans to repay the notes as its cash resources allow.

Loans and Notes Payable

Loans and Notes Payable	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Debt Disclosure [Abstract]
Loans and Notes Payable	NOTE 4 – LOANS AND NOTES PAYABLE Loans from Directors and Officer - Related Parties Loans from the Company’s directors and officer at December 31, 2019 and June 30, 2019 were $52,022 and $51,867, respectively. The loans bear no interest and are all payable on demand. The Company did not repay any amount on these loans during the six months ended December 31, 2019.	NOTE 5 – LOANS AND NOTES PAYABLE Loans from Directors and Officer - Related Parties Loans from the Company’s directors and officer at June 30, 2019 and 2018 were $51,867 and $54,753, respectively. The loans bear no interest and are all payable on demand. The Company did not repay any amount on these loans during the fiscal year ended June 30, 2019.

Convertible Notes

Convertible Notes	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Debt Disclosure [Abstract]
Convertible Notes	NOTE 5 – CONVERTIBLE NOTES The Company’s convertible notes outstanding at December 31, 2019 were as follows: Convertible notes and debenture $ 2,016,365 Unamortized discounts (415,712 ) Accrued interest 182,581 Premiums 1,151,106 Convertible notes, net $ 2,934,340 Eagle Equities Financing Agreements December 29, 2017 Securities Purchase Agreement The Company entered into an executory contract on December 29, 2017, whereby the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “December 2017 Eagle Note”) from the Company in the aggregate principal amount of $532,435, with principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities at any time. The transactions closed on January 2, 2018. The December 2017 Eagle Note contains an original issue discount of $25,354 such that the purchase price was $507,081. The maturity date of the December 2017 Eagle Note was December 29, 2018. The Company is currently in discussions with Eagle Equities to extend the maturity date. The December 2017 Eagle Note bears interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of the Company’s common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time. The Company has recorded $9,630 of accrued interest for the December 2017 Eagle Note and total principal outstanding as of December 31, 2019 under the December 2017 Eagle Note was $13,865 following conversion of $158,100 of principal and $22,478 of accrued interest during the six months to December 31, 2019. Eagle Equities has the option to convert all or any amount of the principal face amount of the December 2017 Eagle Note, at any time, for shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price of the Company’s common stock as reported on the OTCQB for the ten prior trading days, including the day upon which the Company receives a notice of conversion from Eagle Equities. The note is treated as stock settled debt under ASC 480 and accordingly the Company recorded a $354,956 put premium of which of which $240,313 was released to additional paid in capital following conversion of $360,470 of principal during the fiscal year to June 30, 2019, and a further $105,400 was released to additional paid in capital following conversion of $158,100 of principal during the six months to December 31, 2019. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. July 13, 2018 Securities Purchase Agreement Effective July 13, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “July 2018 Note”) from the Company in the aggregate principal amount of $75,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six month anniversary of the July 2018 Eagle Note. The transaction closed on July 16, 2018 and on July 19, 2018 the Company received proceeds of $71,250 as $3,750 was paid directly to legal fees. The maturity date of the July 2018 Eagle Note was July 13, 2019. The Company is currently in discussions with Eagle Equities to extend the maturity date. The July 2018 Eagle Note bears interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of the Company’s common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time after the six-month anniversary of the Note. Additionally, Eagle Equities has the option to convert all or any amount of the principal face amount of the July 2018 Eagle Note, at any time, for shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price of the Company’s common stock for the ten prior trading days, including the day upon which the Company receives a notice of conversion, subject to adjustment in certain events. Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The July 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded a $50,000 put premium. The Company has recorded $14,860 of accrued interest and the total principal outstanding under the July 2018 Eagle Note was $75,000 as of December 31, 2019. The Company had the right to prepay the July 2018 Eagle Note with certain penalties until January 9, 2019. No prepayment was made as of such date. As a result, the July 2018 Eagle Note is now convertible. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. August 29, 2018 Securities Purchase Agreement Effective August 29, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “August 2018 Eagle Note”) from the Company in the aggregate principal amount of $105,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six-month anniversary of the August 2018 Eagle Note. The transactions contemplated by the agreement closed on August 30, 2018. The maturity date of the August 29, 2018 Eagle Note was August 2019. The Company is currently in discussions with Eagle Equities to extend the maturity date. The August 2018 Eagle Note bears interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of the Company’s common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time after the six-month anniversary of the August 2018 Eagle Note. Additionally, Eagle Equities has the option to convert all or any amount of the principal face amount of the August 2018 Eagle Note, at any time, into shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price (the “Closing Bid Price”) of the Company’s common stock as reported on the OTC Markets quotation system for the ten prior trading days, including the day upon which the Company receives a notice of conversion from Eagle Equities (the “Conversion Price”). However, in the event that the Company’s common stock is restricted by the DTC for any reason, the Conversion Price shall be lowered to 50% of the lowest Closing Bid Price for the duration of such restriction. If the Company fails to maintain a reserve of shares of its common stock at least four times the number of shares issuable upon conversion of the August 2018 Eagle Note for at least 60 days after the issuance of the August 28, 2018 Eagle Note, the conversion discount shall be increased by 10%. Notwithstanding the foregoing, Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The August 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded a $70,000 put premium. The Company has recorded $19,746 of accrued interest and the total principal outstanding under the August 2018 Eagle Note was $105,000 as of December 31, 2019. The Company had the right to prepay the August 2018 Eagle Note with certain penalties until February 25, 2019. No prepayment was made as of such date. As a result, the August 2018 Eagle Note is now convertible. Upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24% per annum or at the highest rate permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. October 2, 2018 Securities Purchase Agreement Effective October 2, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “October 2018 Eagle Note”) from the Company in the aggregate principal amount of $210,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six-month anniversary of the October 2018 Eagle Note. The transactions contemplated by the purchase agreement closed on October 3, 2018. Pursuant to the terms of the purchase agreement, Eagle Equities deducted $10,000 from the principal payment due under the October 2018 Eagle Note, at the time of closing, to be applied to its legal expenses. The maturity date of the October 2018 Eagle Note was October 2, 2019. The October 2018 Eagle Note shall bear interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time after the six-month anniversary of the October 2018 Eagle Note. Additionally, Eagle Equities has the option to convert all or any amount of the principal amount of the October 2018 Eagle Note, at any time, for shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price of the Company’s common stock for the ten prior trading days, including the day upon which the Company receives a notice of conversion, subject to adjustment in certain events. Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The October 2, 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded a $140,000 put premium. The Company has recorded $29,227 of accrued interest and the total principal outstanding under the October 2018 Eagle Note was $210,000 as of December 31, 2019. The Company had the right to prepay the October 2018 Eagle Note with certain penalties until December 31, 2019. No prepayment has been made as of such date. As a result, the October 2018 Eagle Note is now convertible. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. November 30, 2018 Securities Purchase Agreement Effective November 30, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “November 2018 Eagle Note”) from the Company in the aggregate principal amount of $105,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six-month anniversary of the November 2018 Eagle Note. The transactions contemplated by the purchase agreement closed on December 3, 2018. Pursuant to the terms of the purchase agreement, Eagle Equities deducted $5,000 from the principal payment due under the November 2018 Eagle Note, at the time of closing, to be applied to its legal expenses. The maturity date of the November 2018 Eagle Note was November 30, 2019. The November 2018 Eagle Note shall bear interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time after the six-month anniversary of the November 2018 Eagle Note. Additionally, Eagle Equities has the option to convert all or any amount of the principal amount of the November 2018 Eagle Note, at any time, for shares of the Company’s common stock at a price equal to 61% of the lowest closing bid price (the “Closing Bid Price”) of the Company’s common stock as reported on the OTC Markets Group, Inc. quotation system for the ten prior trading days, including the day upon which the Company receives a notice of conversion from Eagle Equities (the “Conversion Price”). However, in the event that the Company’s common stock is restricted by the Depository Trust Company for any reason, the Conversion Price shall be lowered to 51% of the lowest Closing Bid Price for the duration of such restriction. If the Company fails to maintain a reserve of shares of its common stock at least two and a half times the number of shares issuable upon conversion of the November 2018 Eagle Note for at least 60 days after the issuance of the November 2018 Eagle Note, the conversion discount shall be increased by 10%. Notwithstanding the foregoing, Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The November 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded a $67,131 put premium. The Company has recorded $10,540 of accrued interest and the total principal outstanding under the November 2018 Eagle Note was $105,000 as of December 31, 2019. The November 2018 Eagle Note may be prepaid with certain penalties by the Company until May 29, 2019. No prepayment has been made as of December 31, 2019. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. December 24, 2018 Securities Purchase Agreement Effective December 24, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “December 2018 Eagle Note”) from the Company in the aggregate principal amount of $126,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six-month anniversary of the December 2018 Eagle Note. The transactions contemplated by the purchase agreement closed on December 24, 2018. Pursuant to the terms of the purchase agreement, Eagle Equities deducted $6,000 from the principal payment due under the December 2018 Eagle Note, at the time of closing, to be applied to its legal expenses. The Company used the net proceeds from the December 2018 Eagle Note to repay an outstanding convertible promissory note before such note became convertible. The maturity date of the December 2018 Eagle Note was December 24, 2019. The December 2018 Eagle Note shall bear interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time after the six-month anniversary of the December 2018 Eagle Note. Additionally, Eagle Equities has the option to convert all or any amount of the principal amount of the December 2018 Eagle Note, at any time, for shares of the Company’s common stock at a price equal to 61% of the lowest closing bid price (the “Closing Bid Price”) of the Company’s common stock as reported on the OTC Markets Group, Inc. quotation system for the ten prior trading days, including the day upon which the Company receives a notice of conversion from Eagle Equities (the “Conversion Price”). However, in the event that the Company’s common stock is restricted by the Depository Trust Company for any reason, the Conversion Price shall be lowered to 51% of the lowest Closing Bid Price for the duration of such restriction. If the Company fails to maintain a reserve of shares of its common stock at least two and a half times the number of shares issuable upon conversion of the December 2018 Eagle Note for at least 60 days after the issuance of the December 2018 Eagle Note, the conversion discount shall be increased by 10%. Notwithstanding the foregoing, Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The December 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded an $80,557 put premium. The Company has recorded $10,688 of accrued interest and the total principal outstanding under the November 2018 Eagle Note was $126,000 as of December 31, 2019. The December 2018 Eagle Note may be prepaid with certain penalties until June 22, 2019. No prepayment has been made as of December 31, 2019. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. The total principal amount outstanding under the above Eagle Equities financing agreements, specifically the December 29, 2017, the July 13, 2018, the August 29, 2018, the October 2, 2018, the November 30, 2018 and the December 24, 2018 agreements was $634,865 as of December 31, 2019 and accrued interest totaled $94,691. GS Capital Financing Agreements October 2, 2018 Securities Purchase Agreement Effective October 2, 2018, the Company entered into a securities purchase agreement with GS Capital, pursuant to which GS Capital purchased two 8% unsecured convertible redeemable notes (the “October 2, 2018 GS Notes”) from the Company in the aggregate principal amount of $212,000, such principal and the interest thereon convertible into shares of the Company’s common stock. The purchase price of $106,000 of the first note (the “October 2018 GS Note”) was paid in cash by GS Capital on October 3, 2018. After payment of certain legal fees and expenses, net proceeds to the Company from the October 2018 GS Note totaled $100,700. The purchase price of $106,000 of the second note (the “October 2, 2018 GS Back End Note”) was initially paid for by GS Capital issuing to the Company an offsetting $106,000 collateralized secured note (the “October 2, 2018 GS Secured Note”). The terms of the October 2018 GS Back End Note require cash funding prior to any conversion thereunder, and such cash funding shall occur on or before June 2, 2019. Both the October 2, 2018 GS Note and the October 2, 2018 GS Back End Note, which was funded on February 27, 2019, mature on October 2, 2019, upon which any outstanding principal and interest thereon is due and payable. The amounts cash funded plus accrued interest under both the October 2018 GS Note and the October 2018 GS Back End Note are convertibles into shares of the Company’s common stock, at any time after April 2, 2019, at a conversion price for each share of common stock equal to 61% of the lowest closing bid price of the Company’s common stock for the ten prior trading days including the day upon which a notice of conversion is received by the Company from GS Capital, subject to adjustment in certain events. GS Capital shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by GS Capital and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The October 2018 GS Note and the October 2018 GS Back End Note are treated as stock settled debt under ASC 480 and accordingly, the Company recorded a total $67,771 put premium for each note of which $44,690 was released in respect of the October 2018 GS Note in the fiscal year ended June 30, 2019, and a further $22,901 was released in the six months ended December 31, 2019 following full conversion of the October 2018 GS Note resulting from conversion of the remaining principal balance of $35,820 and $2,434 in accrued interest. $31,903 of the put premium was released in respect of the October 2018 GS Back-End Note during the six months to December 31, 2019 following conversion $49,900 of the principal balance. The total principal amount outstanding under the October 2018 GS Note, was $35,820 and accrued interest thereunder totaled $7,813 as of June 30, 2019 and was fully converted as of December 31, 2019 (see Note 6 – Stockholders’ Deficit). The maturity date of the October 2, 2018 GS Back-Note was October 2019. The total principal balance under the October 2018 GS Back-End Note, was $106,000 and accrued interest thereunder totaled $5,715 as of June 30, 2019 and the principal balance was $56,100 and accrued interest totaled $11,814 as of December 31, 2019 (see Note 6 – Stockholders’ Deficit). The October 2, 2018 GS Notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. Consulting Agreement On August 10, 2017, the Company entered into a consulting agreement, retroactive to May 16, 2017, with a certain consultant, pursuant to which the consultant agreed to provide certain consulting and business advisory services in exchange for a $310,000 junior subordinated convertible note. The maturity date of the August 10, 2017 Convertible Note is August 2019.The note accrues interest at a rate of 10% per annum and is convertible into common stock at the lesser of $750 or 65% of the three lowest trades in the ten trading days prior to the conversion. The note was fully earned upon signing the agreement and matures on August 10, 2019. The Company accrued $155,000 related to this expense at June 30, 2017 and recorded the remaining $155,000 related to this expense in fiscal year 2018. Upon an event of default, principal and accrued interest will become immediately due and payable under the note. Additionally, upon an event of default, at the election of the holder, the note would accrue interest at a default interest rate of 18% per annum or the highest rate of interest permitted by law. The consulting agreement had a three-month term and expired on August 16, 2017. An aggregate total of $578,212 of this note was bifurcated with the embedded conversion option recorded as a derivative liability at fair value. During the year ended June 30, 2018, the consultant converted $140,000 of principal and $10,764 of interest. During the year ended June 30, 2019, the consultant converted an additional $161,000 of principal and $19,418 of interest, such that the remaining principal outstanding and accrued interest under this note as of December 31, 2019 was $9,000 and $26,653, respectively. Redstart Holdings Finance Agreements May 23, 2019 Securities Purchase Agreement Effective May 23, 2019, the Company issued a convertible promissory note (the “May 23 Redstart Holdings Note”) to Redstart Holdings Corp (“Redstart Holdings”) in the aggregate principal amount of $133,000, with principal and the interest thereon convertible into shares of the Company’s common stock at the option of Redstart Holdings any time after 180 days of issuance. At the time of closing on May 31, 2019, Redstart Holdings deducted $3,000 from the principal payment due under the May 2019 Redstart Holdings Note to be applied to its legal expenses, such that the Company received aggregate net proceeds of $130,000 at closing. The maturity date of the May 2019 Redstart Holdings Note is May 23, 2020 and bears interest at a rate of 8% per annum. Additionally, Redstart Holdings has the option to convert all or any amount of the principal face amount of the May 2019 Redstart Note, starting on November 19, 2019 at a conversion price subject to certain Market Price (as defined below) adjustment. If the Market Price is greater than or equal to $50.00, the conversion price shall be the greater of 65% of the Market Price (“Variable Conversion Price”) and $32.50. In the event Market Price is less than $50.00, the conversion price shall be the Variable Conversion Price. As defined in the May 2019 Redstart Holdings Note, the “Market Price” shall be the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Redstart Holdings on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Redstart Holdings. Notwithstanding the foregoing, Redstart Holdings shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Redstart Holdings and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. An aggregate total of $166,564 of this note was bifurcated with the embedded conversion option recorded as a derivative liability at fair value (See Note 10 - Derivative Financial Instruments and Fair Value Measurements). The Company had the right to prepay the May 2019 Redstart Holdings Note until November 19, 2019. If the May 2019 Redstart Holdings Note was prepaid within 90 days of the issuance date, then the prepayment premium shall be 115% of the face amount plus any accrued interest; if the May 2019 Redstart Holdings Note was prepaid after 91 days from the issuance date, but prior to 121 days from the issuance date, then the prepayment premium shall be 120% of the face amount plus any accrued interest; and if the May 2019 Redstart Holdings Note was prepaid after 121 days from the issuance date, but prior to 150 days from the issuance date, then the prepayment premium shall be 125% of the face amount plus any accrued interest; and if the May 2019 Redstart Holdings Note was prepaid after 151 days from the issuance date, but prior to 180 days from the issuance date, then the prepayment premium shall be 129% of the face amount plus any accrued interest. The May 23, 2019 Redstart Holdings Note contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. The total principal amount outstanding and accrued interest under the above Redstart Holdings financing agreement, specifically the May 23, 2019 agreement at June 30, 2019 was $133,000 and $1,137 respectively and as of December 31, 2019 total principal amount outstanding and accrued interest totaled $86,400 and $6,322 respectively following conversion of $46,600 of the principal balance during the six months to December 31, 2019. The Company also recorded an amount of $18,266 of debt discount amortization related to the conversions during the six months to December 31, 2019. Power Up Lending Group Financing Agreements July 3, 2019 Securities Purchase Agreement Effective July 3, 2019, the Company entered into a securities purchase agreement with Power Up Lending Group Ltd. (“Power Up”), pursuant to which Power Up purchased a convertible promissory note (the “July 3, 2019 Power Up Note”) from the Company in the aggregate principal amount of $78,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Power Up. The transaction closed on July 3, 2019 and the Company received payment on July 8, 2019 in the amount of $78,000, of which $2,500 was paid directly toward legal fees and $500 to Power Up for due diligence fees resulting in net cash proceeds of $75,000. The maturity date of the July 3, 2019 Power Up Note is July 3, 2020. The July 3, 2019, Power Up Note bears interest at a rate of 8% per annum, which interest may be paid by the Company to Power Up in shares of the Company’s common stock, but shall not be payable until the July 3, 2019 Power Up Note becomes payable, whether at the maturity date or upon acceleration or by prepayment. Additionally, Power Up has the option to convert all or any amount of the principal face amount of the July 3, 2019 Power Up Note, starting on December 30, 2019 and ending on the later of the maturity date or the date the Default Amount, which is an amount equal to 150% of an amount equal to the then outstanding principal amount of the July 3, 2019 Power Up Note plus any interest accrued, is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the July 3, 2019 Power Up Note shall be $3.25, subject to certain Market Price (as defined below) adjustment. If the Market Price is greater than or equal to $5.00, the conversion price shall be the greater of 65% of the Market Price (“Variable Conversion Price”) and $3.25. In the event Market Price is less than $5.00, the conversion price shall be the Variable Conversion Price. As defined in the July 3, 2019 Power Up Note, the “Market Price” shall be the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Power Up on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Power Up. Notwithstanding the foregoing, Power Up shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Power Up and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. An aggregate total of $155,904 of this note was bifurcated with the embedded conversion option recorded as a derivative liability at fair value (See Note 10 - Derivative Financial Instruments and Fair Value Measurements). The July 3, 2019 Power Up Note contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. The total principal amount outstanding under the above Power Up financing agreement, specifically the July 3, 2019 Power Up Note, was $78,00	NOTE 6 – CONVERTIBLE NOTES The Company’s convertible notes outstanding at June 30, 2019 and 2018 were as follows: June 30, 2019 June 30, 2018 Convertible notes and debenture $ 1,076,785 $ 3,096,935 Unamortized discounts (131,893 ) (277,733 ) Accrued interest 99,482 148,930 Premium, net 613,003 1,731,167 Convertible notes, net $ 1,657,377 $ 4,699,299 Delafield Financing Agreements Initial Securities Purchase Agreement and Debenture On October 28, 2015, the Company entered into a securities purchase agreement with Delafield Investments Limited (the “Purchaser” or “Delafield”), whereby the Purchaser purchased a $4,000,000 5% convertible debenture in the principal amount of $4,350,000 from the Company. Additionally, Delafield received 4-year warrants to purchase an aggregate of 104,762 shares of the Company’s common stock with an exercise price of $1,500 per share. As of June 30, 2017, the principal balance of the convertible debenture was $720,271 and the related derivative liability associated with the convertible debenture was $252,303. During the year ended June 30, 2018, the Company converted $380,090 in principal and $8,250 in accrued interest under the debenture into shares of the Company’s common stock (see Note 8 – Stockholders’ Deficit). On January 2, 2018, the Company repaid the remaining principal balance of $340,181, the derivative liability was revalued, and the Company recorded $199,339 gain on the extinguishment of debt. Additional Debenture On September 13, 2016, the Company entered into an Additional Issuance Agreement (“Additional Debenture”) with the Purchaser whereby the Purchaser loaned an additional $150,000 to the Company in exchange for a 5% Original Issue Discount Senior Secured Convertible Debenture of the Company in the principal amount of $165,000. As of June 30, 2017, the Company recorded accrued interest of $8,250 and had a principal balance of $165,000 outstanding under the Additional Debenture. Additional at June 30, 2017, the derivative liability related to the Additional Debenture was $54,727. At June 30, 2018, all $165,000 in outstanding principal under the Additional Debenture along with $8,250 of accrued interest was fully converted into shares of the Company’s common stock (see Note 8 – Stockholders’ Deficit). December 2016 Letter Agreement On December 2, 2016, the Company entered into a Letter Agreement with the Purchaser pursuant to which the parties agreed to cancel the warrants to purchase up to 960,000 shares of the Company’s common stock issued to the Purchaser as of such date in exchange for an 8% convertible redeemable promissory note in the principal amount of $150,000. As of June 30, 2017, the Company recorded accrued interest of $6,937 and had a principal balance of $150,000 outstanding. On January 2, 2018, the Company repaid the remaining principal balance of $150,000 and accrued interest of $16,899. In connection with the Letter Agreement, the Company issued the Purchaser a 2-year common stock purchase warrants to purchase 208 shares of Company’s common stock at an exercise price of $6,250 per share. Eagle Equities Financing Agreements December 12, 2016 Securities Purchase Agreement On December 12, 2016, the Company entered into a Securities Purchase Agreement, with Eagle Equities, pursuant to which Eagle Equities purchased two 8% convertible redeemable junior subordinated promissory notes, each in the principal amount of $100,000. The first note (the “December 12 Note”) was funded with cash and the second note (the “December 12 Eagle Back-End Note”) was initially paid for by an offsetting promissory note issued by Eagle Equities to the Company (the “December 12 Note Receivable”). The terms of the December 12 Eagle Back-End Note require cash funding prior to any conversion thereunder. The December 12 Note Receivable is due December 12, 2017, unless certain conditions are not met, in which case both the December 12 Eagle Back-End Note and the December 12 Note Receivable may both be cancelled. Both the December 12 Note and the December 12 Eagle Back-End Note have a maturity date one year from the date of issuance upon which any outstanding principal and interest is due and payable. The outstanding principal amounts plus accrued interest under both the December 12 Note and the December 12 Eagle Back-End Note are convertible into the Company’s common stock at a conversion price equal to 60% of the lowest closing bid price of the common stock for the ten trading days prior to the conversion, subject to adjustment in certain events. On April 11, 2017, the Company received payment of the December 12 Note Receivable in the amount of $100,000 that offset the December Eagle Back-End Note. Proceeds from the Note Receivable of $5,000 were paid directly to legal fees resulting in net cash proceeds of $95,000 received by the Company. As a result, the December 12 Eagle Back-End Note is now convertible. The December 12 Note and the December 12 Eagle Back-End Note are treated as stock settled debt under ASC 480 and accordingly the Company recorded a put premium of $66,667 as each of the notes were funded. As of June 30, 2018, the outstanding principal under the December 12 Note along with $8,296 of accrued interest was fully converted into shares of the Company’s common stock. As of June 30, 2019, the outstanding balance of $100,000 under the December 12 Eagle Back-End Note along with $13,144 of accrued interest was fully converted (see Note 8 – Stockholders’ Deficit) resulting in full repayment of the note and a full reduction of the put premium. December 21, 2016 Securities Purchase Agreement On December 21, 2016, the Company entered into a Securities Purchase Agreement with Eagle Equities pursuant to which Eagle Equities purchased two 8% convertible redeemable junior subordinated promissory notes, each in the principal amount of $157,500. The first note (the “December 21 Eagle Note”) was funded with cash and the second note (the “December 21 Eagle Back-End Note”) was initially paid for by an offsetting promissory note issued by Eagle Equities to the Company (the “December 21 Eagle Note Receivable”). The terms of the December 21 Eagle Back-End Note require cash funding prior to any conversion thereunder. The December 21 Eagle Note Receivable was due December 21, 2017, unless certain conditions were not met, in which case both the December 21 Eagle Back-End Note and the December 21 Eagle Note Receivable may have both been cancelled. Both the December 21 Eagle Note and the December 21 Eagle Back-End Note had a maturity date one year from the date of issuance upon which any outstanding principal and interest is due and payable. The outstanding principal amounts plus accrued interest under both the December 21 Eagle Note and the December 21 Eagle Back-End Note were convertible into shares of the Company’s common stock at a conversion price equal to 60% of the lowest closing bid price of the common stock for the ten trading days prior to the conversion, subject to adjustment in certain events. On May 4, 2017, the Company received payment of the December 21 Eagle Note Receivable in the amount of $157,500 that offset the December 21 Eagle Back-End Note. Proceeds from the December 21 Eagle Note Receivable of $7,500 were paid directly to legal fees resulting in net cash proceeds of $150,000 received by the Company. As a result, the December 21 Eagle Back-End Note then became convertible. The December 21 Eagle Note and the December 21 Eagle Back-End Note are treated as stock settled debt under ASC 480 and accordingly the Company recorded a put premium of $105,000 as each of the notes were funded. As of June 30, 2018, the outstanding principal under the December 21 Eagle Note and the December 21 Eagle Back-End Note along with $7,773 and $5,656, respectively, of accrued interest was fully converted (see Note 8 – Stockholders’ Deficit) and the repayments resulted in a full reduction of the put premiums. January 27, 2017 Securities Purchase Agreement On January 27, 2017, the Company entered into a Securities Purchase Agreement with Eagle Equities, LLC, pursuant to which Eagle Equities purchased two 8% convertible redeemable junior subordinated promissory notes, each in the principal amount of $230,000. The first note (the “January 2017 Eagle Note”) was funded with cash and the second note (the “January 2017 Eagle Back-End Note”) was initially paid for by an offsetting promissory note issued by Eagle Equities to the Company (the “January 2017 Eagle Note Receivable”). The terms of the January 2017 Eagle Back-End Note require cash funding prior to any conversion thereunder. The January 2017 Eagle Note Receivable is due September 27, 2017, unless certain conditions are not met, in which case both the January 2017 Eagle Back-End Note and the January 2017 Eagle Note Receivable may both be cancelled. Both the January 2017 Eagle Note and the January 2017 Eagle Back-End Note have a maturity date one year from the date of issuance upon which any outstanding principal and interest is due and payable. The outstanding principal amounts plus accrued interest under both the January 2017 Eagle Note and the January 2017 Eagle Back-End Note are convertible into common stock of the Company at a conversion price equal to 60% of the lowest closing bid price of the common stock for the ten trading days prior to the conversion, subject to adjustment in certain events. On May 4, 2017, the Company received a partial payment of the January 2017 Note Receivable in the amount of $40,000 and on June 3, 2017 the balance of $190,000 was funded, of which $11,250 was paid directly to legal fees. As a result, the January 2017 Eagle Back-End Note is now convertible. The January 2017 Eagle Note and the January 2017 Eagle Back-End Note are treated as stock settled debt under ASC 480 and accordingly the Company is recording a put premium of $153,333 as each of the notes were funded. As of June 30, 2018, the outstanding principal under the January 2017 Eagle Note along with $14,988 of accrued interest was fully converted. As of June 30, 2019, the outstanding balance of $230,000 under the January 2017 Eagle Back-End Note along with $33,356 of accrued interest was fully converted (see Note 8 – Stockholders’ Deficit) resulting in full repayment of the note and a full reduction of the put premium. March 1, 2017 Securities Purchase Agreement On March 1, 2017, the Company entered into a Securities Purchase Agreement with Eagle Equities, pursuant to which Eagle Equities purchased two 8% convertible redeemable junior subordinated promissory notes, each in the principal amount of $220,500. The first note (the “March 2017 Eagle Note”) was funded with cash and the second note (the “March 2017 Eagle Back-End Note”) was initially paid for by an offsetting promissory note issued by Eagle Equities to the Company (the “March 2017 Eagle Note Receivable”). The terms of the March 2017 Eagle Back-End Note require cash funding prior to any conversion thereunder. Both the March 2017 Eagle Note and the March 2017 Eagle Back-End Note had a maturity date of March 1, 2018, upon which any outstanding principal and interest was due and payable. The outstanding principal amounts plus accrued interest under both the March 2017 Eagle Note and the March 2017 Eagle Back-End Note are convertible into shares of common stock, of the Company at a conversion price equal to 60% of the lowest closing bid price of the common stock for the ten trading days prior to the conversion, subject to adjustment in certain events. On July 5, 2017, the Company received payment of the March 2017 Eagle Note Receivable in the amount of $220,500 that offset the March 2017 Eagle Back-End Note. Proceeds from the March 2017 Eagle Note Receivable of $10,500 were paid directly to legal fees resulting in net cash proceeds of $210,000 received by the Company. As a result, the March 2017 Eagle Back-End Note is now convertible. The March 2017 Eagle Note and the March 2017 Eagle Back-End Note are treated as stock settled debt under ASC 480 and accordingly the Company recorded a put premium of $147,000 as each of the notes were funded. As of June 30, 2018, the outstanding principal balance under the March 2017 Eagle Note along with $20,061 of accrued interest was fully converted. As of June 30, 2019, the outstanding balance of $220,500 under the March 2017 Back-End Note along with $19,526 of accrued interest was fully converted (see Note 8 – Stockholders’ Deficit) resulting in a full reduction of the put premium. August 9, 2017 Securities Purchase Agreement On August 9, 2017, the Company entered into a Securities Purchase Agreement dated as of August 8, 2017, with Eagle Equities, pursuant to which Eagle Equities purchased two 8% convertible redeemable junior subordinated promissory notes, each in the principal amount of $200,000. The first note (the “August 2017 Eagle Note”) was funded with cash and the second note (the “August 2017 Eagle Back-End Note”) was initially paid for by an offsetting promissory note issued by Eagle Equities to the Company (the “August 2017 Eagle Note Receivable”). The terms of the August 2017 Eagle Back-End Note require cash funding prior to any conversion thereunder. The August 2017 Eagle Note Receivable is due August 8, 2018, unless certain conditions are not met, in which case both the August 2017 Eagle Back-End Note and the August 2017 Eagle Note Receivable may both be cancelled. Both the August 2017 Eagle Note and the August 2017 Eagle Back-End Note have a maturity date one year from the date of issuance upon which any outstanding principal and interest is due and payable. The outstanding principal amounts plus accrued interest under both the August 2017 Eagle Note and the August 2017 Eagle Back-End Note are convertible into common stock of the Company at a conversion price equal to 60% of the lowest closing bid price of the common stock for the ten trading days prior to the conversion, subject to adjustment in certain events. On September 14, 2017, the Company received payment of the August 2017 Eagle Note Receivable in the amount of $200,000 that offset the August 2017 Eagle Back-End Note. Proceeds from the August 2017 Eagle Note Receivable of $10,000 were paid directly to legal fees resulting in net cash proceeds of $190,000 received by the Company. As a result, the August 2017 Eagle Back-End Note is now convertible. The August 2017 Eagle Note and the August 2017 Eagle Back-End Note are treated as stock settled debt under ASC 480 and accordingly the Company recorded a put premium of $133,333 as each of the notes were funded. As of June 30, 2018 $120,000 of principal under the August 2017 Eagle Note along with $5,273 in interest was converted. As of June 30, 2019, the remaining outstanding balance of $80,000 under the August 2017 Eagle Note along with $6,850 of accrued interest was fully converted (see Note 8 – Stockholders’ Deficit) resulting in full repayment of the note and a full reduction of the put premium. As of June 30, 2019, the remaining outstanding principal balance of $200,000 under the August 2017 Eagle Back-Note along with $30,568 of accrued interest was fully converted (see Note 8 – Stockholders’ Deficit) resulting in full repayment of the note and a full reduction of the put premium. The Company is currently in discussions with Eagle Equities to extend the maturity date. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. October 25, 2017 Securities Purchase Agreement On November 3, 2017, the Company entered into a Securities Purchase Agreement dated as of October 25, 2017, with Eagle Equities, pursuant to which Eagle Equities purchased two 8% convertible redeemable junior subordinated promissory notes, each in the principal amount of $200,000. The first note (the “October 2017 Eagle Note”) was funded with cash and the second note (the “October 2017 Eagle Back-End Note”) was initially paid for by an offsetting promissory note issued by Eagle Equities to the Company (the “October 2017 Eagle Note Receivable”). The terms of the October 2017 Eagle Back-End Note require cash funding prior to any conversion thereunder. The October 2017 Eagle Note Receivable is due June 25, 2018, unless certain conditions are not met, in which case both the October 2017 Eagle Back-End Note and the October 2017 Eagle Note Receivable may both be cancelled. Both the October 2017 Eagle Note and the October 2017 Eagle Back-End Note have a maturity date one year from the date of issuance upon which any outstanding principal and interest is due and payable. The amounts cash funded plus accrued interest under both the October 2017 Eagle Note and the October 2017 Eagle Back-End Note are convertible into common stock, par value $0.001 of the Company at a conversion price equal to 60% of the lowest closing bid price of the common stock for the ten trading days prior to the conversion, subject to adjustment in certain events. On December 6, 2017, the Company received payment of the October 2017 Eagle Note Receivable in the amount of $200,000 that offset the October 2017 Eagle Back-End Note. Proceeds from the October 2017 Eagle Note Receivable of $10,000 were paid directly to legal fees resulting in net cash proceeds of $190,000 received by the Company. As a result, the October 2017 Eagle Back-End Note is now convertible. The October 2017 Eagle Note and the October 2017 Eagle Back-End Note are treated as stock settled debt under ASC 480 and accordingly the Company recorded a put premium of $133,333 as each of the notes were funded. As of June 30, 2019, the outstanding principal balance under the October 2017 Eagle Note along with $14,653 of accrued interest was fully converted (see Note 8 – Stockholders’ Deficit) resulting in full repayment of the note and a full reduction of the put premium. December 29, 2017 Securities Purchase Agreement The Company entered into an executory contract on December 29, 2017, whereby the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “December 2017 Eagle Note”) from the Company in the aggregate principal amount of $532,435, with principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities at any time. The transactions closed on January 2, 2018. The December 2017 Eagle Note contains an original issue discount of $25,354 such that the purchase price was $507,081. The maturity date of the December 2017 Eagle Note was December 29, 2018. The December 2017 Eagle Note bears interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of the Company’s common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time. The Company has recorded $20,065 of accrued interest for the December 2017 Eagle Note and total principal outstanding as of June 30, 2019 under the December 2017 Eagle Note was $171,965 following conversion of $360,470 of principal and $43,535 of accrued interest during the fiscal year ended June 30, 2019. The Company is currently in discussions with Eagle Equities to extend the maturity date. Eagle Equities has the option to convert all or any amount of the principal face amount of the December 2017 Eagle Note, at any time, for shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price of the Company’s common stock as reported on the OTCQB for the ten prior trading days, including the day upon which the Company receives a notice of conversion from Eagle Equities. The note is treated as stock settled debt under ASC 480 and accordingly the Company recorded a $354,956 put premium of which $240,313 was released to additional paid in capital following conversion of $360,470 of principal during the fiscal year to June 30, 2019. June 14, 2018 Securities Purchase Agreement Effective June 14, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “June 2018 Eagle Note”) from the Company in the aggregate principal amount of $105,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six-month anniversary of the June 2018 Eagle Note. The transactions contemplated by the Purchase Agreement closed on June 19, 2018. Pursuant to the terms of the Purchase Agreement, Eagle Equities deducted $5,000 from the principal payment due under the June 2018 Eagle Note, at the time of closing, to be applied to its legal expenses. The maturity date of the June 2018 Eagle Note is June 14, 2019. The June 2018 Eagle Note bears interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of the Company’s common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time after the six-month anniversary of the June 2018 Eagle Note. As of June 30, 2019, the remaining outstanding principal balance of $105,000 under the June 14, 2018 Eagle Equities Note along with $6,674 of accrued interest was fully converted (see Note 8 – Stockholders’ Deficit) resulting in full repayment of the note and a full reduction of the put premium. Additionally, Eagle Equities has the option to convert all or any amount of the principal face amount of the June 2018 Eagle Note, at any time, for shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price of the Company’s common stock as reported on the OTC quotation system for the ten prior trading days, including the day upon which the Company receives a notice of conversion from Eagle Equities. However, in the event that the Company’s common stock is restricted by the Depository Trust Company (“DTC”) for any reason, the Conversion Price shall be lowered to 50% of the lowest closing bid price for the duration of such restriction. If the Company fails to maintain a reserve of shares of its common stock at least four times the number of shares issuable upon conversion of the Note for at least 60 days after the issuance of the Note, the conversion discount shall be increased by 10%. Notwithstanding the foregoing, Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The June 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded a $70,000 put premium which was released to additional paid in capital upon conversion of the note as discussed above. Upon an event of default, principal and accrued interest will become immediately payable under the note. Interest on the outstanding principal shall accrue at a default interest rate of 24% per annum or at the highest rate permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. July 13, 2018 Securities Purchase Agreement Effective July 13, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “July 2018 Note”) from the Company in the aggregate principal amount of $75,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six month anniversary of the July 2018 Eagle Note. The transaction closed on July 16, 2018 and on July 19, 2018 the Company received proceeds of $71,250 as $3,750 was paid directly to legal fees. The maturity date of the July 2018 Eagle Note is July 13, 2019. The July 2018 Eagle Note bears interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of the Company’s common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time after the six-month anniversary of the Note. Additionally, Eagle Equities has the option to convert all or any amount of the principal face amount of the July 2018 Eagle Note, at any time, for shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price of the Company’s common stock for the ten prior trading days, including the day upon which the Company receives a notice of conversion, subject to adjustment in certain events. Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The July 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded a $50,000 put premium. The Company has recorded $5,786 of accrued interest and the total principal outstanding under the July 2018 Eagle Note was $75,000 as of June 30, 2019. The Company had the right to prepay the July 2018 Eagle Note with certain penalties until January 9, 2019. No prepayment was made as of such date. As a result, the July 2018 Eagle Note is now convertible. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. August 29, 2018 Securities Purchase Agreement Effective August 29, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “August 2018 Eagle Note”) from the Company in the aggregate principal amount of $105,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six-month anniversary of the August 2018 Eagle Note. The transactions contemplated by the agreement closed on August 30, 2018 the Company received proceeds of $100,000 as $5,000 was paid directly to legal fees. The maturity date of the August 29, 2018 Eagle Note is August 2019. The August 2018 Eagle Note bears interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of the Company’s common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time after the six-month anniversary of the August 2018 Eagle Note. Additionally, Eagle Equities has the option to convert all or any amount of the principal face amount of the August 2018 Eagle Note, at any time, into shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price (the “Closing Bid Price”) of the Company’s common stock as reported on the OTC Markets quotation system for the ten prior trading days, including the day upon which the Company receives a notice of conversion from Eagle Equities (the “Conversion Price”). However, in the event that the Company’s common stock is restricted by the DTC for any reason, the Conversion Price shall be lowered to 50% of the lowest Closing Bid Price for the duration of such restriction. If the Company fails to maintain a reserve of shares of its common stock at least four times the number of shares issuable upon conversion of the August 2018 Eagle Note for at least 60 days after the issuance of the August 28, 2018 Eagle Note, the conversion discount shall be increased by 10%. Notwithstanding the foregoing, Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The August 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded a $70,000 put premium. The Company has recorded $7,042 of accrued interest and the total principal outstanding under the August 2018 Eagle Note was $105,000 as of June 30, 2019.The Company had the right to prepay the August 2018 Eagle Note with certain penalties until February 25, 2019. No prepayment was made as of such date. As a result, the August 2018 Eagle Note is now convertible. Upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24% per annum or at the highest rate permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. October 2, 2018 Securities Purchase Agreement Effective October 2, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “October 2018 Eagle Note”) from the Company in the aggregate principal amount of $210,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six-month anniversary of the October 2018 Eagle Note. The transactions contemplated by the purchase agreement closed on October 3, 2018. Pursuant to the terms of the purchase agreement, Eagle Equities deducted $10,000 from the principal payment due under the October 2018 Eagle Note, at the time of closing, to be applied to its legal expenses. The maturity date of the October 2018 Eagle Note is October 2, 2019. The October 2018 Eagle Note shall bear interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time after the six-month anniversary of the October 2018 Eagle Note. Additionally, Eagle Equities has the option to convert all or any amount of the principal amount of the October 2018 Eagle Note, at any time, for shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price of the Company’s common stock for the ten prior trading days, including the day upon which the Company receives a notice of conversion, subject to adjustment in certain events. Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The October 2, 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded a $140,000 put premium. The Company has recorded $12,473 of accrued interest and the total principal outstanding under the October 2018 Eagle Note was $210,000 as of June 30, 2019. The Company had the right to prepay the October 2018 Eagle Note with certain penalties until March 31, 2019. No prepayment has been made as of such date. As a result, the October 2018 Eagle Note is now convertible. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. November 30, 2018 Securities Purchase Agreement Effective November 30, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “November 2018 Eagle Note”) from the Company in the aggregate principal amount of $105,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six-month anniversary of the November 2018 Eagle Note. The transactions contemplated by the purchase agreement closed on December 3, 2018. Pursuant to the terms of the purchase agreement, Eagle Equities deducted $5,000 from the principal payment due under the November 2018 Eagle Note, at the time of closing, to be applied to its legal expenses. The matur

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 7 – INCOME TAXES The Company follows ASC 740-10-10, under which an entity recognizes deferred tax assets and liabilities for future tax consequences or for events that were previously recognized in the Company’s financial statements or tax returns. The measurement of deferred tax assets and liabilities is based on enacted tax law provisions. The effects of future changes in tax laws or rates are not anticipated. Through June 30, 2010, the Company operated exclusively in Australia. The Company was wholly subject to Australian income tax laws and regulations, which are administered by the Australian Taxation Office for the years ended June 30, 2010 and all prior years. On November 23, 2010, the Company was incorporated in the state of Delaware. In January 2011, the Company acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis with Propanc PTY LTD becoming a wholly owned subsidiary of the Company. As a result of these transactions, the Company is subject to the income tax laws of both the United States and Australia for the years ended June 30, 2013 through June 30, 2019. The reconciliation of income tax expense computed at the U.S. federal statutory rate to the income tax provision for the years ended June 30, 2019 and 2018 is as follows: Year Ended US June 30, 2019 June 30, 2018 Income before Income taxes $ (5,758,369 ) $ (7,039,155 ) Taxes under statutory US tax rates $ (1,209,258 ) $ (1,478,222 ) Increase (decrease) in valuation allowance 1,394,444 1,418,349 Change in Federal tax rates - (99,013 ) Foreign tax rate differential (186,286 ) (5,043 ) Other 1,100 (114,391 ) Income tax (expense) benefit $ - $ (278,320 ) On December 22, 2017, the Tax Cuts and Jobs Act (“The Act”), was signed into law by President Trump. The Act includes a number of provisions, including the lowering of the U.S. corporate tax rate from 34 percent to 21 percent, effective January 1, 2018 and the establishment of a territorial-style system for taxing foreign-source income of domestic multinational corporations. In December 2017, the SEC issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Act (“SAB118”), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment. The Company remeasured its deferred tax assets and liabilities as of June 30, 2018 applying the reduced corporate income tax rate and recorded a decrease to the deferred tax assets of $416,339, with a corresponding adjustment to the valuation allowance. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities consist of the following: Year Ended June 30, 2019 June 30, 2018 Deferred tax assets Warrant Derivative Liability $ 7,403 $ 7,403 Provision for Annual Leave 96,759 44,969 Superannuation 9,473 4,041 Prepaid Investor Services 414,396 353,553 Capital Raising Costs - 23,559 Legal Costs 91,961 23,885 Intellectual Property 41,686 11,760 Patent Costs 171,195 171,195 Formation Expense 7,208 7,208 Net Operating Loss CF 6,573,215 5,668,743 Foreign Exchange Loss (OCI) (39,379 ) (39,379 ) Revalue of derivative liability 519,151 - Stock Based Compensation 51,481 - Total Deferred tax assets $ 7,944,549 $ 6,276,937 Deferred tax liabilities R&D $ (139,833 ) $ - Capital Raising Costs (133,335 ) - Total deferred tax liabilities $ (273,168 ) $ - Net deferred tax assets (liabilities) $ 7,671,381 $ 6,276,937 Valuation allowance (7,671,381 ) (6,276,937 ) Net deferred tax assets (liabilities) $ - $ - At June 30, 2019, the Company had U.S. net operating loss carry forwards of $2,942,144 that may be offset against future taxable income, subject to limitation under IRC Section 382. Of the $2.9 million, of Federal net operating loss carryforwards, $2.7 million begin to expire in 2030. The remaining balance of $0.2 million is limited in annual usage of 80% of current years taxable income, but do not have an expiration. At June 30, 2019, the Company had Australia net operating loss carry forwards of approximately $21,655,871 million which can be carried forward without expiration. No tax benefit has been reported in the June 30, 2019 and 2018 consolidated financial statements due to the uncertainty surrounding the realizability of the benefit, based on a more likely than not criteria and in consideration of available positive and negative evidence. The Company applied the “more-likely-than-not” recognition threshold to all tax positions taken or expected to be taken in a tax return, which resulted in no unrecognized tax benefits as of June 30, 2019 and 2018, respectively. Management has determined that the realization of the net deferred tax asset is not assured and has created a valuation allowance for the entire amount of such benefits. The Company follows ASC 740-10, which provides guidance for the recognition and measurement of certain tax positions in an enterprise’s financial statements. Recognition involves a determination whether it is more likely than not that a tax position will be sustained upon examination with the presumption that the tax position will be examined by the appropriate taxing authority having full knowledge of all relevant information. The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of June 30, 2019, the Company had no unrecognized tax benefits. There were no changes in the Company’s unrecognized tax benefits during the years ended June 30, 2019 and 2018. The Company did not recognize any interest or penalties during fiscal 2019 or 2018 related to unrecognized tax benefits. The income tax returns filed for the tax years from inception will be subject to examination by the relevant taxing authorities.

Stockholders' Deficit

Stockholders' Deficit	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Equity [Abstract]
Stockholders' Deficit	NOTE 6 – STOCKHOLDERS’ DEFICIT On June 24, 2019, the Company effected a one-for-five hundred (1:500) reverse stock split whereby the Company (i) decreased the number of authorized shares of common stock, $0.001 par value per share, to 100,000,000 and (ii) decreased by a ratio of one-for-five hundred (1:500) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts have been retroactively adjusted as of the earliest period, presented in the consolidated financial statements to reflect the reverse stock split. Preferred Stock: The total number of shares of preferred stock that the Company is authorized to issue is 1,500,005, $0.01 par value per share. These preferred shares have no rights to dividends, profit sharing or liquidation preferences. Of the total preferred shares authorized, 500,000 have been designated as Series A Preferred Stock (“Series A Preferred Stock”), pursuant to the Certificate of Designation filed with the Secretary of State of the State of Delaware on December 9, 2014. James Nathanielsz, the Company’s Chief Executive Officer beneficially owns all of the shares of Series A Preferred Stock via North Horizon Pty Ltd., which entitles him, as a holder of Series A Preferred Stock, to vote on all matters submitted or required to be submitted to a vote of the Company’s stockholders, except election and removal of directors, and each share of Series A Preferred Stock entitles him to two votes per share of Series A Preferred Stock. North Horizon Pty Ltd. is a Nathanielsz Family Trust. Mr. James Nathanielsz, the Chief Executive Officer and a director of our Company, has voting and investment power over these shares. 500,000 shares of Series A Preferred Stock are issued and outstanding as of December 31, 2019. Of the total preferred shares authorized, pursuant to the Certificate of Designation filed with the Secretary of State of the State of Delaware on June 16, 2015, up to five shares have been designated as Series B Preferred Stock (“Series B Preferred Stock”). Each holder of outstanding shares of Series B Preferred Stock is entitled to voting power equivalent to the number of votes equal to the total number of shares of common stock outstanding as of the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company and entitled to vote on all matters submitted or required to be submitted to a vote of the stockholders of the Company. One share of Series B Preferred Stock is issued and outstanding as of December 31, 2019. Mr. Nathanielsz directly beneficially owns such one share of Series B Preferred Stock. Common Stock: Shares issued for conversion of convertible debt During the six months ended December 31, 2019, the Company issued 1,246,859 shares of its common stock at an average contractual conversion price of $0.3575, ranging from $0.067 to $0.906, as a result of the conversion of principal and interest in the aggregate amount of $318,768 underlying certain outstanding convertible notes converted during such period. The total recorded to equity was $343,179. Notes totaling $46,600 contained bifurcated embedded conversion option derivatives. Accordingly, the fair market value of the shares issued was $71,011 resulting in a loss on extinguishment at the time of conversion of $24,411, $44,587 of derivative fair value was recorded as a gain on extinguishment at the time of conversion. The Company reclassified $160,205 in put premiums to additional paid in capital following conversions during the six months ended December 31, 2019. The Company has 77,292,139 shares of its common stock reserved for future issuances based on lender reserve requirements pursuant to underlying financing agreements at December 31, 2019. Shares issued for services On July 19, 2019, the Company entered into an agreement with a certain consultant to provide services over a two-month period beginning July 1, 2019 and ending September 1, 2019 in exchange for 20,000 shares of the Company’s common stock. On July 19, 2019, the Company issued the 20,000 shares of the Company’s common stock valued at $1.99 per share; being the closing price of the stock on the date of the agreement, to such consultant, or $39,800, which will be amortized over the term of the agreement. The Company recorded $39,800 of consulting expense with respect to such shares of its common stock during the six months ended December 31, 2019. Restricted Stock Units Pursuant to employment agreements dated in May 2019 (see Note 8), the Company granted an aggregate of 78,000 and 39,000 restricted stock unit to the Company’s Chief Executive Officer and Chief Scientific Officer, respectively. The total 117,000 restricted stock units are subject to vesting terms as defined in the employment agreements. The 117,000 restricted stock units were valued at the fair value of $4.25 per unit or $497,240 based on the quoted trading price on the date of grant. During the six months ended December 31, 2019, the Company recognized stock-based compensation of $108,771 related to vested restricted stock units. There were $357,392 unrecognized restricted stock units expense as of December 31, 2019. Warrants: In connection with the issuance of the August 2019 Auctus Note, the Company issued common stock purchase warrants to Auctus to purchase 450,000 shares of the Company’s common stock (the “First Warrant”) as a commitment fee upon the terms and subject to the limitations and conditions set forth in such First Warrant at an “Exercise Price” of $2.25. In connection with the issuance of the Note, the Company shall issue a common stock purchase warrant to Buyer to purchase 300,000 shares of the Company’s common stock (the “Second Warrant”) as a commitment fee upon the terms and subject to the limitations and conditions set forth in such Second Warrant at an “Exercise Price” of $3.33. In connection with the issuance of the Note, the Company shall issue a common stock purchase warrant to Buyer to purchase 225,000 shares of the Company’s common stock (the “Third Warrant”) as a commitment fee upon the terms and subject to the limitations and conditions set forth in such Third Warrant at an “Exercise Price” of $4.50. The First Warrant, Second Warrant, and Third Warrant shall collectively be referred as the “Warrants”. The Warrants have an “Exercise Period” of five years form the date of issuance being August 30, 2019 (see Note 5). On September 10, 2019, the Company entered into an agreement with a certain consultant to provide services over a three-month period beginning September 10, 2019 and ending December 10, 2019 in exchange for 1,000,000 warrants to purchase the Company’s common stock at $2.00 per share with an expiry date of September 10, 2022. The Fair Market Value of the warrants was $984,810 on the date of grant as calculated under the Black Scholes Option Pricing model. The Company recorded $984,810 of share based compensation expenses with respect to the grant of such warrants during the six months ended December 31, 2019. As of December 31, 2019, there were 1,975,059 warrants outstanding and exercisable with expiration dates commencing May 2020 and continuing through August 2024, with a weighted average exercise price per share of $2.69. Options: As of December 31, 2019, the Company had entered into agreements to grant options to purchase 59,644 shares of its common stock, with a weighted average exercise price per share of $76.37. Pursuant to employment agreements dated in May 2019 (see Note 8), the Company granted options to purchase 39,000 and 19,500 shares of the Company’s common stock to the Company’s Chief Executive Officer and Chief Scientific Officer, respectively. The total 58,500 options have a term of 10 years from the date of grant and exercise price ranging from $4.25 to $4.675 per share. 1/3rd of these options shall vest every successive one-year anniversary, provided, that on each such vesting date, the Chief Executive Officer and Chief Scientific Officer are employed by the Company and subject to the other provisions of the employment agreement. The 58,500 stock options were valued using a Black-Scholes model with the following assumptions: stock price at valuation date of $4.25 based on quoted trading price on date of grant, exercise price of $4.65, dividend yield of zero, years to maturity of 10.00, a risk free rate of 2.42%, and expected volatility 268% for a total value of $248,620. During the six months ended December 31, 2019, the Company recognized stock-based compensation of $41,437 related to vested stock options. There was $196,824 of unvested stock options expense as of December 31, 2019 that will be recognized in future periods. No stock options were issued during the six months ended December 31, 2019.	NOTE 8 – STOCKHOLDERS’ DEFICIT Increase in Authorized Shares of Common Stock and Reverse Stock Split On September 21, 2018, the Company filed a Certificate of Amendment to its Certificate of Incorporation to increase the number of authorized shares of its common stock from 400,000,000 to 4,000,000,000, which was approved by the Company’s board of directors and holders of a majority of the Company’s voting stock on August 28, 2018. On June 24, 2019, the Company effected a one-for-five hundred (1:500) reverse stock split whereby the Company (i) decreased the number of authorized shares of common stock, $0.001 par value per share, to 100,000,000 and (ii) decreased by a ratio of one-for-five hundred (1:500) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts have been restated as of the earliest period, presented in the consolidated financial statements to reflect the reverse stock split. Preferred Stock The total number of shares of preferred stock that the Company is authorized to issue is 1,500,005, $0.01 par value per share. These preferred shares have no rights to dividends, profit sharing or liquidation preferences. Of the total preferred shares authorized, 500,000 have been designated as Series A Preferred Stock (“Series A Preferred Stock”), pursuant to the Certificate of Designation filed with the Secretary of State of the State of Delaware on December 9, 2014. James Nathanielsz, the Company’s Chief Executive Officer and Chief Financial Officer, beneficially owns all of the shares of Series A Preferred Stock via North Horizon Pty Ltd., which entitles him, as a holder of Series A Preferred Stock, to vote on all matters submitted or required to be submitted to a vote of the Company’s stockholders, except election and removal of directors, and each share of Series A Preferred Stock entitles him to two votes per share of Series A Preferred Stock. North Horizon Pty Ltd. is a Nathanielsz Family Trust. Mr. James Nathanielsz, the Chief Executive Officer, Chief Financial Officer and a director of our Company, has voting and investment power over these shares. 500,000 shares of Series A Preferred Stock are issued and outstanding as of June 30, 2019 and 2018. Of the total preferred shares authorized, pursuant to the Certificate of Designation filed with the Secretary of State of the State of Delaware on June 16, 2015, up to five shares have been designated as Series B Preferred Stock (“Series B Preferred Stock”). Each holder of outstanding shares of Series B Preferred Stock is entitled to voting power equivalent to the number of votes equal to the total number of shares of common stock outstanding as of the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company and entitled to vote on all matters submitted or required to be submitted to a vote of the stockholders of the Company. One share of Series B Preferred Stock is issued and outstanding as of June 30, 2019 and 2018. Mr. Nathanielsz directly beneficially owns such one share of Series B Preferred Stock. No shares of Series A Preferred Stock or Series B Preferred Stock were issued in fiscal years 2019 or 2018. Common Stock Shares Issued for Services Fiscal 2018: On August 1, 2017, the Company received an invoice for $30,000 from a third party for six months of consulting services provided to the Company during the period of February 1, 2017 through July 31, 2017. The invoice was payable in shares of the Company’s common stock. The Company recorded $25,000 in consulting fees related to this invoice for the year ended June 30, 2017 and the balance was recorded in fiscal year 2018. On February 15, 2018, the Company issued 469 shares of its common stock and an additional loss on settlement of debt was recorded of $68,438 based on the fair market value on July 31, 2017, when the shares were fully earned, of $210 per share. On December 29, 2017, the Company entered into a one-year consulting agreement with a certain consultant (the “Consultant”) for certain consulting, advisory and media services to be provided to the Company. As compensation for such services, the Company agreed to pay the consultant (i) an hourly fee of $950 per hour, for up to $71,250 of time-based services; (ii) $9,772 for the preparation of certain marketing materials; (iii) an upfront fee of 1,000 restricted shares of the Company’s common stock, with up to 1,500 additional shares to be issued on the six month anniversary of the date of the consulting agreement at the Company’s sole discretion, and (iv) a marketing bonus equal to 6% of the value of any: (x) business collaboration with the Company which is identified or introduced by the Consultant; or (y) joint venture, licensing, collaboration or similar monetization or strategic transaction (other than any capital-raising transaction) which is identified or introduced by the Consultant. The Company could, in its sole discretion, pay any of the aforementioned fees in cash or shares of the Company’s common stock. If such fees are paid in stock, the number of shares to be paid was to be calculated by dividing the dollar amount of time (or value of the transaction, as the case may be) invoiced in such pay period by, as of the applicable calculation date, the most recent price at which the Company has sold shares of its common stock (or securities convertible into common stock) in a bona fide public or private financing including third party investors. The Company valued the 1,000 shares based on the market price on the agreement date of $70 and will recognize $70,000 of consulting expense through the term of the agreement. For the year ended June 30, 2018, the Company recorded $35,287 of expense related to this agreement. On February 15, 2018, the Company issued the 1,000 shares to the Consultant. On February 1, 2018, the Company received an invoice for $30,000 from a third party for six months of consulting services provided to the Company during the period of August 1, 2017 through January 31, 2018. The invoice was payable in shares of the Company’s common stock. The Company issued 469 shares on February 15, 2018 and recorded $30,000 in consulting fees during fiscal 2018. An additional loss on settlement of debt was recorded of $2,813 based on the fair market value on January 31, 2018, when the shares were fully earned, or $70 per share. Fiscal 2019: On December 6, 2018, the Company entered into an agreement with a certain consultant to provide services over a six-month period beginning November 1, 2018 and ending May 1, 2019 in exchange for 4,000 shares of the Company’s common stock. On December 27, 2018, the Company issued the 4,000 shares of the Company’s common stock valued at $10.00 per share to such consultant, or $39,000, which will be amortized over the term of the agreement. The Company recorded $39,000 of consulting expense with respect to such shares of its common stock during the year ended June 30, 2019. On November 20, 2018, the Company’s Board of Directors authorized the issuance of 2,000 shares of the Company’s common stock in connection with certain legal services provided to the Company. On November 28, 2018, the Company issued such 2,000 shares of its common stock valued at $15.00, or $30,000. In March 2019 and effective as of December 21, 2018, the Company entered into a certain consulting services agreement with a certain consultant to provide services over a twelve-month period beginning December 21, 2018 in exchange for issuance of two tranches of 10,000 shares (subject to certain true-up provisions), for services to be rendered between December 21, 2018 and March 20, 2019, and 6,000 shares (subject to certain true-up provisions), for services to be rendered between March 21, 2019 and December 20, 2019 of the Company’s common stock. On May 8, 2019, the Company terminated the agreement with the consent of the consultant. The consultant agreed that the issuance of the first tranche of 10,000 shares (including the true-up provision) together with cash payments already made by the Company to the consultant fully satisfied the obligations (past and future) that the Company has under the consulting agreement including any claims under the true-up provisions of the agreement. In March 2019, the Company issued the first tranche of 10,000 shares of its common stock valued at $10.00 per share based on the quoted trading price to the consultant, or $100,000. The Company recorded $100,000 of consulting expense with respect to such shares of its common stock during the fiscal year ended June 30, 2019. Restricted Stock Units Pursuant to employment agreements dated in May 2019 (see Note 10), the Company granted an aggregate of 78,000 and 39,000 restricted stock unit to the Company’s Chief Executive Officer and Chief Scientific Officer, respectively. The total 117,000 restricted stock units are subject to vesting terms as defined in the employment agreements. The 117,000 restricted stock units were valued at the fair value of $4.25 per unit or $497,240 based on the quoted trading price on the date of grant. During the year ended June 30, 2019, the Company recognized stock-based compensation of $31,077 related to vested restricted stock units. There were $466,163 unrecognized restricted stock units expense as of June 30, 2019. Shares Issued for Cash October 5, 2018 Equity Purchase Agreement On October 5, 2018 (the “L2 Closing Date”), the Company entered into an Equity Purchase Agreement (the “L2 Purchase Agreement”) with L2 Capital, LLC (“L2 Capital”) pursuant to which L2 Capital committed to purchase up to $10,000,000 (the “Maximum Amount”) of the Company’s common stock (the “L2 Financing”). On the L2 Closing Date, the Company issued 7,701 shares of its common stock to L2 Capital as a commitment fee (the “Commitment Shares”), at a fair market value of $41.30 or $318,059, which was recorded as deferred offing costs and were amortized as a percentage of the Maximum Amount on a pro-rata conversion amount. Additionally, the proceeds received from the first put notice were net of $15,000 in legal fees and were recorded as deferred offering costs. Total amortization expense for the fiscal year ended June 30, 2019 was $333,059. The Commitment Shares are subject to a lock-up/leak-out limitation as described below. In connection with the L2 Financing, on the L2 Closing Date, the Company and L2 Capital also entered into a Registration Rights Agreement (the “L2 Registration Rights Agreement”, and together with the Purchase Agreement, the “L2 Transaction Documents”). The Company received net proceeds from the sale of the Put Shares directly to the Investor pursuant to the Purchase Agreement, however, the Company did not receive any proceeds from the resale of the Put Shares by L2 Capital thereafter. Upon filing and effectiveness of the Company’s Registration Statement on Form S-1, which was declared effective by the SEC on October 30, 2018, and provided other closing conditions are met, from time to time over the term of the Purchase Agreement, the Company had the right, but not the obligation, to direct the Investor to purchase shares of the Company’s common stock (the “L2 Put Shares”) in a maximum amount of $1,000,000, provided that the number of L2 Put Shares did not exceed 250% of the Average Daily Trading Volume (as defined in the L2 Purchase Agreement). At any time and from time to time during the 3-year term of the L2 Purchase Agreement (the “Commitment Period”), the Company had the right to deliver a notice L2 Capital (the “L2 Put Notice”) and was obligated to deliver the Put Shares to Investor via DWAC (as defined in the L2 Purchase Agreement) within two trading days. The purchase price (the “L2 Purchase Price”) for the Put Shares was 87.5% of the one lowest daily volume weighted average price on the Principal Market (as defined in the L2 Purchase Agreement) (as reported by Bloomberg Finance L.P.) during the five trading days immediately following the date L2 Capital receives the L2 Put Shares via DWAC associated with the applicable Put Notice (the “L2 Valuation Period”). The closing of a Put Notice occurred within one trading day following the end of the respective L2 Valuation Period, whereby (i) L2 Capital was obligated to deliver the L2 Investment Amount (as defined below) to the Company by wire transfer of immediately available funds and (ii) L2 Capital was obligated to return surplus L2 Put Shares if the value of the L2 Put Shares delivered to L2 Capital caused the Company to exceed the maximum commitment amount. The Company could not deliver another L2 Put Notice to L2 Capital within ten trading days of a prior Put Notice. The “L2 Investment Amount” means the aggregate L2 Purchase Price for the L2 Put Shares purchased by L2 Capital, minus clearing costs due to L2 Capital’s broker or to the Company’s transfer agent for the issuance of the L2 Put Shares (the “L2 Clearing Costs”). The right of the Company to issue and sell the L2 Put Shares to L2 Capital was subject to the satisfaction of certain closing conditions, including, but not limited to, (i) the Company’s Registration Statement on Form S-1 registering for resale by the Investor of the L2 Put Shares and Commitment Shares continuing to be effective as was declared by the U.S. Securities and Exchange Commission (the “SEC”) on October 30, 2018, (ii) accuracy of the Company’s representations and warranties, (iii) the Company’s performance under the L2 Purchase Agreement in all material respects, (iv) no suspension of trading or delisting of the Company’s common stock, (v) limitation of L2 Capital’s beneficial ownership to no more than 9.99%, (vi) the Company maintaining its DWAC-eligible status, (vii) the Company maintaining a sufficient share reserve, and (viii) the minimum pricing for the L2 Put Shares must exceed $.05. Pursuant to the terms of the L2 Registration Rights Agreement, the Company filed the L2 Registration Statement on October 17, 2018 and the Registration Statement was declared effective by the SEC on October 30, 2018. L2 Capital agreed, for a period of 180 days from the L2 Closing Date, not to sell, on any given day, a number of Commitment Shares that exceeds the greater of (i) 5% of the average daily trading volume of the Company’s shares of common stock for the period ended one trading day prior to the date of such sale, as reported on the Principal Market; and (ii) such number of Commitment Shares that equals (x) $5,000, divided by, (y) the closing price of the Company’s shares of common stock one trading day prior to the date of such sale, as reported on the Principal Market. Effective as of the L2 Closing Date, the Company reserved 924,143 shares of its common stock from its authorized and unissued shares of common stock to provide for all issuances of shares of common stock under the L2 Transaction Documents (in the event that the Company issued and sold the L2 Put Shares up to the Maximum Amount) and was required to reserve and keep available out of its authorized and unissued shares of common stock a number of shares of common stock at least three times the number of shares of common stock obtained by dividing the remaining balance on the maximum commitment amount by the L2 Purchase Price. While the Company had the obligation to maintain such reserve while the Purchase Agreement was effective, the Company did not have the obligation to sell any L2 Put Shares to L2 Capital. L2 Capital agreed, and agreed to cause any affiliate of L2 Capital acting on its behalf or pursuant to any understanding with it, not to execute any short sales during the period from the date hereof to the end of the Commitment Period. As of about February 7, 2019, the Company reached the maximum number of shares that it could put under the L2 Purchase Agreement, and therefore, the Company would have had to file with the SEC a new registration statement registering additional shares under the L2 Purchase Agreement if the Company had determined to continue to utilize the L2 Purchase Agreement. During the fiscal year ended June 30, 2019, the Company issued 113,200 shares of its common stock at an average price per share of $8.50, ranging from $6.50 to $20.00, as a result of delivering 14 L2 Put Notices to L2 Capital. As of June 30, 2019, the Company received gross aggregate proceeds of $964,009 from such put notices. Effective as of February 25, 2019, the Company terminated the L2 Purchase Agreement. February 25, 2019 Equity Purchase Agreement On February 25, 2019 (the “Closing Date”), the Company entered into an Equity Purchase Agreement (the “Purchase Agreement”) with a certain institutional investor (the “Investor”) pursuant to which the Investor committed to purchase up to $10,000,000 (the “Maximum Amount”) of the Company’s common stock (the “Financing”). In connection with the Financing, on the Closing Date, the Company and the Investor also entered into a Registration Rights Agreement (the “Registration Rights Agreement”, and together with the Purchase Agreement, the “Transaction Documents”). The Company will receive net proceeds from the sale of the Put Shares directly to the Investor pursuant to the Purchase Agreement, however, the Company will not receive any proceeds from the resale of the Put Shares by the Investor thereafter. Upon filing and effectiveness of the Company’s Registration Statement on Form S-1, which was declared effective by the SEC on March 7, 2019, and provided other closing conditions are met, from time to time over the term of the Purchase Agreement, the Company has the right, but not the obligation, to direct the Investor to purchase shares of the Company’s common stock (the “Put Shares”) in a maximum amount of $1,000,000, provided that the number of Put Shares did not exceed 250% of the Average Daily Trading Volume (as defined in the Purchase Agreement). At any time and from time to time during the 3-year term of the Purchase Agreement (the “Commitment Period”), the Company has the right to deliver a notice to the Investor (the “Put Notice”) and is obligated to deliver the Put Shares to Investor via DWAC (as defined in the Purchase Agreement) within two trading days. The purchase price (the “Purchase Price”) for the Put Shares was 87.5% of the one lowest daily volume weighted average price on the Principal Market (as defined in the Purchase Agreement) (as reported by Bloomberg Finance L.P.) during the five trading days immediately following the date the Investor receives the Put Shares via DWAC associated with the applicable Put Notice (the “Valuation Period”). The closing of a Put Notice occurs within one trading day following the end of the respective Valuation Period, whereby (i) the Investor is obligated to deliver the Investment Amount (as defined below) to the Company by wire transfer of immediately available funds and (ii) the Investor is obligated to return surplus Put Shares if the value of the Put Shares delivered to the Investor causes the Company to exceed the maximum commitment amount. The Company cannot deliver another Put Notice to the Investor within ten trading days of a prior Put Notice. The “Investment Amount” means the aggregate Purchase Price for the Put Shares purchased by the Investor, minus clearing costs due to the Investor’s broker or to the Company’s transfer agent for the issuance of the Put Shares (the “Clearing Costs”). The right of the Company to issue and sell the Put Shares to the Investor is subject to the satisfaction of certain closing conditions, including, but not limited to, (i) the Company’s Registration Statement on Form S-1 registering for resale by the Investor of the Put Shares continuing to be effective as was declared by the SEC on March 7, 2019, (ii) accuracy of the Company’s representations and warranties, (iii) the Company’s performance under the Purchase Agreement in all material respects, (iv) no suspension of trading or delisting of the Company’s common stock, (v) limitation of the Investor’s beneficial ownership to no more than 9.99%, (vi) the Company maintaining its DWAC-eligible status, (vii) the Company maintaining a sufficient share reserve, and (viii) the minimum pricing for the Put Shares must exceed $0.05. Pursuant to the terms of the Registration Rights Agreement, the Company filed the Registration Statement on February 25, 2019 and the Registration Statement was declared effective by the SEC on March 7, 2019. Effective as of the Closing Date, the Company reserved 1,333,333 shares of its common stock from its authorized and unissued shares of common stock to provide for all issuances of shares of common stock under the Transaction Documents (in the event that the Company issued and sold the Put Shares up to the Maximum Amount) and was required to reserve and keep available out of its authorized and unissued shares of common stock a number of shares of common stock at least three times the number of shares of common stock obtained by dividing the remaining balance on the maximum commitment amount by the Purchase Price. While the Company has the obligation to maintain such reserve while the Purchase Agreement was effective, the Company does not have the obligation to sell any Put Shares to the Investor. The Investor agreed, and agreed to cause any affiliate of the Investor acting on its behalf or pursuant to any understanding with it, not to execute any short sales during the period from the date hereof to the end of the Commitment Period. During the year ended June 30, 2019, the Company issued 34,000 shares of its common stock at an average price per share of $4.01, ranging from $3.06 to $4.90, as a result of delivering five Put Notices to the Investor. As of June 30, 2019, the Company received gross aggregate proceeds of $136,371 from such put notices. Shares issued for conversion of convertible debt Fiscal 2018: On July 5, 2017, pursuant to a conversion notice, $26,000 of principal and $1,121 of interest was converted at $270 per share into 100 shares of common stock. On July 13, 2017, pursuant to a conversion notice, $42,500 of principal was converted at $315 per share into 135 shares of common stock. On July 17, 2017, pursuant to a conversion notice, $16,000 of principal and $732 of interest was converted at $200 per share into 83 shares of common stock. On July 20, 2017, pursuant to a conversion notice, $28,000 of principal and $1,300 of interest was converted at $145 per share into 203 shares of common stock. On July 28, 2017, pursuant to a conversion notice, $22,500 in principal and $1,593 in interest was converted at $130 per share into 187 shares of common stock. On August 2, 2017, pursuant to a conversion notice, $20,000 of principal was converted at $140 per share into 142 shares of common stock. On August 2, 2017, pursuant to a conversion notice, $25,000 of principal and $1,233 of interest was converted at $105 per share into 250 shares of common stock. On August 16, 2017, pursuant to a conversion notice, $25,000 of principal and $1,311 of interest was converted at $115 per share into 224 shares of common stock. On August 17, 2017, pursuant to a conversion notice, $20,000 of principal was converted at $150 per share into 132 shares of common stock. On August 22, 2017, pursuant to a conversion notice, $20,000 of principal and $1,500 of interest was converted at $125 per share into 170 shares of common stock. On August 25, 2017, pursuant to a conversion notice, $25,000 of principal and $1,361 of interest was converted at $115 per share into 225 shares of common stock. On August 29, 2017, pursuant to a conversion notice, $20,000 of principal was converted at $120 per share into 164 shares of common stock. On September 3, 2017, pursuant to a conversion notice, $20,000 of principal and $1,661 of interest was converted at $100 per share into 213 shares of common stock. On September 6, 2017, pursuant to a conversion notice, $12,500 of principal and $714 of interest was converted at $95 per share into 142 shares of common stock. On September 8, 2017, pursuant to a conversion notice, $20,000 of principal was converted at 120 per share into 166 shares of common stock. On September 14, 2017, pursuant to a conversion notice, $15,000 of principal and $450 of interest was converted at $75 per share into 206 shares of common stock. On September 14, 2017, pursuant to a conversion notice, $20,000 of principal and $1,665 of interest was converted at $80 per share into 278 shares of common stock. On September 18, 2017, pursuant to a conversion notice, $20,000 of principal was converted at $95 per share into 215 shares of common stock. On September 25, 2017, pursuant to a conversion notice, $20,000 of principal and $649 of interest was converted at $70 per share into 299 shares of common stock. On September 26, 2017, pursuant to a conversion notice, $30,000 of principal was converted at $90 per share into 337 shares of common stock. On September 26, 2017, pursuant to a conversion notice, $20,000 of principal and $1,716 of interest was converted at $75 per share into 291 shares of common stock. On October 2, 2017, pursuant to a conversion notice, $25,000 of principal and $850 of interest was converted at $70 per share into 375 shares of common stock. On October 4, 2017, pursuant to a conversion notice, $40,000 of principal was converted at $90 per share into 449 shares of common stock. On October 5, 2017, pursuant to a conversion notice, $20,000 of principal and $1,716 of interest was converted at $75 per share into 291 shares of common stock. On October 9, 2017, pursuant to a conversion notice, $30,000 of principal and $1,067 of interest was converted at $70 per share into 431 shares of common stock. On October 10, 2017, pursuant to a conversion notice, $45,000 of principal was converted at $95 per share into 484 shares of common stock. On October 11, 2017, pursuant to a conversion notice, $20,000 of principal and $1,812 of interest was converted at $80 per share into 280 shares of common stock. On October 16, 2017, pursuant to a conversion notice, $20,000 of principal and $1,834 of interest was converted at $80 per share into 269 shares of common stock. On October 18, 2017, pursuant to a conversion notice, $25,000 of principal and $939 of interest was converted at $65 per share into 393 shares of common stock. On October 19, 2017, pursuant to a conversion notice, $30,000 of principal was converted at $80 per share into 387 shares of common stock. On October 23, 2017, pursuant to a conversion notice, $20,000 of principal and $1,884 of interest was converted at $55 per share into 396 shares of common stock. On October 24, 2017, pursuant to a conversion notice, $21,000 of principal and $817 of interest was converted at $55 per share into 404 shares of common stock. On October 27, 2017, pursuant to a conversion notice, $15,000 of principal was converted at $45 per share into 320 shares of common stock. On October 30, 2017, pursuant to a conversion notice, $8,750 of principal and $352 of interest was converted at $35 per share into 289 shares of common stock. On October 30, 2017, pursuant to a conversion notice, $20,000 of principal and $1,902 of interest was converted at $35 per share into 602 shares of common stock. On November 2, 2017, pursuant to a conversion notice, $5,000 of principal and $8,250 of interest was converted at $45 per share into 311 shares of common stock. On November 6, 2017, pursuant to a conversion notice, $12,750 of principal and $533 of interest was converted at $25 per share into 490 shares of common stock. On November 6, 2017, pursuant to a conversion notice, $17,500 of principal was converted at $35 per share into 502 shares of common stock. On November 8, 2017, pursuant to a conversion notice, $20,000 in principal and $2,356 in interest was converted at $30 per share into 764 shares of common stock. On November 13, 2017, pursuant to a conversion notice, $11,000 in principal and $623 in interest was converted at $25 per share into 430 shares of common stock. On November 15, 2017, pursuant to a conversion notice, $20,000 in principal and $2,443 in interest was converted at $30 per share into 767 shares of common stock. On November 17, 2017, pursuant to a conversion notice, $15,000 in principal was converted at $35 per share into 430 shares of common stock. On November 26, 2017, pursuant to a conversion notice, $20,000 in principal and $2,568 in interest was converted at $30 per share into 772 shares of common stock. On November 27, 2017, pursuant to a conversion notice, $20,000 in principal and $1,196 in interest was converted at $25 per share into 785 shares of common stock. On December 1, 2017, pursuant to a conversion notice, $20,000 in principal and $802 in interest was converted at $30 per share into 746 shares of common stock. On December 6, 2017, pursuant to a conversion notice, $21,000 in principal and $1,297 in interest was converted at $25 per share into 826shares of common stock. On December 8, 2017, pursuant to a conversion notice, $9,900 in principal and $792 in interest was converted at $25 per share into 396 shares of common stock. On December 8, 2017, pursuant to a conversion notice, $42,666 in principal was converted at $35 per share into 1,223 shares of common stock. On December 11, 2017, pursuant to a conversion notice, $9,900 in principal and $799 in interest was converted at $25 per share into 396 shares of common stock. On December 11, 2017, pursuant to a conversion notice, $27,000 in principal and $1,142 in interest was converted at $30 per share into 1,009 shares of common stock. On December 11, 2017, pursuant to a conversion notice, $42,666 in principal was converted at $35 per share into 1,223 shares of common stock. On December 15, 2017, pursuant to a conversion notice, $56,758 in principal was converted at $40 per share into 1,465 shares of common stock. On December 18, 2017, pursuant to a conversion notice, $30,000 in principal and $2,467 in interest was converted at $35 per share into 958 shares of common stock. On December 19, 2017, pursuant to a conversion notice, $23,000 in principal and $1,013 in interest was converted at $35 per share into 738 shares of common stock. On December 21, 2017, pursuant to a conversion notice, $63,000 in principal was converted at $40 per share into 1,578 shares of common stock. On December 22, 2017, pursuant to a conversion notice, $25,000 in principal and $2,078 in interest was converted at per share into 860 shares of common stock. On January 2, 2018, pursuant to a conversion notice, $25,000 in principal and $1,178 in interest was converted at $35 per share into 804 shares of common stock. On January 3, 2018, pursuant to a conversion notice, $25,200 in principal and $2,162 in interest was converted at $30 per share into 869 shares of common stock. On January 4, 2018, pursuant to a conversion notice, $25,000 in principal and $1,372 in interest was converted at $35 per share into 798 shares of common stock. On January 9, 2018, pursuant to a conversion notice, $40,000 in principal and $4,581 in interest was converted at $35 per share into 1,261 shares of common stock. On January 12, 2018, pursuant to a conversion notice, $25,000 in principal and $1,233 in interest was converted at $40 per share into 691 shares of common stock. On January 12, 2018, pursuant to a conversion notice, $7,500 in principal and $875 in interest was converted at $35 per share into 232 shares of common stock. On January 26, 2018, pursuant to a conversion notice, $30,000 in principal and $1,793 in interest was converted at $45 per share into 707 shares of common stock. On January 30, 2018, pursuant to a conversion notice, $40,000 in principal and $2,130 in interest was converted at $45 per share into 985 shares of common stock. On February 4, 2018, pursuant to a conversion notice, $22,500 in principal and $2,650 in interest was converted at $40 per share into 629 shares of common stock. On February 13, 2018, pursuant to a conversion notice, $20,000 in principal and $1,276 in interest was converted at $35 per share into 572 shares of common stock. On February 21, 2018, pursuant to a conversion notice, $40,000 in principal and $4,986 in interest was converted at $40 per share into 1,144 shares of common stock On February 23, 2018, pursuant to a conversion notice, $25,000 in principal and $1,173 in interest was converted at $35 per share into 704 shares of common stock. On February 23, 2018, pursuant to a conversion

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 7 – COMMITMENTS AND CONTINGENCIES Legal Matters A complaint against us, dated September 26, 2019, has been filed by Foley Shechter Ablovatskiy (“Foley Shechter”), our former counsel, seeking $151,031.50 in legal fees, in addition to interest and costs of suit. The Company believes these claims to be unfounded and is vigorously defending itself. To that end, the Company filed a motion to dismiss certain counts of the complaint, with prejudice. That motion remains pending with the Supreme Court of the State of New York, County of New York. Upon resolution of the motion, the Company shall file an answer, together with affirmative defenses and counterclaims. The counterclaims shall include, without limitation, malpractice claims, arising out of Foley Shechter’s grossly negligent mishandling of certain transactions and excessive billing related thereto. Certain amounts related to this claim are included in accounts payable and accrued expenses in the accompanying Financial Statements. Regal Consulting, LLC (“Regal”) initiated litigation against the Company in Clark County District Court, Nevada. The Court entered a default judgment against the Company on December 17, 2019. However, Regal, through counsel, has agreed to execute a stipulation to vacate the default and proceed with litigation. Regal is demanding approximately $400,000 and 60,000 shares of the Company’s common stock as payment for services that Regal purports to have performed. The Company intends to vigorously defend itself against Regal’s unsubstantiated claims and no loss contingency can be estimated at this time. In addition to the above, from time to time, we may be involved in litigation in the ordinary course of business. Other than as set forth above, we are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. Other than as set forth above, to our knowledge, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of our executive officers or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or any of our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect. IRS Liability As part of its requirement for having a foreign operating subsidiary, the Company’s parent U.S. entity is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $10,000 per year, or $30,000 in total, plus accrued interest, such penalty and interest having been accrued and is included in the Accrued expenses and other payable figure in the Balance Sheet. The Company recorded the penalties for all three years during the year ended June 30, 2018 and is negotiating a payment plan. The Company is current on all subsequent filings. Operating Agreements In November 2009, the Company entered into a commercialization agreement with the University of Bath (UK) (the “University”) whereby the Company and the University co-owned the intellectual property relating to the Company’s pro-enzyme formulations. In June 2012, the Company and the University entered into an assignment and amendment whereby the Company assumed full ownership of the intellectual property while agreeing to pay royalties of 2% of net revenues to the University. Additionally, the Company agreed to pay 5% of each and every license agreement subscribed for. The contract is cancellable at any time by either party. To date, no amounts are owed under the agreement. Operating Leases On May 5, 2016, the Company entered into a new five-year operating lease agreement with a Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our CEO, CFO and a director, and his wife are owners and directors, with monthly rent of $3,606 AUD or $2,469 USD, inclusive of GST (See Note 8 – Related Party Transactions). ROU is summarized below: December 31, 2019 Office lease ROU $ 48,662 Less accumulated reduction (13,271 ) Balance of ROU asset as of December 31, 2019 $ 35,391 Operating lease liability related to the ROU asset is summarized below: December 31, 2019 Office lease liability $ 48,662 Reduction of lease liability (11,352 ) Total 37,310 Less: current portion (14,216 ) Long term portion of lease liability as of December 31, 2019 $ 23,094 Future Minimum lease payments under non-cancelable operating lease at December 31, 2019 are as follows: Remainder Fiscal Year 2020 $ 15,120 Year 2021 23,119 Total 38,239 Imputed interest (929 ) Total operating lease liability $ 37,310 Amatsigroup Agreement The Company entered into a Manufacturing Services Agreement (the “MSA”) and Quality Assurance Agreement (the “QAA”), each with an effective date of August 12, 2016, with Amatsigroup NV (“Amatsigroup”), formerly known as Q-Biologicals, NV, a contract manufacturing organization located in Belgium. Pursuant to the MSA, Amatsigroup produces certain drug substances and products containing certain enzymes for the Company at its facility in Belgium. The Company uses these substances and products for development purposes, including but not limited to future clinical trials. The MSA contemplates payment to Amatsigroup pursuant to a pre-determined fee schedule based on the completion of certain milestones that depend on our manufacturing requirements and final batch yield. The Company anticipates that its payments to Amatsigroup under the MSA will range between $2.5 million and $5.0 million over three years, when the finished drug product is manufactured and released for clinical trials. The Company has spent a total of $1,689,146 of costs to date under this contract of which $1,689,146 was expensed in prior years. The MSA shall continue for a term of three years unless extended by mutual agreement in writing. The Company can terminate the MSA early for any reason upon the required notice period, however, in such event, the pre-payment paid upon signing the MSA is considered non-refundable. Each party to the MSA shall have the right to terminate the MSA by written notice to the other party if the other party commits a material breach of the MSA (subject to a 30-day cure period). The QAA sets forth the parties respective obligations and responsibilities relating to the manufacturing and testing of the products under the MSA. The agreements with Amatsigroup contain certain customary representations, warranties and limitations of liabilities, and confidentiality and indemnity obligations. Collaboration Agreement On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaen (the “University”) to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 52,000 Euros ($59,508 USD) in year one and a maximum of 40,000 Euros ($45,775 USD) in year two. Additionally, in exchange for full ownership of the intellectual property the Company agreed to pay royalties of 2% of net revenues to the University.	NOTE 9 – COMMITMENTS AND CONTINGENCIES Legal Matters A complaint against us, dated September 26, 2019, has been filed by Foley Shechter Ablovatskiy (“Foley Shechter”), our former counsel, seeking $150,000 for legal fees, among other fees. The Company believes these claims to be unfounded and the Company is continuing to vigorously defend itself against this lawsuit and is preparing to file an answer with the Supreme Court of the State of New York County of New York, together with counterclaims against the plaintiff, including, without limitation, malpractice claims, arising out of Foley Shechter’s grossly negligent mishandling of the matter and excessive billing. Certain amounts related to this claim are included in accounts payable and accrued expenses in the accompanying Financial Statements. We have received a demand letter, dated October 10, 2019, from Regal Consulting, LLC (“Regal”), our former consultant. Notwithstanding the termination of our agreement with Regal, Regal is demanding approximately $400,000 and 60,000 shares of our common stock as payment for services that Regal purports to have performed, even though no timely invoices were sent and no descriptions of the services were ever provided. The Company is continuing to vigorously defend itself against Regal’s unsubstantiated claims and no loss contingency can be estimated at this time. In addition to the above, from time to time, we may be involved in litigation in the ordinary course of business. Other than as set forth above, we are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. Other than as set forth above, to our knowledge, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of our executive officers or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or any of our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect. IRS Liability As part of its requirement for having a foreign operating subsidiary, the Company is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $10,000 per year, or $30,000 in total, plus accrued interest. The Company recorded the penalties for all three years during the year ended June 30, 2018 and is negotiating a payment plan. The Company is current on all subsequent filings. Operating Agreements In November 2009, the Company entered into a commercialization agreement with the University of Bath (UK) (the “University”) whereby the Company and the University co-owned the intellectual property relating to the Company’s pro-enzyme formulations. In June 2012, the Company and the University entered into an assignment and amendment whereby the Company assumed full ownership of the intellectual property while agreeing to pay royalties of 2% of net revenues to the University. Additionally, the Company agreed to pay 5% of each and every license agreement subscribed for. The contract is cancellable at any time by either party. To date, no amounts are owed under the agreement. Operating Leases On May 4, 2016, the Company entered into a new five-year operating lease agreement with a Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our CEO and a director, and his wife are owners and directors, with monthly rent of $3,300 AUD or $2,325 USD, inclusive of GST (See Note 10 – Related Party Transactions). Future minimum operating lease commitments consisted of the following at June 30, 2019: Fiscal Year Ended June 30, Amount 2020 $ 27,756 2021 $ 25,443 Rent expense for the fiscal year ended June 30, 2019 and 2018 was $28,062 and $30,521, respectively. Amatsigroup Agreement The Company entered into a Manufacturing Services Agreement (the “MSA”) and Quality Assurance Agreement (the “QAA”), each with an effective date of August 12, 2016, with Amatsigroup NV (“Amatsigroup”), formerly known as Q-Biologicals, NV, a contract manufacturing organization located in Belgium. Pursuant to the MSA, Amatsigroup produces certain drug substances and products containing certain enzymes for the Company at its facility in Belgium. The Company uses these substances and products for development purposes, including but not limited to future clinical trials. The MSA contemplates payment to Amatsigroup pursuant to a pre-determined fee schedule based on the completion of certain milestones that depend on our manufacturing requirements and final batch yield. The Company anticipates that its payments to Amatsigroup under the MSA will range between $2.5 million and $5.0 million over three years, when the finished drug product is manufactured and released for clinical trials. The Company has spent a total of $1,689,146 of costs to date under this contract of which $1,639,192 was expensed in prior years and $49,854 was expensed in the year ended June 30, 2019. The MSA shall continue for a term of three years unless extended by mutual agreement in writing. The Company can terminate the MSA early for any reason upon the required notice period, however, in such event, the pre-payment paid upon signing the MSA is considered non-refundable. Each party to the MSA shall have the right to terminate the MSA by written notice to the other party if the other party commits a material breach of the MSA (subject to a 30-day cure period). The QAA sets forth the parties’ respective obligations and responsibilities relating to the manufacturing and testing of the products under the MSA. The agreements with Amatsigroup contain certain customary representations, warranties and limitations of liabilities, and confidentiality and indemnity obligations. Investment Banking Agreements On February 23, 2018, the Company entered into an agreement with an effective date of February 14, 2018 with a certain investment bank, pursuant to which the Company retained the investment bank as its placement agent. As of December 31, 2018, no funds have been raised pursuant to this agreement and the agreement expired on its terms. On February 4, 2019, the Company entered into an agreement with a certain investment bank (the “Investment Bank”), pursuant to which the Company retained the Investment Bank as its exclusive placement agent through May 31, 2019. In the event of the closing of an offering during such period (or the tail period after, if applicable) the Investment Bank would receive a percentage of the proceeds in cash and a percentage of the shares of common stock issued by the Company in the offering as warrants. As of June 30, 2019, no funds have been raised pursuant to this agreement. Collaboration Agreement On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 52,000 Euros ($59,508 USD) in year one and a maximum of 40,000 Euros ($45,775 USD) in year two. Additionally, in exchange for full ownership of the intellectual property the Company agreed to pay royalties of 2% of net revenues to the University.

Related Party Transactions

Related Party Transactions	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 8 – RELATED PARTY TRANSACTIONS Since its inception, the Company has conducted transactions with its directors and entities related to such directors. These transactions have included the following: As of December 31, 2019 and June 30, 2019, the Company owed a current and a former director a total of $52,022 and $51,867, respectively, for money loaned to the Company throughout the years. The total loans balance owed at December 31, 2019 and June 30, 2019 is not interest bearing (See Note 4 – Loans and Notes Payable). As of December 31, 2019 and June 30, 2019, the Company owed its former director a total of $31,257 and $31,164, respectively, related to expenses paid on behalf of the Company related to corporate startup costs and intellectual property (See Note 3 – Due to Former Director – Related Party). Effective May 5, 2016, the Company entered into an agreement for the lease of its principal executive offices with North Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our CEO, CFO and a director, and his wife are owners and directors. The lease has a five-year term and provides for annual rental payments of $42,048 AUD or $28,790 USD, which includes $3,823 AUD or $2,618 USD of goods and service tax for total payments of $210,242 AUD or $143,953 USD during the term of the lease. As of December 31, 2019, total payments of $59,943AUD or $41,044 USD remain on the lease. (See Note 7 – Commitments and Contingencies) The Company and Mr. Nathanielsz entered into an employment agreement as of February 25, 2015 (the “Nathanielsz Employment Agreement”) setting forth the terms and conditions of Mr. Nathanielsz employment as the Company’s President and Chief Executive Officer. The Nathanielsz Employment Agreement was scheduled to expire on February 25, 2019; however, the term of the Nathanielsz Employment Agreement automatically renews for successive one-year periods unless either party provides 30 days’ prior written notice of its intent not to renew. The Nathanielsz Employment Agreement continues in effect as of December 31, 2019. The Nathanielsz Employment Agreement provides Mr. Nathanielsz with a base salary of $25,000 AUD per month ($300,000 AUD annually or $205,680 USD) and a monthly contribution to Mr. Nathanielsz’s pension equal to 9.5% of his monthly salary. Mr. Nathanielsz has the ability to convert any accrued but unpaid salary into common stock at the end of each fiscal year at a conversion price to be determined by Mr. Nathanielsz and the Company, which will in no event be lower than par value or higher than the closing bid price on the date of conversion. Pursuant to the Nathanielsz Employment Agreement, Mr. Nathanielsz is entitled to an annual discretionary bonus in an amount up to 200% of his annual base salary, which bonus shall be determined by the Company’s board of directors based upon the performance of the Company. On March 16, 2018, the Company’s board of directors approved an increase of Mr. Nathanielsz’s annual base salary from $300,000 AUD ($205,680 USD) to $400,000 AUD ($274,240 USD), effective February 2018. Mr. Nathanielsz’s wife, Sylvia Nathanielsz, is and has been a non-executive part-time employee of the Company since October 2015. Effective February 1, 2018. Mrs. Nathanielsz receives an annual salary of $82,272 and is entitled to customary benefits. Pursuant to a February 25, 2016 board resolution, James Nathanielsz shall be paid $4,481 AUD ($3,205 USD), on a monthly basis for the purpose of acquiring and maintaining an automobile. For the six months ended December 31, 2019, a total of $21,378 AUD ($14,638 USD) in payments have been made with respect to Mr. Nathanielsz’s car allowance. Pursuant to the approval of the Company’s board of directors, on March 16, 2018, Mr. Nathanielsz was granted a $300,000 AUD ($210,090 USD) bonus for accomplishments achieved while serving as the Company’s Chief Executive Officer during the fiscal year ended June 30, 2018. A total of $80,046 AUD ($56,056 USD) in payments were made in the year ended June 30, 2018. During the nine months ended March 31, 2019, an additional $219,954 AUD ($154,100 USD) was paid. Such bonus was fully paid to Mr. Nathanielsz as of June 30, 2019. Pursuant to the approval of the Company’s board of directors, on May 14, 2019, Mr. Nathanielsz was granted a $460,000 AUD ($315,376 USD) bonus for accomplishments achieved while serving as the Company’s Chief Executive Officer during the fiscal year ended June 30, 2019 with $200,000 AUD ($137,120 USD) of such bonus payable by the Corporation to the CEO throughout the Corporation’s 2019 fiscal year as the Corporation’s cash resources allow, with the remaining $260,000 AUD ($178,256 USD) of such bonus to be deferred by the CEO until a future date when the Corporation’s cash resources allow for such payment, as agreed to by the CEO. A total of $90,000 AUD ($64,377 USD) in payments were made in the year ended June 30, 2019. A total of $137,620 AUD ($94,228 USD) in payments were made in the six months ended December 31, 2019, with $232,380 AUD ($163,363 USD) remaining due and payable. New Employment and Services Agreements with Management Amended and Restated Employment Agreement ― On May 14, 2019 (the “Effective Date”), the Company entered into an Amended and Restated Employment Agreement (the “Employment Agreement”) with James Nathanielsz, the Company’s Chief Executive Officer, Chairman, acting Chief Financial Officer and a director, for a term of three years, subject to automatic one-year renewals, at an annual salary of $400,000 AUD. Pursuant to the Employment Agreement, Mr. Nathanielsz was granted options to purchase 39,000 shares of the Company’s common stock (the “Nathanielsz Options”), with an exercise price per share of $4.675 (110% of the closing market price of the Company’s common stock on May 14, 2019 (or $4.25), the date of approval of such grant by the Company’s board of directors), (ii) 39,000 restricted stock units of the Company (the “Initial Nathanielsz RSUs”), and (iii) an additional 39,000 restricted stock units of the Company (the “Additional Nathanielsz RSUs”). Such options and restricted stock units were granted pursuant to the 2019 Plan (as defined below) approved by the Company’s board of directors on the Effective Date. The Nathanielsz Options have a term of 10 years from the date of grant. 1/3rd of the Nathanielsz Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Mr. Nathanielsz is employed by the Company and subject to the other provisions of the Employment Agreement. The Initial Nathanielsz RSUs shall vest on the one-year anniversary of the Effective Date, subject to Mr. Nathanielsz’s continued employment with the Company through such vesting date. The Additional Nathanielsz RSUs will vest as follows, subject to Mr. Nathanielsz’s continued employment with the Company through the applicable vesting date: (i) 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company submitting Clinical Trial Application (the “CTA”) for PRP, the Company’s lead product candidate (“PRP”), for a First-In-Human study for PRP (the “Study”) in an applicable jurisdiction to be selected by the Company, (ii) 7,800 of the Additional Nathanielsz RSUs shall vest upon the CTA being approved in an applicable jurisdiction, (iii) 7,800 of the Additional RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iv) 7,800 of the Additional Nathanielsz RSUs shall vest upon the shares of the Company’s Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (v) the remaining 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested restricted stock unit shall be settled by delivery to Mr. Nathanielsz of one share of the Company’s common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company’s board of directors and subject to the 2019 Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Employment Agreement), (ii) the date that is ten business days following the vesting of such restricted stock unit, (iii) the date of Mr. Nathanielsz’s death or Disability (as defined in the Employment Agreement), and (iv) Mr. Nathanielsz’s employment being terminated either by the Company without Cause or by Mr. Nathanielsz for Good Reason (each as defined in the Employment Agreement). In the event of a Change of Control, any unvested portion of the Nathanielsz Options and such restricted stock units shall vest immediately prior to such event. The 78,000 restricted stock units were valued at the fair value of $4.25 per unit or $331,500 based on the quoted trading price on the date of grant. The 39,000 stock options were valued using a Black-Scholes model with the following assumptions: stock price at valuation date of $4.25 based on quoted trading price on date of grant, exercise price of $4.65, dividend yield of zero, years to maturity of 10.00, a risk free rate of 2.42%, and expected volatility 268% for a total value of $165,747 (see Note 6 – Stockholders’ Deficit). Amended and Restated Services Agreement ― On the Effective Date, the Company also entered into an Amended and Restated Services Agreement (the “Services Agreement”) with Dr. Kenyon, the Company’s Chief Scientific Officer and a director, for a term of three years, subject to automatic one-year renewals, at an annual salary of $54,000 AUD. In connection with the execution of the Services Agreement, Dr. Kenyon was designated as an executive officer of the Company and assumed a more active executive role with the Company. Pursuant to the Services Agreement, Dr. Kenyon was granted options to purchase 19,500 shares of the Company’s common stock (the “Kenyon Options”), with an exercise price per share of $4.25 (100% of the closing market price of the Company’s common stock on May 14, 2019, the date of approval of such grant by the Company’s board of directors), (ii) 19,500 restricted stock units of the Company (the “Initial Kenyon RSUs”), and (iii) an additional 19,500 restricted stock units of the Company (the “Additional Kenyon RSUs”). Such options and restricted stock units were granted pursuant to the 2019 Plan (as defined below) approved by the Company’s board of directors on the Effective Date. The Kenyon Options have a term of 10 years from the date of grant. 1/3rd of the Kenyon Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Dr. Kenyon is employed by the Company and subject to the other provisions of the Services Agreement. The Initial Kenyon RSUs shall vest on the one-year anniversary of the Effective Date, subject to Dr. Kenyon’s continued employment with the Company through such vesting date. The Additional Kenyon RSUs will vest as follows, subject to Dr. Kenyon’s continued employment with the Company through the applicable vesting date: (i) 4,875 of the Additional Kenyon RSUs shall vest upon the Company submitting the CTA for PRP for the Study in an applicable jurisdiction to be selected by the Company, (ii) 4,875 of the Additional Kenyon RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iii) 4,875 of the Additional Kenyon RSUs shall vest upon the shares of the Company’s Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (iv) the remaining 4,875 of the Additional Kenyon RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested Kenyon RSU shall be settled by delivery to Mr. Kenyon of one share of the Company’s common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company’s board of directors and subject to the Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Services Agreement), (ii) the date that is ten business days following the vesting of such Kenyon RSU, (iii) the date of Dr. Kenyon’s death or Disability (as defined in the Services Agreement), and (iv) Dr. Kenyon’s employment being terminated either by the Company without Cause or by Dr. Kenyon for Good Reason (as defined in the Services Agreement). In the event of a Change of Control (as defined in the Services Agreement), 50% of any unvested portion of the Kenyon Options and the Kenyon RSUs shall vest immediately prior to such event. The 39,000 restricted stock units were valued at the fair value of $4.25 per unit or $165,750 based on the quoted trading price on the date of grant. The 19,500 stock options were valued using a Black-Scholes model with the following assumptions: stock price at valuation date of $4.25 based on quoted trading price on date of grant, exercise price of $4.25, dividend yield of zero, years to maturity of 10.00, a risk free rate of 2.42%, and expected volatility 268% for a total value of $82,873 (see Note 6 – Stockholders’ Deficit).	NOTE 10 – RELATED PARTY TRANSACTIONS Since its inception, the Company has conducted transactions with its directors and entities related to such directors. These transactions have included the following: As of June 30, 2019 and 2018, the Company owed a current and a former director a total of $51,867 and $54,753, respectively, for money loaned to the Company throughout the years. The total loans balance owed at June 30, 2019 and 2018 is not interest bearing (See Note 5 – Loans and Notes Payable). As of June 30 2019, and 2018, the Company owed its former director a total of $31,164 and $32,898, respectively, related to expenses paid on behalf of the Company related to corporate startup costs and intellectual property (See Note 4 – Due to Former Director – Related Party). Effective May 5, 2016, the Company entered into an agreement for the lease of its principal executive offices with North Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our CEO, CFO and a director, and his wife are owners and directors. The lease has a five-year term and provides for annual rental payments of $39,600 AUD or $28,325 USD, which includes $3,600 AUD or $2,575 USD of goods and service tax for total payments of $198,000 AUD or $141,629 USD during the term of the lease. As of June 30, 2019, total payments of $75,900 AUD or $54,291 USD remain on the lease. The Company and Mr. Nathanielsz entered into an employment agreement as of February 25, 2015 (the “Nathanielsz Employment Agreement”) setting forth the terms and conditions of Mr. Nathanielsz employment as the Company’s President and Chief Executive Officer. The Nathanielsz Employment Agreement was scheduled to expire on February 25, 2019; however, the term of the Nathanielsz Employment Agreement automatically renews for successive one-year periods unless either party provides 30 days’ prior written notice of its intent not to renew. The Nathanielsz Employment Agreement continues in effect as of June 30, 2019. Also see Note 13 – Subsequent Events. The Nathanielsz Employment Agreement provides Mr. Nathanielsz with a base salary of $25,000 AUD per month ($300,000 AUD annually or $214,590 USD) and a monthly contribution to Mr. Nathanielsz’s pension equal to 9.5% of his monthly salary. Mr. Nathanielsz has the ability to convert any accrued but unpaid salary into common stock at the end of each fiscal year at a conversion price to be determined by Mr. Nathanielsz and the Company, which will in no event be lower than par value or higher than the closing bid price on the date of conversion. Pursuant to the Nathanielsz Employment Agreement, Mr. Nathanielsz is entitled to an annual discretionary bonus in an amount up to 200% of his annual base salary, which bonus shall be determined by the Company’s board of directors based upon the performance of the Company. On March 16, 2018, the Company’s board of directors approved an increase of Mr. Nathanielsz’s annual base salary from $300,000 AUD ($211,380 USD) to $400,000 AUD ($286,120 USD), effective February 2018. Mr. Nathanielsz’s wife, Sylvia Nathanielsz, is and has been a non-executive part-time employee of the Company since October 2015. Effective February 1, 2018, Mrs. Nathanielsz receives an annual salary of $75,000 AUD ($53,648 USD) and is entitled to customary benefits. Pursuant to a February 25, 2016 board resolution, James Nathanielsz shall be paid $4,481 AUD ($3,205 USD), on a monthly basis for the purpose of acquiring and maintaining an automobile. For the fiscal year ended June 30, 2019, a total of $53,772 AUD ($38,463 USD) in payments have been made with respect to Mr. Nathanielsz’s car allowance. Pursuant to the approval of the Company’s board of directors, on March 16, 2018, Mr. Nathanielsz was granted a $300,000 AUD bonus for accomplishments achieved while serving as the Company’s Chief Executive Officer during the fiscal year ended June 30, 2018. A total of $80,046 AUD in payments were made in the year ended June 30, 2018. During the nine months ended March 31, 2019, an additional $219,954 AUD was paid. Such bonus was fully paid to Mr. Nathanielsz as of June 30, 2019. Pursuant to the approval of the Company’s board of directors, on May 14, 2019, Mr. Nathanielsz was granted a $460,000 AUD ($329,038 USD) bonus for accomplishments achieved while serving as the Company’s Chief Executive Officer during the fiscal year ended June 30, 2019 with $200,000 AUD ($143,060 USD) of such bonus payable by the Corporation to the CEO throughout the Corporation’s 2019 fiscal year as the Corporation’s cash resources allow, with the remaining $260,000 AUD ($185,978 USD) of such bonus to be deferred by the CEO until a future date when the Corporation’s cash resources allow for such payment, as agreed to by the CEO. A total of $90,000 AUD ($64,377 USD) in payments were made in the year ended June 30, 2019. During the fiscal year ended June 30, 2019, an additional $219,954 AUD ($157,333) was paid in relation to the bonus awarded to Mr. Nathanielsz on March 16, 2018. Such bonus has now been fully paid to Mr. Nathanielsz. New Employment and Services Agreements with Management Amended and Restated Employment Agreement ― On May 14, 2019 (the “Effective Date”), the Company entered into an Amended and Restated Employment Agreement (the “Employment Agreement”) with James Nathanielsz, the Company’s Chief Executive Officer, Chairman, acting Chief Financial Officer and a director, for a term of three years, subject to automatic one-year renewals, at an annual salary of $400,000 AUD. Pursuant to the Employment Agreement, Mr. Nathanielsz was granted options to purchase 39,000 shares of the Company’s common stock (the “Nathanielsz Options”), with an exercise price per share of $4.675 (110% of the closing market price of the Company’s common stock on May 14, 2019 (or $4.25), the date of approval of such grant by the Company’s board of directors), (ii) 39,000 restricted stock units of the Company (the “Initial Nathanielsz RSUs”), and (iii) an additional 39,000 restricted stock units of the Company (the “Additional Nathanielsz RSUs”). Such options and restricted stock units were granted pursuant to the 2019 Plan (as defined below) approved by the Company’s board of directors on the Effective Date. The Nathanielsz Options have a term of 10 years from the date of grant. 1/3 rd The 78,000 restricted stock units were valued at the fair value of $4.25 per unit or $331,500 based on the quoted trading price on the date of grant. The 39,000 stock options were valued using a Black-Scholes model with the following assumptions: stock price at valuation date of $4.25 based on quoted trading price on date of grant, exercise price of $4.65, dividend yield of zero, years to maturity of 10.00, a risk free rate of 2.42%, and expected volatility 268% for a total value of $165,747 (see Note 8 – Stockholders’ Deficit). Amended and Restated Services Agreement ― On the Effective Date, the Company also entered into an Amended and Restated Services Agreement (the “Services Agreement”) with Dr. Kenyon, the Company’s Chief Scientific Officer and a director, for a term of three years, subject to automatic one-year renewals, at an annual salary of $54,000 AUD. In connection with the execution of the Services Agreement, Dr. Kenyon was designated as an executive officer of the Company and assumed a more active executive role with the Company. Pursuant to the Services Agreement, Dr. Kenyon was granted options to purchase 19,500 shares of the Company’s common stock (the “Kenyon Options”), with an exercise price per share of $4.25 (100% of the closing market price of the Company’s common stock on May 14, 2019, the date of approval of such grant by the Company’s board of directors), (ii) 19,500 restricted stock units of the Company (the “Initial Kenyon RSUs”), and (iii) an additional 19,500 restricted stock units of the Company (the “Additional Kenyon RSUs”). Such options and restricted stock units were granted pursuant to the 2019 Plan (as defined below) approved by the Company’s board of directors on the Effective Date. The Kenyon Options have a term of 10 years from the date of grant. 1/3 rd The 39,000 restricted stock units were valued at the fair value of $4.25 per unit or $165,750 based on the quoted trading price on the date of grant. The 19,500 stock options were valued using a Black-Scholes model with the following assumptions: stock price at valuation date of $4.25 based on quoted trading price on date of grant, exercise price of $4.25, dividend yield of zero, years to maturity of 10.00, a risk free rate of 2.42%, and expected volatility 268% for a total value of $82,873 (see Note 8 – Stockholders’ Deficit).

Concentrations and Risks

Concentrations and Risks	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Risks and Uncertainties [Abstract]
Concentrations and Risks	NOTE 9 – CONCENTRATIONS AND RISKS Concentration of Credit Risk The Company maintains its cash in banks and financial institutions in Australia. Bank deposits in Australian banks are uninsured. The Company has not experienced any losses in such accounts through December 31, 2019. Receivable Concentration As of December 31, 2019 and June 30, 2019, the Company’s receivables were 100% related to reimbursements on GST taxes paid. Patent and Patent Concentration The Company has filed multiple patent applications relating to its lead product, PRP. The Company’s lead patent application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Mexico, Republic of Korea and India. In Brazil and Canada, the patent application remains under examination. In 2016 and early 2017, we filed other patent applications. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries. Once filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national phase. One of the PCT applications filed in November 2016, entered national phase in July 2018 and another PCT application is currently entering national phase in August 2018. A third PCT application entered the national phase in October 2018. Further patent applications are expected to be filed to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer. Foreign Operations As of December 31, 2019 and June 30, 2019, the Company’s operations are based in Camberwell, Australia, however the majority of research and development is being conducted in the European Union. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application with the European Medicines Agency as a small and medium-sized enterprise. As of December 31, 2019, there has been no activity within this entity.	NOTE 11 – CONCENTRATIONS AND RISKS Concentration of Credit Risk The Company maintains its cash in banks and financial institutions in Australia. Bank deposits in Australian banks are uninsured. The Company has not experienced any losses in such accounts through June 30, 2019. The Company currently primarily relies on funding from two convertible debt lenders. Proceeds received in the year from each of the two lenders were $1,577,018 and $951,900, respectively, which represents approximately 55% and 33%, respectively of total proceeds received by the Company during fiscal year 2018. The Company currently primarily relies on funding from three convertible debt lenders. Proceeds received in the year from each of the three lenders were $621,000, $362,000 and $200,000, respectively, which represents approximately 45%, 26% and 15%, respectively of total proceeds received by the Company during fiscal year 2019. Receivable Concentration As of June 30, 2019 and 2018, the Company’s receivables were 100% related to reimbursements on GST taxes paid. Patent and Patent Concentration The Company has filed multiple patent applications relating to its lead product, PRP. The Company’s lead patent application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Mexico, Republic of Korea and India. In Brazil and Canada, the patent application remains under examination. In 2016 and early 2017, we filed other patent applications. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries. Once filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national phase. One of the PCT applications filed in November 2016, entered national phase in July 2018 and another PCT application is currently entering national phase in August 2018. A third PCT application entered the national phase in October 2018. Further patent applications are expected to be filed to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer. Foreign Operations As of June 30, 2019 and 2018, the Company’s operations are based in Camberwell, Australia, however the majority of research and development is being conducted in the European Union. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application with the European Medicines Agency as a small and medium-sized enterprise. As of June 30, 2019, there has been no activity within this entity.

Derivative Financial Instrument

Derivative Financial Instruments and Fair Value Measurements	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments and Fair Value Measurements	NOTE 10 - DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivative Financial Instruments: The Company had $216,400 of convertible debt, that contain embedded conversion options and is treated as derivative instruments outstanding at December 31, 2019. The Company calculates the estimated fair values of the liabilities for derivative instruments using the Binomial Trees Method. The closing price of the Company’s common stock at December 31, 2019, the last trading day of the quarter ended December 31, 2019, was $0.38. Volatility, expected remaining term and risk free interest rates used to estimate the fair value of derivative liabilities at December 31, 2019 are indicated in the table that follows. The expected term is equal to the remaining term of the warrants or convertible instruments and the risk free rate is based upon rates for treasury securities with the same term. Convertible Debt Initial Valuations into during the six December 31, 2019 Volatility 227.82 % 227.82 % Expected Remaining Term (in years) 1 00.39 – 0.91 Risk Free Interest Rate 1.59 % 1.48% – 1.59 % Expected dividend yield None None Fair Value Measurements: The Company measures and reports at fair value the liability for derivative instruments. The fair value liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the Binomial Trees model. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2019: Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 924,744 $ — $ — $ 924,744 Total $ 924,744 $ — $ — $ 924,744 The following is a roll forward for the six months ended December 31, 2019 of the fair value liability of price adjustable derivative instruments: Fair Value of Liability for Derivative Instruments Balance at June 30, 2019 $ 698,264 Initial fair value of embedded conversion option derivative liability recorded as debt discount 115,000 Initial fair value of embedded conversion option derivative liability recorded as expense 93,125 Reductions due to conversions (44,588 ) Change in fair value included in statements of operations 62,943 Balance at December 31, 2019 $ 924,744	NOTE 12 - DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivative Financial Instruments: The Company applies the provisions of ASC 815-40, Contracts in Entity’s Own Equity The Company calculates the estimated fair values of the liabilities for derivative instruments using the Binomial Trees Method. The closing price of the Company’s common stock at June 28, 2019, the last trading day of the fiscal year ended June 30, 2019, was $6.00. Volatility, expected remaining term and risk free interest rates used to estimate the fair value of derivative liabilities at June 30, 2019 are indicated in the table that follows. The expected term is equal to the remaining term of the warrants or convertible instruments and the risk free rate is based upon rates for treasury securities with the same term. Warrants June 30, 2018 June 30, 2019 Volatility 110 % N/A Expected remaining term .25 N/A Risk-free interest rate 1.93 % N/A Expected dividend yield None N/A Convertible Debt Initial Valuations June 30, 2018 June 30, 2019 Volatility 320 % 191 - 221 % 355 % Expected remaining term 1.00 0.56 - 1.1 0.11 - 0.90 Risk-free interest rate 2.32 % 2.11 - 2.33 % 1.92 - 2.15 % Expected dividend yield None None None Fair Value Measurements: The Company measures and reports at fair value the liability for derivative instruments. The fair value liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the Binomial Trees model. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2019: Balance at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 698,264 $ — $ — $ 698,264 Total $ 698,264 $ — $ — $ 698,264 The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2018: Balance at Quoted Prices Significant Significant (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 371,532 $ — $ — $ 371,532 Total $ 371,532 $ — $ — $ 371,532 The following is a roll forward for the years ended June 30, 2019 and 2018 of the fair value liability of price adjustable derivative instruments: Fair Value of Liability for Derivative Instruments Balance at June 30, 2017 $ 881,172 Effects of foreign currency exchange rate changes 38 Reductions due to conversions (861,695 ) Reductions due to repayment of debt (199,339 ) Initial fair value of embedded conversion option derivative liability recorded as debt discount 543,744 Initial fair value of embedded conversion option derivative liability recorded as change in fair value of embedded conversion option 313,694 Change in fair value included in statements of operations (306,082 ) Balance at June 30, 2018 371,532 Reductions due to repayment of debt (936,650 ) Reduction due to conversions (1,388,764 ) Initial fair value of embedded conversion option derivative liability recorded as debt discount 180,000 Initial fair value of embedded conversion option derivative liability recorded as change in fair value of embedded conversion option 382,944 Change in fair value included in statements of operations 2,089,202 Balance at June 30, 2019 $ 698,264

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 11 – SUBSEQUENT EVENTS Note Conversions From January 1, 2020 through the date of this filing , the Company issued 2,804,424 shares of its common stock at an average contractual conversion price of $0.1654, ranging from $0.0672 to $0.75, as a result of the conversion of principal and interest in the aggregate amount of $267,187 underlying certain outstanding convertible notes converted during such period. Notes totaling $82,500 contained bifurcated embedded conversion option derivatives. Accordingly the fair market value of shares issued was $228,863 resulting in a loss on extinguishment of $146,367. The Company reclassified $410,750 in put premiums to additional paid in capital following conversions from January 1, 2020 through the date of this filing. Increase in Authorized Common Stock On February 4, 2020 the Directors resolved to increase the Common Stock of the Company from 100,000,000 authorized shares to 1,000,000,000 authorized shares and believes that such number of authorized shares of Common Stock will be in the best interests of the Corporation and its stockholders because the Board believes that the availability of more shares of Common Stock for issuance will allow the Corporation greater flexibility in pursuing financing from investors, meeting business needs as they arise, taking advantage of favorable opportunities and responding to a changing corporate environment. The Company filed the necessary documents with the U.S. Securities and Exchange Commission on February 6, 2020 and at the date of this filing the increase in authorized shares to 1,000,000,000 has not yet been effected. January 7, 2020 Power Up Lending Group Securities Purchase Agreement Effective January 7, 2020, the Company entered into a securities purchase agreement with Power Up Lending Group Ltd. (“Power Up”), pursuant to which Power Up purchased a convertible promissory note (the “January 7, 2020 Power Up Note”) from the Company in the aggregate principal amount of $75,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Power Up. The transaction closed on January 7, 2020 and the Company received payment on January 13, 2020 in the amount of $72,000, net of $2,500 paid directly toward legal fees and $500 to Power Up for due diligence fees. The maturity date of the January 7, 2020 Power Up Note is January 7, 2021. The January 7, 2020, Power Up Note bears interest at a rate of 8% per annum, which interest may be paid by the Company to Power Up in shares of the Company’s common stock, but shall not be payable until the January 7, 2020 Power Up Note becomes payable, whether at the maturity date or upon acceleration or by prepayment. Additionally, Power Up has the option to convert all or any amount of the principal face amount of the January 7, 2020 Power Up Note, starting on July 4, 2020 and ending on the later of the maturity date or the date the Default Amount, which is an amount equal to 150% of an amount equal to the then outstanding principal amount of the January 7, 2020 Power Up Note plus any interest accrued, is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the January 7, 2020 Power Up Note shall be $3.05, subject to certain Market Price (as defined below) adjustment. If the Market Price is greater than or equal to $5.00, the conversion price shall be the greater of 65% of the Market Price (“Variable Conversion Price”) and $3.05. In the event Market Price is less than $5.00, the conversion price shall be the Variable Conversion Price. As defined in the January 7, 2020 Power Up Note, the “Market Price” shall be the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Power Up on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Power Up. Notwithstanding the foregoing, Power Up shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Power Up and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. An aggregate total of $307,400 of this note was bifurcated with the embedded conversion option recorded as a derivative liability at fair value. The January 7, 2020 Power Up Note contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. January 7, 2020 Consulting Services Agreement On February 4, 2020, the Company entered into an agreement with a certain consultant in relation to services provided during the period ended December 31, 2019 whereby the Company agreed to issue 150,000 vested shares of the Company’s common stock to the consultant in satisfaction of those services. On February 4, 2020, the Company issued the 150,000 shares of the Company’s common stock valued at $0.14 per share; being the closing price of the stock on the date of the agreement, to such consultant, or $21,000, which amount was recorded as a share based expense in the financial statements for the six months ended December 31, 2019. January 13, 2020 Ader Alef Securities Purchase Agreements Effective January 13, 2020, the Company entered into a securities purchase agreement with Ader Alef, pursuant to which Ader Alef purchased a convertible promissory note (the “January 13, 2020 Ader Alef Note”) from the Company in the aggregate principal amount of $110,250, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Ader Alef any time after the six month anniversary of the January 13, 2020 Ader Alef Note. The January 13, 2020 Ader Alef Note contains an original discount of $5,250. The transactions contemplated by the Ader Alef Securities Purchase Agreement closed on January 13, 2020. Pursuant to the terms of the Ader Alef Securities Purchase Agreement, Ader Alef deducted $5,000 from the principal payment due under the January 13, 2020 Ader Alef Note at the time of closing, to be applied to its legal expenses and the Company received net cash proceeds of $100,000 on January 15, 2020. The Company intends to use the net proceeds from the January 13, 2020 Ader Alef Note for general working capital purposes. The maturity date of the January 13, 2020 Ader Alef is January 13, 2021. The January 13, 2020 Ader Alef Note bears interest at a rate of 8% per annum, which interest may be paid by the Company to Ader Alef in shares of the Company’s common stock; but shall not be payable until the January 13, 2020 Ader Alef Note becomes payable, whether at the maturity date or upon acceleration or by prepayment. Additionally, Ader Alef has the option to convert all or any amount of the principal face amount of the January 13, 2020 Ader Alef Note at any time from the date of issuance and ending on the later of the maturity date and the date the Default Amount, which is an amount between 112% and 135% of an amount equal to the then outstanding principal amount of the January 13, 2020 Ader Alef Note plus any interest accrued, is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the January 13, 2020 Ader Alef Note during the first 6 months the January 13, 2020 Ader Alef Note is in effect shall be fixed at $2.50 and thereafter shall be equal to a 35% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, Ader Alef shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Ader Alef and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock which may be increased up to 9.99% upon 60 days prior written notice by the Ader Alef to the Company. The note is treated as stock settled debt under ASC 480 and accordingly the Company recorded a $59,365 put premium. The January 13, 2020 Ader Alef Note contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. January 22, 2020 GS Capital Securities Purchase Agreements Effective January 22, 2020, the Company entered into a securities purchase agreement with GS Capital, pursuant to which GS Capital purchased a convertible promissory note (the “January 22, 2020 GS Note”) from the Company in the aggregate principal amount of $58,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of GS Capital any time after the six month anniversary of the January 22, 2020 GS Capital Note. The January 22, 2020 GS Note contains an original discount of $3,500. The transactions contemplated by the GS Capital Securities Purchase Agreement closed on January 22, 2020. Pursuant to the terms of the GS Capital Securities Purchase Agreement, GS Capital deducted $2,500 from the principal payment due under the January 22, 2020 GW Note, at the time of closing, to be applied to its legal expenses and received net cash proceeds of $52,000 on January 28, 2020. The Company intends to use the net proceeds from the January 22, 2020 GW Note for general working capital purposes. The maturity date of the January 22, 2020 GS Capital is January 22, 2021. The January 22, 2020 GS Capital Note bears interest at a rate of 10% per annum, which interest may be paid by the Company to GS Capital in shares of the Company’s common stock; but shall not be payable until the January 22, 2020 GS Capital Note becomes payable, whether at the maturity date or upon acceleration or by prepayment. Additionally, GS Capital has the option to convert all or any amount of the principal face amount of the January 22, 2020 GS Capital Note at any time from the date of issuance and ending on the later of the maturity date and the date the Default Amount, which is an amount between 112% and 130% of an amount equal to the then outstanding principal amount of the January 22, 2020 GS Capital Note plus any interest accrued, is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the January 22, 2020 GS Capital Note shall be equal to a 40% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, GS Capital shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by GS Capital and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock which may be increased up to 9.99% upon 60 days prior written notice by the GS Capital to the Company. The note is treated as stock settled debt under ASC 480 and accordingly the Company recorded a $38,667 put premium. The January 22, 2020 GS Note contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions.	NOTE 13 – SUBSEQUENT EVENTS On July 19, 2019, pursuant to a consulting agreement 20,000 shares of common stock were issued to the contractor as compensation for services rendered. Note Conversions On July 10, 2019, pursuant to a conversion notice, $16,500 in principal and $2,031 in interest was converted at $0.91 per share into 20,454 shares of common stock. On August 8, 2019, pursuant to a conversion notice, $21,000 in principal and $2,720.67 in interest was converted at $0.798 per share into 29,725 shares of common stock. On August 8, 2019, pursuant to a conversion notice, $28,000 in principal and $1,859.51 in interest was converted at $0.8113 per share into 36,804 shares of common stock. On September 4, 2019, pursuant to a conversion notice, $20,000 in principal and $2,711 in interest was converted at $0.63 per share into 36,049 shares of common stock. On September 9, 2019, pursuant to a conversion notice, $7,820 in principal and $574 in interest was converted at $0.63 per share into 13,360 shares of common stock. On September 18, 2019, pursuant to a conversion notice, $18,000 in principal and $2,496 in interest was converted at $0.45 per share into 45,547 shares of common stock. July 3, 2019 Securities Purchase Agreement - Power Up Lending Effective July 3, 2019, the Company entered into a securities purchase agreement with Power Up Lending Group Ltd. (“Power Up”), pursuant to which Power Up purchased a convertible promissory note (the “July 2019 Power Up Note”) from the Company in the aggregate principal amount of $78,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Power Up. The transaction closed on July 3, 2019 and the Company received payment on July 8, 2019 in the amount of $78,000, of which $2,500 was paid directly toward legal fees and $500 to Power Up for due diligence fees resulting in net cash proceeds of $75,000. The maturity date of the July 2019 Power Up Note is July 3, 2020. The July 2019, Power Up Note bears interest at a rate of 8% per annum, which interest may be paid by the Company to Power Up in shares of the Company’s common stock, but shall not be payable until the July 2019 Power Up Note becomes payable, whether at the maturity date or upon acceleration or by prepayment. Additionally, Power Up has the option to convert all or any amount of the principal face amount of the July 2019 Power Up Note, starting on December 30, 2019 and ending on the later of the maturity date and the date the Default Amount, which is an amount equal to 150% of an amount equal to the then outstanding principal amount of the July 2019 Power Up Note plus any interest accrued, is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the July 2019 Power Up Note shall be $3.25, subject to certain Market Price (as defined below) adjustment. If the Market Price is greater than or equal to $5.00, the conversion price shall be the greater of 65% of the Market Price (“Variable Conversion Price”) and $3.25. In the event Market Price is less than $5.00, the conversion price shall be the Variable Conversion Price. As defined in the July 2019 Power Up Note, the “Market Price” shall be the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Power Up on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Power Up. Notwithstanding the foregoing, Power Up shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Power Up and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. July 30, 2019 Securities Purchase Agreement - Odyssey Capital Funding LLC Effective July 30, 2019, the Company entered into a securities purchase agreement with Odyssey Capital Funding LLC,. (“Odyssey”), pursuant to which Odyssey purchased a convertible promissory note (the “July 2019 Odyssey Note”) from the Company in the aggregate principal amount of $320,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Odyssey. The July 2019 Odyssey Note contains an original discount of $25,000. The transaction closed on July 30, 2019 and the Company received payment on August 1, 2019 in the amount of $295,000, of which $10,000 was paid directly toward legal fees, resulting in net cash proceeds of $285,000. The maturity date of the July 2019 Odyssey Note is July 30, 2020. The July 2019 Odyssey Note bears interest at a rate of 10% per annum, which interest may be paid by the Company to Odyssey in shares of the Company’s common stock, but shall not be payable until the July 2019 Odyssey Note becomes payable, whether at the maturity date or upon acceleration or by prepayment. Additionally, Odyssey has the option to convert all or any amount of the principal face amount of the July 2019 Odyssey Note, starting on January 31, 2020 and ending on the later of the maturity date and the date the Default Amount, which is an amount equal to 120% of an amount equal to the then outstanding principal amount of the July 2019 Odyssey Note plus any interest accrued from July 30, 2019 at the default interest rate of 24% per annum, is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the July 2019 Odyssey Note shall be equal to 65% of the lowest closing bid price of the Common Stock as reported on the OTC Markets on which the Company’s shares are then traded or any exchange upon which the Common Stock may be traded in the future, for the ten prior trading days including the day upon which a Notice of Conversion is received by the Company. Common Stock beneficially owned by the Holder and its affiliates would exceed 4.99% of the outstanding shares of the Common Stock of the Company (which may be increased up to 9.9% upon 60 days’ prior written notice by the Holder to the Company). August 30, 2019 Securities Purchase Agreement – Auctus Fund, LLC Effective August 30, 2019, the Company entered into a securities purchase agreement with Auctus Fund, LLC (“Auctus”), pursuant to which Auctus purchased a convertible promissory note (the “August 2019 Auctus Note”) from the Company in the aggregate principal amount of $550,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Auctus. The transaction closed on August 30, 2019 and the Company received payment on September 4, 2019 in the amount of $550,000, of which $5,000 was paid directly toward legal fees and $40,000 to Auctus for due diligence fees resulting in net cash proceeds of $505,000. The maturity date of the August 2019 Auctus Note is August 30, 2020. The August 2019 Auctus Note bears interest at a rate of 10% per annum, which interest may be paid by the Company to Auctus in shares of the Company’s common stock, but shall not be payable until the August 2019 Auctus Note becomes payable, whether at the maturity date or upon acceleration or by prepayment. The August 2019 Auctus Note may not be prepaid without the written consent of Auctus. Any amount of principal or interest which is not paid when due shall bear interest at the rate of 24% per annum. Additionally, Auctus has the option to convert all or any amount of the principal face amount of the August 2019 Auctus Note, at any time following the issue date and ending on the later of the maturity date and the date the Default Amount, which is an amount equal to 125% of an amount equal to the then outstanding principal amount of the August 2019 Auctus Note (but not less than $15,000) plus any interest accrued from August 30, 2019 at the default interest rate of 24% per annum, is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the August 2019 Auctus Note shall be the Variable Conversion Price, being 60% of the Market Price. Notwithstanding the foregoing, Auctus shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Auctus and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. In connection with the issuance of the August 2019 Auctus Note, the Company issued common stock purchase warrants to Auctus to purchase 450,000 shares of the Company’s common stock (the “First Warrant”) as a commitment fee upon the terms and subject to the limitations and conditions set forth in such First Warrant at an “Exercise Price” of $2.25. In connection with the issuance of the Note, the Company shall issue a common stock purchase warrant to Buyer to purchase 300,000 shares of the Company’s common stock (the “Second Warrant”) as a commitment fee upon the terms and subject to the limitations and conditions set forth in such Second Warrant at an “Exercise Price” of $3.33. In connection with the issuance of the Note, the Company shall issue a common stock purchase warrant to Buyer to purchase 225,000 shares of the Company’s common stock (the “Third Warrant”) as a commitment fee upon the terms and subject to the limitations and conditions set forth in such Third Warrant at an “Exercise Price” of $4.50. The First Warrant, Second Warrant, and Third Warrant shall collectively be referred as the “Warrants”. The Warrants have an “Exercise Period” of five years form the date of issuance being August 30, 2019. October 1, 2019 Securities Purchase Agreement – GW Holdings Group, LLC Effective October 1, 2019, the Company entered into a securities purchase agreement with GW Holdings Group, LLC. (“GW Holdings”), pursuant to which GW Holdings purchased a convertible promissory note (the “October 2019 GW Holdings Note”) from the Company in the aggregate principal amount of $131,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of GW Holdings. The transaction closed on October 1, 2019 and the Company received payment on October 3, 2019 in the amount of $131,000, of which $6,000 was paid directly toward legal fees resulting in net cash proceeds of $125,000. The maturity date of the October 2019 GW Holdings is October 1, 2020. The October 2019 GW Holdings Note bears interest at a rate of 8% per annum, which interest may be paid by the Company to GW Holdings in shares of the Company’s common stock, but shall not be payable until the October 2019 GW Holdings Note becomes payable, whether at the maturity date or upon acceleration or by prepayment. Additionally, GW Holdings has the option to convert all or any amount of the principal face amount of the October 2019 GW Holdings Note at any time from the date of issuance and ending on the later of the maturity date and the date the Default Amount, which is an amount between 110% and 150% of an amount equal to the then outstanding principal amount of the October 2019 GW Holdings Note plus any interest accrued, is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the October 2019 GW Holdings Note shall be equal to a 40% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, GW Holdings shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by GW Holdings and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock which may be increased up to 9.99% upon 60 days prior written notice by the GW Holdings to the Company. October 3, 2019 Securities Purchase Agreement – Crown Bridge Partners, LLC Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge Partners, LLC. (“Crown Bridge”), pursuant to which Crown Bridge purchased a convertible promissory note (the “October 2019 Crown Bridge Note”) from the Company in the aggregate principal amount of $108,000, with an original issue discount of $5,000; such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Crown Bridge. The transaction closed on October 3, 2019 and the Company received payment on October 8, 2019 in the amount of $103,000, of which $3,000 was paid directly toward legal fees resulting in net cash proceeds of $100,000. The maturity date of the October 2019 Crown Bridge is October 3, 2020. The October 2019 Crown Bridge Note bears interest at a rate of 10% per annum, which interest may be paid by the Company to Crown Bridge in shares of the Company’s common stock, but shall not be payable until the October 2019 Crown Bridge Note becomes payable, whether at the maturity date or upon acceleration or by prepayment. Additionally, Crown Bridge has the option to convert all or any amount of the principal face amount of the October 2019 Crown Bridge Note at any time from the date of issuance and ending on the later of the maturity date and the date the Default Amount, which is an amount of 140% of an amount equal to the then outstanding principal amount of the October 2019 Crown Bridge Note plus any interest accrued, is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the October 2019 Crown Bridge Note shall be equal to a 40% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the Conversion Date in accordance with the Notice of Conversion. Notwithstanding the foregoing, Crown Bridge shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Crown Bridge and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock which may be increased up to 9.99% upon 60 days prior written notice by the Crown Bridge to the Company.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting and Reporting Policies (Policies)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated in Melbourne, Victoria Australia on October 15, 2007 as Propanc PTY LTD, and continues to be based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. On November 23, 2010, the Company was incorporated in the state of Delaware as Propanc Health Group Corporation. In January 2011, to reorganize the Company, we acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of December 31, 2019, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to better reflect the Company’s stage of operations and development. The Company has filed multiple patent applications relating to its lead product, PRP. The first application was filed in October 2010 in each of the countries listed in the table below. This application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Hong Kong, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Mexico, Republic of Korea and India. In Brazil and Canada, the patent application remains under examination. In 2016 and 2017 we filed other patent applications, as indicated below. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, which allows the applicants to seek protection for an invention in over 150 countries. Once national or regional applications are filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national or regional phase. One PCT application, filed in November 2016, entered the national phase in July 2018 in each of the countries listed in the table below. A second application filed in January 2017 entered the national phase commencing July 2018. A third application entered the national phase in October 2018. No. Title Country Case Status Date Filed 1. A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic reduction agent. USA, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Hong Kong, Japan, Indonesia, Israel, New Zealand, Malaysia, Singapore, Malaysia South Africa, Mexico, Republic of Korea and India Granted Oct-22-2010 Brazil and Canada Under Examination Divisional applications filed and under examination in Mexico and China USA Divisional application granted 2. Proenzyme composition Australia, Canada, China, Europe, Hong Kong, India, Indonesia, Israel, Japan, Malaysia, New Zealand, Singapore, South Africa and USA Application filed and pending Nov-11-2016 3. Cancer Treatment Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Malaysia, New Zealand, Singapore and USA Application filed and pending Jan-27-2017 4. Composition of proenzymes for cancer treatment Australia, China, Europe, Japan and USA Application filed and pending Apr-12-2017 The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development.	Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated in Melbourne, Victoria Australia on October 15, 2007 as Propanc PTY LTD, and continues to be based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. On November 23, 2010, the Company was incorporated in the state of Delaware as Propanc Health Group Corporation. In January 2011, to reorganize the Company, we acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of June 30, 2019, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to better reflect the Company’s stage of operations and development. The Company has filed multiple patent applications relating to its lead product, PRP. The first application was filed in October 2010 in each of the countries listed in the table below. This application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Mexico, Republic of Korea and India. In Brazil and Canada, the patent application remains under examination. In 2016 and 2017 we filed other patent applications, as indicated below. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, which allows the applicants to seek protection for an invention in over 150 countries. Once national or regional applications are filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national or regional phase. One PCT application, filed in November 2016, entered the national phase in July 2018 in each of the countries listed in the table below. A second application filed in January 2017 entered the national phase commencing July 2018. A third application entered the national phase in October 2018. No. Title Country Case Status Date Filed 1. A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic reduction agent. USA, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Malaysia, Singapore, Malaysia, South Africa, Mexico, Republic of Korea and India Granted Oct-22-2010 Brazil and Canada Under Examination Divisional applications filed and under examination in Mexico and China USA Divisional application granted 2. Proenzyme composition Australia, Canada, China, Europe, Hong Kong, India, Indonesia, Israel, Japan, Malaysia, New Zealand, Singapore, South Africa and USA Application filed and pending Nov-11-2016 3. Cancer Treatment Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Malaysia, New Zealand, Singapore and USA Application filed and pending Jan-27-2017 4. Composition of proenzymes for cancer treatment Australia, China, Europe, Japan and USA Application filed and pending Apr-12-2017 The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development.
Increase in Authorized Common Stock and Reverse Stock Split		Increase in Authorized Common Stock and Reverse Stock Split On January 23, 2018, Company filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock from 100,000,000 to 400,000,000. On September 21, 2018, the Company filed a Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock from 400,000,000 to 4,000,000,000, which was approved by the Company’s board of directors and holders of a majority of the Company’s voting stock on August 28, 2018. On June 24, 2019, the Company effected a one-for-five hundred (1:500) reverse stock split whereby the Company (i) decreased the number of authorized shares of common stock, $0.001 par value per share, to 100,000,000 and (ii) decreased by a ratio of one-for-five hundred (1:500) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts have been restated as of the earliest period, presented in the consolidated financial statements to reflect the reverse stock split.
Decrease in Authorized Common Stock and Reverse Split	Decrease in Authorized Common Stock and Reverse Split On June 24, 2019, the Company effected a one-for-five hundred (1:500) reverse stock split whereby the Company (i) decreased the number of authorized shares of common stock, $0.001 par value per share, to 100,000,000 and (ii) decreased by a ratio of one-for-five hundred (1:500) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts have been retroactively adjusted as of the earliest period presented in the consolidated financial statements to reflect the reverse stock split. On February 4, 2020 the Directors resolved to increase the Common Stock of the Company from 100,000,000 authorized shares to 1,000,000,000 authorized shares and believes that such number of authorized shares of Common Stock will be in the best interests of the Corporation and its stockholders because the Board believes that the availability of more shares of Common Stock for issuance will allow the Corporation greater flexibility in pursuing financing from investors, meeting business needs as they arise, taking advantage of favorable opportunities and responding to a changing corporate environment. The Company filed the necessary documents with the U.S. Securities and Exchange Commission on February 6, 2020 and at the date of this filing the increase in authorized shares to 1,000,000,000 has not yet been effected.
Basis of Presentation	Basis of Presentation The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three and six months ended December 31, 2019 and 2018 and cash flows for the six months ended December 31, 2019 and 2018 and our financial position at December 31, 2019 have been made. The Company’s results of operations for the three and six months ended December 31, 2019 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2020. Reference is frequently made herein to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”). This is the source of authoritative US GAAP recognized by the FASB to be applied to non-governmental entities. Each ASC reference in this Quarterly Report is presented with a three-digit number, which represents its Topic. As necessary for explanation and as applicable, an ASC topic may be followed with a two-digit subtopic, a two-digit section or a two-or-three-digit paragraph. Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2019. The June 30, 2019 balance sheet is derived from those statements.
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive subsidiary at December 31, 2019.	Principles of Consolidation The consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive subsidiary at June 30, 2019.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with the accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying unaudited condensed consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of beneficial conversion features on convertible debt, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.	Use of Estimates The preparation of financial statements in conformity with the accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of derivatives, valuation of beneficial conversion features on convertible debt, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.
Foreign Currency Translation and Other Comprehensive Income (Loss)	Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar ($) and/or (USD) as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. For the six months ended December 31, 2019, the Company recognized an exchange loss of approximately $575,700 on intercompany loans made by the parent to the subsidiary which have not been repaid as at December 31, 2019. As of December 31, 2019 and June 30, 2019, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: December 31, 2019 June 30, 2019 Exchange rate on balance sheet dates USD : AUD exchange rate 0.7030 0.7153 Average exchange rate for the period USD : AUD exchange rate 0.6847 0.7009 The exchange rates used to translate amounts in AUD into USD for the period ended December 31, 2018 are: 0.7046 as of the balance sheet date and 0.7248 average exchange rate for that period. Change in Accumulated Other Comprehensive Income (Loss) by component during the six months ended December 31, 2019 was as follows: Foreign Beginning balance, June 30, 2019 $ 1,066,998 Foreign currency translation loss (65,807 ) Ending balance, December 31, 2019 $ 1,001,191	Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar ($) and/or (USD) as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. As of June 30, 2019 and 2018, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: June 30, 2019 June 30, 2018 Exchange rate on balance sheet dates USD : AUD exchange rate 0.7153 0.7399 Average exchange rate for the period USD : AUD exchange rate 0.7009 0.7753 Change in Accumulated Other Comprehensive Income (Loss) by component during the years ended June 30, 2019 and 2018 was as follows: Foreign Beginning balance, June 30, 2017 $ (141,749 ) Foreign currency translation gain 499,678 Balance, June 30, 2018 357,929 Foreign currency translation gain 709,069 Ending balance, June 30, 2019 $ 1,066,998
Fair Value of Financial Instruments and Fair Value Measurements	Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 10 - Derivative Financial Instruments and Fair Value Measurements.	Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 12 - Derivative Financial Instruments and Fair Value Measurements.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no cash equivalents as of December 31, 2019 or June 30, 2019.	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no cash equivalents as of June 30, 2019 or June 30, 2018.
Receivables		Receivables As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of uncollectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical write-off experience. The Company’s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions.
Property and Equipment		Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: Machinery and equipment - 5 years Furniture - 7 years
Patents	Patents Patents are stated at cost and classified as intangible assets and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any product costs as long as we are in the startup stage. Accordingly, as the Company’s products were and are not currently approved for market, all historical patent costs incurred through December 31, 2019 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency.	Patents Patents are stated at cost and reclassified to intangible assets and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any product costs as long as we are in the startup stage. Accordingly, as the Company’s products were and are not currently approved for market, all patent costs incurred from 2013 through June 30, 2019 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets In accordance with ASC 360-10, “ Long-lived assets,”	Impairment of Long-Lived Assets In accordance with ASC 360-10, “ Long-lived assets,”
Employee Benefit/Liability		Employee Benefit/Liability Liabilities arising in respect of wages and salaries, annual leave, accumulated sick leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured at their nominal amounts based on remuneration rates which are expected to be paid when the liability is settled. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months and therefore, recorded at nominal value.
Australian Goods and Services Tax ("GST")	Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of December 31, 2019 and June 30, 2019, the Company was owed $2,432 and $5,439, respectively, from the Australian Taxation Office. These amounts were fully collected subsequent to the balance sheet reporting dates.	Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of June 30, 2019 and 2018, the Company was owed $5,439 and $6,257, respectively, from the Australian Taxation Office. These amounts were fully collected subsequent to the balance sheet reporting dates.
Derivative Instruments	Derivative Instruments ASC Topic 815, Derivatives and Hedging	Derivative Instruments ASC Topic 815, Derivatives and Hedging
Convertible Notes with Variable Conversion Options	Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480, “ Distinguishing Liabilities from Equity	Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480, “ Distinguishing Liabilities from Equity
Income Taxes	Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act (“TCJA”) was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for fiscal years beginning after December 31, 2017. On December 22, 2017, the SEC Staff Accounting Bulletin No. 118 (“SAB 118”) was issued, which allows a company to recognize provisional tax amounts when it does not have the necessary information available, prepared or analyzed, including computations, in reasonable detail to complete its accounting for the change in tax law. SAB 118 provides for a measurement of up to one year from the date of enactment.	Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act (“TCJA”) was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for fiscal years beginning after December 31, 2017. On December 22, 2017, the SEC Staff Accounting Bulletin No. 118 (“SAB 118”) was issued, which allows a company to recognize provisional tax amounts when it does not have the necessary information available, prepared or analyzed, including computations, in reasonable detail to complete its accounting for the change in tax law. SAB 118 provides for a measurement of up to one year from the date of enactment.
Research and Development Costs and Tax Credits	Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as an income tax benefit, in operations, upon receipt. During each of the six months ended December 31, 2019 and 2018, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $108,751 and $116,970, respectively, which is reflected as a tax benefit in the accompanying condensed consolidated statements of operations and comprehensive income (loss).	Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as an income tax benefit, in operations, upon receipt. During each of the fiscal years ended June 30, 2019 and 2018, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $115,437 and $179,306, respectively, which is reflected as a tax benefit in the accompanying consolidated statements of operations and comprehensive income (loss).
Stock Based Compensation	Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption. There was no cumulative effect of adoption on July 1, 2019.	Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation Share Based Payment The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 505-50 “ Equity-Based Payments to Non-Employees
Revenue Recognition		Revenue Recognition The Company adopted and implemented on July 1, 2018, ASC 606 – Revenue from Contracts with Customers (“ASC 606”). ASC 606 did not have a material impact on the consolidated financial statements. Upon implementation of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun.
Legal Expenses		Legal Expenses All legal costs for litigation are charged to expense as incurred.
Basic and Diluted Net Loss Per Common Share	Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. As of December 31, 2019, there were 1,975,059 warrants outstanding, 59,644 stock options and 15 convertible notes payable, which notes are convertible into approximately 10,200,000 shares of the Company’s common stock (based on the closing price on the last trading day of the quarter ended December 31, 2019). Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance. Such securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.	Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. As of June 30, 2019 and 2018, there were 59 and 291 warrants outstanding, 59,644 and 1,144 stock options and 10 and 20 convertible notes payable, which notes are convertible into approximately 1,810,347 and 207,397 shares of the Company’s common stock respectively. Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance. Such securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.
Leases	Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases On July 1, 2019, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Operating lease ROU assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the condensed consolidated statements of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management.	Recent Accounting Pronouncements Certain FASB Accounting Standard Updates (“ASU”) that are not effective until after June 30, 2019 are not expected to have a significant effect on the Company’s consolidated financial position or results of operations. Future pronouncements are as follows: ASU 2016-02 ASU 2017-11 - ASU 2018-07

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting and Reporting Policies (Tables)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Accounting Policies [Abstract]
Schedule of Translation Exchange Rates	As of December 31, 2019 and June 30, 2019, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: December 31, 2019 June 30, 2019 Exchange rate on balance sheet dates USD : AUD exchange rate 0.7030 0.7153 Average exchange rate for the period USD : AUD exchange rate 0.6847 0.7009	As of June 30, 2019 and 2018, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: June 30, 2019 June 30, 2018 Exchange rate on balance sheet dates USD : AUD exchange rate 0.7153 0.7399 Average exchange rate for the period USD : AUD exchange rate 0.7009 0.7753
Schedule of Change in Accumulated Other Comprehensive Income (Loss)	Change in Accumulated Other Comprehensive Income (Loss) by component during the six months ended December 31, 2019 was as follows: Foreign Beginning balance, June 30, 2019 $ 1,066,998 Foreign currency translation loss (65,807 ) Ending balance, December 31, 2019 $ 1,001,191	Change in Accumulated Other Comprehensive Income (Loss) by component during the years ended June 30, 2019 and 2018 was as follows: Foreign Beginning balance, June 30, 2017 $ (141,749 ) Foreign currency translation gain 499,678 Balance, June 30, 2018 357,929 Foreign currency translation gain 709,069 Ending balance, June 30, 2019 $ 1,066,998
Schedule of Property and Equipment Estimated Useful Lives		The estimated useful lives are as follows: Machinery and equipment - 5 years Furniture - 7 years

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following as of June 30, 2019 2018 Office equipment at cost $ 26,749 $ 25,244 Less: Accumulated depreciation (18,332 ) (16,967 ) Total property, plant, and equipment $ 8,417 $ 8,277

Convertible Notes (Tables)

Convertible Notes (Tables)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Debt Disclosure [Abstract]
Schedule of Convertible Notes	The Company’s convertible notes outstanding at December 31, 2019 were as follows: Convertible notes and debenture $ 2,016,365 Unamortized discounts (415,712 ) Accrued interest 182,581 Premiums 1,151,106 Convertible notes, net $ 2,934,340	The Company’s convertible notes outstanding at June 30, 2019 and 2018 were as follows: June 30, 2019 June 30, 2018 Convertible notes and debenture $ 1,076,785 $ 3,096,935 Unamortized discounts (131,893 ) (277,733 ) Accrued interest 99,482 148,930 Premium, net 613,003 1,731,167 Convertible notes, net $ 1,657,377 $ 4,699,299

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Schedule of Income Tax Provision	The reconciliation of income tax expense computed at the U.S. federal statutory rate to the income tax provision for the years ended June 30, 2019 and 2018 is as follows: Year Ended US June 30, 2019 June 30, 2018 Income before Income taxes $ (5,758,369 ) $ (7,039,155 ) Taxes under statutory US tax rates $ (1,209,258 ) $ (1,478,222 ) Increase (decrease) in valuation allowance 1,394,444 1,418,349 Change in Federal tax rates - (99,013 ) Foreign tax rate differential (186,286 ) (5,043 ) Other 1,100 (114,391 ) Income tax (expense) benefit $ - $ (278,320 )
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities consist of the following: Year Ended June 30, 2019 June 30, 2018 Deferred tax assets Warrant Derivative Liability $ 7,403 $ 7,403 Provision for Annual Leave 96,759 44,969 Superannuation 9,473 4,041 Prepaid Investor Services 414,396 353,553 Capital Raising Costs - 23,559 Legal Costs 91,961 23,885 Intellectual Property 41,686 11,760 Patent Costs 171,195 171,195 Formation Expense 7,208 7,208 Net Operating Loss CF 6,573,215 5,668,743 Foreign Exchange Loss (OCI) (39,379 ) (39,379 ) Revalue of derivative liability 519,151 - Stock Based Compensation 51,481 - Total Deferred tax assets $ 7,944,549 $ 6,276,937 Deferred tax liabilities R&D $ (139,833 ) $ - Capital Raising Costs (133,335 ) - Total deferred tax liabilities $ (273,168 ) $ - Net deferred tax assets (liabilities) $ 7,671,381 $ 6,276,937 Valuation allowance (7,671,381 ) (6,276,937 ) Net deferred tax assets (liabilities) $ - $ -

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Schedule of Stock Option Activity	A summary of the Company’s option activity during the years ended June 30, 2019 and 2018 is presented below: Weighted Number of Average Shares Price Per Share Outstanding at June 30, 2017 1,144 $ 3,750 Issued - - Exercised - - Expired - - Outstanding at June 30, 2018 1,144 $ 3,750 Issued 58,500 $ 4.53 Exercised - - Forfeited - - Expired - - Outstanding at June 30, 2019 59,644 $ 76.37 Exercisable at June 30, 2019 1,144 $ 3,750 Outstanding and Exercisable: Weighted average remaining contractual term 9.72 Weighted average fair value of options granted during the period $ 4.25 Aggregate intrinsic value $ 85,800
Schedule of Option Exercise Price Range	Options Outstanding Options Exercisable Range of Number Weighted Weighted Aggregate Number Weighted Aggregate $ 4.25-4.68 58,500 9.88 Years $ 4.53 $ 85,800 - $ - $ - $ 3,750.00 1,144 1.79 Years 3,750.00 - 1,144 3,750.00 - 59,644 9.72 Years $ 76.37 $ 85,800 1,144 $ 3,750.00 $ -
Schedule of Warrant Activity	The following table summarizes warrant activity for the years ended June 30, 2019 and 2018: Weighted Number of Average Shares Price Per Share Outstanding at June 30, 2017 299 $ 5,625 Issued - - Exercised - - Forfeited - - Expired (8 ) - Outstanding at June 30, 2018 291 $ 5,555 Issued - - Exercised (24 ) - Forfeited - - Expired (208 ) - Outstanding at June 30, 2019 59 $ 4,765 Exercisable at June 30, 2019 59 $ 4,765 Outstanding and Exercisable: Weighted average remaining contractual term 0.50 Aggregate intrinsic value $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Right Use of Asset	ROU is summarized below: December 31, 2019 Office lease ROU $ 48,662 Less accumulated reduction (13,271 ) Balance of ROU asset as of December 31, 2019 $ 35,391
Schedule of Operating Lease Liability	Operating lease liability related to the ROU asset is summarized below: December 31, 2019 Office lease liability $ 48,662 Reduction of lease liability (11,352 ) Total 37,310 Less: current portion (14,216 ) Long term portion of lease liability as of December 31, 2019 $ 23,094
Schedule of Future Minimum Rental Payments for Operating Leases	Future Minimum lease payments under non-cancelable operating lease at December 31, 2019 are as follows: Remainder Fiscal Year 2020 $ 15,120 Year 2021 23,119 Total 38,239 Imputed interest (929 ) Total operating lease liability $ 37,310	Future minimum operating lease commitments consisted of the following at June 30, 2019: Fiscal Year Ended June 30, Amount 2020 $ 27,756 2021 $ 25,443

Derivative Financial Instrume_2

Derivative Financial Instruments and Fair Value Measurements (Tables)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	Convertible Debt Initial Valuations into during the six December 31, 2019 Volatility 227.82 % 227.82 % Expected Remaining Term (in years) 1 00.39 – 0.91 Risk Free Interest Rate 1.59 % 1.48% – 1.59 % Expected dividend yield None None
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2019: Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 924,744 $ — $ — $ 924,744 Total $ 924,744 $ — $ — $ 924,744	The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2019: Balance at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 698,264 $ — $ — $ 698,264 Total $ 698,264 $ — $ — $ 698,264 The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2018: Balance at Quoted Prices Significant Significant (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 371,532 $ — $ — $ 371,532 Total $ 371,532 $ — $ — $ 371,532
Schedule of Derivative Liabilities at Fair Value	The following is a roll forward for the six months ended December 31, 2019 of the fair value liability of price adjustable derivative instruments: Fair Value of Liability for Derivative Instruments Balance at June 30, 2019 $ 698,264 Initial fair value of embedded conversion option derivative liability recorded as debt discount 115,000 Initial fair value of embedded conversion option derivative liability recorded as expense 93,125 Reductions due to conversions (44,588 ) Change in fair value included in statements of operations 62,943 Balance at December 31, 2019 $ 924,744	The following is a roll forward for the years ended June 30, 2019 and 2018 of the fair value liability of price adjustable derivative instruments: Fair Value of Liability for Derivative Instruments Balance at June 30, 2017 $ 881,172 Effects of foreign currency exchange rate changes 38 Reductions due to conversions (861,695 ) Reductions due to repayment of debt (199,339 ) Initial fair value of embedded conversion option derivative liability recorded as debt discount 543,744 Initial fair value of embedded conversion option derivative liability recorded as change in fair value of embedded conversion option 313,694 Change in fair value included in statements of operations (306,082 ) Balance at June 30, 2018 371,532 Reductions due to repayment of debt (936,650 ) Reduction due to conversions (1,388,764 ) Initial fair value of embedded conversion option derivative liability recorded as debt discount 180,000 Initial fair value of embedded conversion option derivative liability recorded as change in fair value of embedded conversion option 382,944 Change in fair value included in statements of operations 2,089,202 Balance at June 30, 2019 $ 698,264
Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques		Warrants June 30, 2018 June 30, 2019 Volatility 110 % N/A Expected remaining term .25 N/A Risk-free interest rate 1.93 % N/A Expected dividend yield None N/A
Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques		Convertible Debt Initial Valuations June 30, 2018 June 30, 2019 Volatility 320 % 191 - 221 % 355 % Expected remaining term 1.00 0.56 - 1.1 0.11 - 0.90 Risk-free interest rate 2.32 % 2.11 - 2.33 % 1.92 - 2.15 % Expected dividend yield None None None

Nature of Operations and Summ_4

Nature of Operations and Summary of Significant Accounting and Reporting Policies (Details Narrative)	Jun. 24, 2019$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)	Jun. 30, 2019USD ($)$ / sharesshares	Jun. 30, 2018USD ($)$ / sharesshares	Feb. 06, 2020shares	Feb. 04, 2020shares	Sep. 21, 2018shares	Sep. 20, 2018shares	Jan. 23, 2018shares	Jan. 22, 2018shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock	one-for-five hundred (1:500)
Common stock, par value | $ / shares	$ 0.001	$ 0.001		$ 0.001		$ 0.001	$ 0.001
Common stock, shares authorized | shares	100,000,000	100,000,000		100,000,000		100,000,000	100,000,000			4,000,000,000	400,000,000	400,000,000	100,000,000
Recognized an exchange loss on foreign currency translation | $		$ (629,494)	$ 358,279	$ (65,807)	$ 634,495	$ 709,069	$ 499,678
Exchange rates to translate amounts		0.7030		0.7030		0.7153	0.7399
Cash equivalents | $
Value added tax receivable | $		2,432		$ 2,432		$ 5,439	6,257
Income tax percentage description				On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act ("TCJA") was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for fiscal years beginning after December 31, 2017.		On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act ("TCJA") was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for fiscal years beginning after December 31, 2017.
Income tax percentage						21.00%
Research and development costs | $		37	94,777	$ 65,409	150,970	$ 260,335	1,825,728
Tax credits | $		$ (143)	$ 116,970	$ 108,751	$ 116,970	$ 115,437	$ 179,306
Debt conversion percentage				4.99%		4.99%
Debt conversion percentage, description				Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders' ability to increase such limitation to 9.99% upon 60 days' notice to the Company)		Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation, (subject to certain noteholders' ability to increase such limitation to 9.99% upon 60 days' notice to the Company)
Share-based Payment Arrangement, Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount | shares				59,644		59,644	1,144
Convertible Notes Payable [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount | shares				15
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount | shares				1,975,059		59	291
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount | shares				10,200,000		1,810,347	207,397
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax percentage				34.00%
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax percentage				21.00%
AUD into USD Currency [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exchange rates to translate amounts			0.7046		0.7046
Average exchange rate			0.7248		0.7248
Intercompany Loans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Recognized an exchange loss on foreign currency translation | $				$ 575,700
Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized | shares								1,000,000,000	1,000,000,000

Nature of Operations and Summ_5

Nature of Operations and Summary of Significant Accounting and Reporting Policies (Details Narrative) (10-K)	Jun. 24, 2019$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)	Jun. 30, 2019USD ($)Integer$ / sharesshares	Jun. 30, 2018USD ($)Integer$ / sharesshares	Sep. 21, 2018shares	Sep. 20, 2018shares	Jan. 23, 2018shares	Jan. 22, 2018shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized	100,000,000	100,000,000		100,000,000		100,000,000	100,000,000	4,000,000,000	400,000,000	400,000,000	100,000,000
Reverse stock	one-for-five hundred (1:500)
Common stock, par value | $ / shares	$ 0.001	$ 0.001		$ 0.001		$ 0.001	$ 0.001
Cash equivalents | $
Value added tax receivable | $		2,432		$ 2,432		$ 5,439	6,257
Income tax percentage description				On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act ("TCJA") was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for fiscal years beginning after December 31, 2017.		On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act ("TCJA") was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for fiscal years beginning after December 31, 2017.
Income tax percentage						21.00%
Research and development costs | $		37	$ 94,777	$ 65,409	$ 150,970	$ 260,335	1,825,728
Tax credits | $		$ (143)	$ 116,970	$ 108,751	$ 116,970	$ 115,437	$ 179,306
Debt conversion percentage				4.99%		4.99%
Debt conversion percentage, description				Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders' ability to increase such limitation to 9.99% upon 60 days' notice to the Company)		Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation, (subject to certain noteholders' ability to increase such limitation to 9.99% upon 60 days' notice to the Company)
Stock Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount				59,644		59,644	1,144
Convertible Notes Payable [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount				15
Number of convertible notes payable converted common shares | Integer						10	20
Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount				1,975,059		59	291
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount				10,200,000		1,810,347	207,397

Nature of Operations and Summ_6

Nature of Operations and Summary of Significant Accounting and Reporting Policies - Schedule of Translation Exchange Rates (Details)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
USD : AUD exchange rate	0.7030	0.7153	0.7399
Weighted Average [Member]
USD : AUD exchange rate	0.6847	0.7009	0.7753

Nature of Operations and Summ_7

Nature of Operations and Summary of Significant Accounting and Reporting Policies - Schedule of Change in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Accounting Policies [Abstract]
Beginning balance			$ 1,066,998	$ 357,929	$ 357,929	$ (141,749)
Foreign currency translation loss	$ (629,494)	$ 358,279	(65,807)	$ 634,495	709,069	499,678
Ending balance	$ 1,001,191		$ 1,001,191		$ 1,066,998	$ 357,929

Nature of Operations and Summ_8

Nature of Operations and Summary of Significant Accounting and Reporting Policies - Schedule of Property and Equipment Estimated Useful Lives (Details)	12 Months Ended
	Jun. 30, 2019
Machinery and Equipment [Member]
Property and equipment estimated useful lives	5 years
Furniture [Member]
Property and equipment estimated useful lives	7 years

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenues
Net loss	(1,867,109)	$ (1,491,940)	(1,450,038)	$ (2,124,936)	(3,359,049)	(3,574,974)	(5,758,369)	(7,039,155)
Net cash used in operating activities					(1,142,877)	(1,056,786)	(2,060,037)	(2,177,645)
Working capital deficit	(5,693,527)				(5,693,527)		(4,311,756)
Stockholders' deficit	(5,671,985)	$ (4,541,732)	$ (3,904,036)	$ (5,558,044)	(5,671,985)	$ (3,904,036)	(4,301,236)	(6,751,920)	$ (5,441,751)
Accumulated deficit	$ (54,400,096)				$ (54,400,096)		$ (51,041,047)	$ (45,282,678)

Going Concern (Details Narrat_2

Going Concern (Details Narrative) (10-K) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenues
Net loss	(1,867,109)	$ (1,491,940)	(1,450,038)	$ (2,124,936)	(3,359,049)	(3,574,974)	(5,758,369)	(7,039,155)
Net cash used in operating activities					(1,142,877)	(1,056,786)	(2,060,037)	(2,177,645)
Working capital deficit	(5,693,527)				(5,693,527)		(4,311,756)
Stockholders' deficit	(5,671,985)	$ (4,541,732)	$ (3,904,036)	$ (5,558,044)	(5,671,985)	$ (3,904,036)	(4,301,236)	(6,751,920)	$ (5,441,751)
Accumulated deficit	$ (54,400,096)				$ (54,400,096)		$ (51,041,047)	$ (45,282,678)

Property and Equipment (Details

Property and Equipment (Details Narrative) (10-K) - USD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,270	$ 1,068	$ 2,306	$ 2,225

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Office equipment at cost		$ 26,749	$ 25,244
Less: Accumulated depreciation		(18,332)	(16,967)
Total property, plant, and equipment	$ 7,137	$ 8,417	$ 8,277

Due to Former Director - Rela_2

Due to Former Director - Related Party (Details Narrative) - USD ($)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Related Party Transactions [Abstract]
Due to directors - related parties	$ 31,257	$ 31,164	$ 32,898

Loans and Notes Payable (Detail

Loans and Notes Payable (Details Narrative) - USD ($)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Directors and Officer [Member]
Loans payable	$ 52,022	$ 51,867	$ 54,753

Loans and Notes Payable (Deta_2

Loans and Notes Payable (Details Narrative) (10-K) - USD ($)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Directors and Officer [Member]
Loans payable	$ 52,022	$ 51,867	$ 54,753

Convertible Notes (Details Narr

Convertible Notes (Details Narrative)	Dec. 03, 2019USD ($)	Nov. 26, 2019USD ($)$ / shares	Oct. 03, 2019USD ($)	Oct. 02, 2019USD ($)	Sep. 04, 2019USD ($)	Aug. 30, 2019USD ($)$ / sharesshares	Aug. 01, 2019USD ($)	Jul. 30, 2019USD ($)	Jul. 08, 2019USD ($)	Jul. 03, 2019USD ($)$ / shares	May 23, 2019USD ($)$ / shares	Dec. 24, 2018USD ($)Integer	Nov. 30, 2018USD ($)	Nov. 30, 2018USD ($)Integer	Oct. 02, 2018USD ($)Integer	Aug. 29, 2018USD ($)Integer	Jul. 19, 2018USD ($)	Jul. 13, 2018USD ($)Integer	Dec. 29, 2017USD ($)Integer	Dec. 29, 2017USD ($)Integer	Aug. 10, 2017USD ($)Integer	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jan. 02, 2020USD ($)$ / shares	Sep. 10, 2019$ / sharesshares	Aug. 31, 2019$ / sharesshares	Oct. 03, 2018USD ($)	Jun. 30, 2017USD ($)
Convertible debt principal amount																										$ 267,187
Original issue discount																						$ 415,712		$ 131,893	$ 277,733
Proceeds from convertible debt																						$ 1,130,000	$ 1,054,089	$ 1,369,000	2,890,080
Common stock trading volume, percent																						4.99%		4.99%
Debt premium amount																						$ 1,151,106		$ 613,003	1,731,167
Additional paid in capital																						47,766,162		45,713,322	38,214,213	$ 410,750
Debt conversion of converted amount																						318,768
Embedded derivative, fair value of embedded derivative liability																						924,744		698,264	371,532
Conversion price, per share | $ / shares																										$ 0.165
Amortization of debt discount																						307,085	$ 303,813	389,673	853,459
Warrants to purchase of common stock, shares | shares																											1,000,000
Warrants exercise price per share | $ / shares																											$ 2
First Warrant [Member]
Warrants to purchase of common stock, shares | shares																												450,000
Warrants exercise price per share | $ / shares																												$ 2.25
Second Warrant [Member]
Warrants to purchase of common stock, shares | shares																												300,000
Warrants exercise price per share | $ / shares																												$ 3.33
Third Warrant [Member]
Warrants to purchase of common stock, shares | shares																												225,000
Warrants exercise price per share | $ / shares																												$ 4.50
Maximum [Member]
Conversion price, per share | $ / shares																										0.75
Minimum [Member]
Conversion price, per share | $ / shares																										$ 0.0672
Eagle Equities, LLC [Member] | December 2017 Eagle Note [Member]
Convertible debt principal amount																								360,470
December 29, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Convertible debt principal amount																						13,865		360,470
Accrued interest																						9,630		43,535
Additional paid in capital																								240,313
December 29, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 2017 Eagle Note [Member]
Convertible debt principal amount																			$ 532,435	$ 532,435		158,100		360,470
Original issue discount																			$ 25,354	$ 25,354
Debt maturity date																				Dec. 29, 2018
Debt instrument, interest rate, stated percentage																			8.00%	8.00%
Accrued interest																						22,478		20,065
Common stock trading volume, percent																				60.00%
Common stock trading days | Integer																				10
Debt premium amount																			$ 354,956	$ 354,956
Additional paid in capital																								240,313
December 29, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 2017 Eagle Note One [Member]
Convertible debt principal amount																						158,100
Additional paid in capital																						105,400
December 29, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 2017 Eagle Note [Member]
Proceeds from convertible debt																			$ 507,081
Debt maturity date																			Dec. 29, 2018
Common stock trading volume, percent																			60.00%
Common stock trading days | Integer																			10
Debt instrument, default, interest rate																			24.00%
July 13, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | July 2018 Eagle Note [Member]
Convertible debt principal amount																		$ 75,000				75,000
Proceeds from convertible debt																	$ 71,250
Debt maturity date																		Jul. 13, 2019
Debt instrument, interest rate, stated percentage																		8.00%
Accrued interest																						$ 14,860
Common stock trading volume, percent																		60.00%
Common stock trading days | Integer																		10
Debt premium amount																		$ 50,000
Debt instrument, default, interest rate																						24.00%
Legal fees																	$ 3,750
Percentage of outstanding shares of common stock																		4.99%
August 29, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | August 2018 Eagle Note [Member]
Convertible debt principal amount																$ 105,000						$ 105,000		105,000
Debt maturity date																Aug. 31, 2019
Debt instrument, interest rate, stated percentage																8.00%
Accrued interest																						$ 19,746		$ 7,042
Common stock trading volume, percent																60.00%
Common stock trading days | Integer																10
Debt premium amount																$ 70,000
Debt instrument, default, interest rate																						24.00%		24.00%
Legal fees																$ 5,000
Percentage of outstanding shares of common stock																4.99%
Debt original issue discount, rate																10.00%
August 29, 2018 Securities Purchase Agreement [Member] | Depository Trust Company [Member] | August 29, 2018 Eagle Note [Member]
Common stock trading volume, percent																50.00%
October 2, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | October 2018 Eagle Note [Member]
Convertible debt principal amount															$ 210,000							$ 210,000		$ 210,000
Debt maturity date															Oct. 2, 2019
Debt instrument, interest rate, stated percentage															8.00%
Accrued interest																						$ 29,227		$ 12,473
Common stock trading volume, percent															60.00%
Common stock trading days | Integer															10
Debt premium amount															$ 140,000
Debt instrument, default, interest rate																						24.00%		24.00%
Percentage of outstanding shares of common stock															4.99%
Debt instrument principal payment															$ 10,000
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Note [Member]
Convertible debt principal amount															212,000							$ 35,820							$ 106,000
Proceeds from convertible debt															$ 100,700
Debt maturity date															Oct. 2, 2019
Debt instrument, interest rate, stated percentage															8.00%
Accrued interest																						2,434
Common stock trading volume, percent															61.00%
Common stock trading days | Integer															10
Debt premium amount															$ 67,771							$ 22,901		$ 44,690
Debt instrument, default, interest rate																						24.00%		24.00%
Percentage of outstanding shares of common stock															4.99%
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Note [Member] | First Note [Member]
Proceeds from convertible debt															$ 106,000
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Note [Member] | Second Note [Member]
Proceeds from convertible debt															$ 106,000
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Back-End Note [Member]
Convertible debt principal amount																						$ 49,900
Debt maturity date																						Oct. 31, 2019
Debt premium amount																						$ 31,903
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Back End Note [Member]
Debt maturity date															Oct. 2, 2019
November 30, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | November 2018 Eagle Note [Member]
Convertible debt principal amount													$ 105,000	$ 105,000								105,000		$ 105,000
Debt maturity date														Nov. 30, 2019
Debt instrument, interest rate, stated percentage													8.00%	8.00%
Accrued interest																						$ 10,540		$ 4,879
Common stock trading volume, percent														61.00%
Common stock trading days | Integer														10
Debt premium amount													$ 67,131	$ 67,131
Debt instrument, default, interest rate																						24.00%		24.00%
Percentage of outstanding shares of common stock														4.99%
Debt original issue discount, rate														10.00%
Debt instrument principal payment														$ 5,000
November 30, 2018 Securities Purchase Agreement [Member] | Depository Trust Company [Member] | November 2018 Eagle Note [Member]
Common stock trading volume, percent													51.00%	51.00%
December 24, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 2018 Eagle Note [Member]
Convertible debt principal amount												$ 126,000										$ 126,000		$ 126,000
Debt maturity date												Dec. 24, 2019
Debt instrument, interest rate, stated percentage												8.00%
Accrued interest																						$ 10,688		$ 5,220
Common stock trading volume, percent												61.00%
Common stock trading days | Integer												10
Debt premium amount												$ 80,557
Debt instrument, default, interest rate																						24.00%		24.00%
Percentage of outstanding shares of common stock												4.99%
Debt original issue discount, rate												10.00%
Debt instrument principal payment												$ 6,000
December 24, 2018 Securities Purchase Agreement [Member] | Depository Trust Company [Member] | December 2018 Eagle Note [Member]
Common stock trading volume, percent												51.00%
December 29, 2017, June 14, 2018, July 13, 2018, August 29, 2018, October 2, 2018, November 30, 2018 and December 24, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Convertible debt principal amount																						$ 634,865		$ 792,965	1,867,935
Accrued interest																						94,691		55,675	107,726
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]
Convertible debt principal amount																								35,820	687,000
Accrued interest																								7,813	19,877
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Back-End Note [Member]
Convertible debt principal amount																								106,000
Accrued interest																								5,715
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Back End Note [Member]
Convertible debt principal amount																						56,100
Accrued interest																						11,814
Securities Purchase Agreement [Member] | Power Up Lending Group Ltd [Member] | July 3, 2019 Power Up Note [Member]
Convertible debt principal amount									$ 78,000	$ 78,000												78,000
Proceeds from convertible debt									75,000
Debt maturity date										Jul. 3, 2020
Debt instrument, interest rate, stated percentage										8.00%
Accrued interest																						3,086
Common stock trading volume, percent										65.00%
Debt instrument, default, interest rate										22.00%
Legal fees									2,500
Percentage of outstanding shares of common stock										150.00%
Embedded derivative, fair value of embedded derivative liability										$ 155,904
Conversion price, per share | $ / shares										$ 3.25
Debt instrument market price per share | $ / shares										$ 5
Debt instrument, description										The conversion price for the July 3, 2019 Power Up Note shall be $3.25, subject to certain Market Price (as defined below) adjustment. If the Market Price is greater than or equal to $5.00, the conversion price shall be the greater of 65% of the Market Price ("Variable Conversion Price") and $3.25. In the event Market Price is less than $5.00, the conversion price shall be the Variable Conversion Price. As defined in the July 3, 2019 Power Up Note, the "Market Price" shall be the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Power Up on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the "pink sheets" during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Power Up. Notwithstanding the foregoing, Power Up shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Power Up and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock.
Diligence fees									$ 500
Securities Purchase Agreement [Member] | Power Up Lending Group Ltd [Member] | November 26, 2019 Power Up Note [Member]
Convertible debt principal amount	$ 40,000	$ 43,000																				43,000
Debt maturity date		Nov. 26, 2020
Debt instrument, interest rate, stated percentage		8.00%
Accrued interest																						329
Common stock trading volume, percent		65.00%
Debt instrument, default, interest rate		22.00%
Legal fees	2,500
Percentage of outstanding shares of common stock		150.00%
Embedded derivative, fair value of embedded derivative liability		$ 52,222
Conversion price, per share | $ / shares		$ 3.25
Debt instrument market price per share | $ / shares		$ 5
Debt instrument, description		The conversion price for the November 26, 2019 Power Up Note shall be $3.05, subject to certain Market Price (as defined below) adjustment. If the Market Price is greater than or equal to $5.00, the conversion price shall be the greater of 65% of the Market Price ("Variable Conversion Price") and $3.05. In the event Market Price is less than $5.00, the conversion price shall be the Variable Conversion Price. As defined in the November 26, 2019 Power Up Note, the "Market Price" shall be the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Power Up on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the "pink sheets" during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Power Up. Notwithstanding the foregoing, Power Up shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Power Up and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock.
Diligence fees	$ 500
Securities Purchase Agreement [Member] | Odyssey Capital Funding LLC [Member] | July 2019 Odyssey Note [Member]
Convertible debt principal amount							$ 295,000	$ 320,000														320,000
Original issue discount								$ 25,000
Proceeds from convertible debt							285,000
Debt maturity date								Jul. 30, 2020
Debt instrument, interest rate, stated percentage								10.00%
Accrued interest																						13,464
Common stock trading volume, percent								65.00%
Debt premium amount								$ 172,308
Debt instrument, default, interest rate								24.00%
Legal fees							$ 10,000
Percentage of outstanding shares of common stock								120.00%
Debt instrument, description								Common Stock beneficially owned by the Holder and its affiliates would exceed 4.99% of the outstanding shares of the Common Stock of the Company (which may be increased up to 9.9% upon 60 days' prior written notice by the Holder to the Company).
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member]
Convertible debt principal amount					$ 550,000	$ 550,000																550,000
Proceeds from convertible debt					505,000
Debt maturity date						Aug. 30, 2020
Debt instrument, interest rate, stated percentage						10.00%
Accrued interest																						$ 18,484
Debt premium amount						$ 366,667
Debt instrument, default, interest rate						24.00%
Legal fees					5,000
Percentage of outstanding shares of common stock						125.00%																4.99%
Debt instrument, description						Upon the holder's election to convert accrued interest, default interest or any penalty amounts as stipulated, the Company may elect to pay those amounts in cash. The note may also be prepaid by the Company at any time between the date of issuance and August 13, 2020 at 135% multiplied by the sum of (a) the then outstanding principal amount plus (b) accrued and unpaid interest plus (c) default interests, if any. The conversion price for the August 30, 2019 Auctus Note shall be the Variable Conversion Price, being 60% of the Market Price. Notwithstanding the foregoing, Auctus shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Auctus and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock.
Diligence fees					$ 40,000
Fair value of warrants																						$ 375,904
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | First Warrant [Member]
Warrants to purchase of common stock, shares | shares						450,000
Warrants exercise price per share | $ / shares						$ 2.25
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Second Warrant [Member]
Warrants to purchase of common stock, shares | shares						300,000
Warrants exercise price per share | $ / shares						$ 3.33
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Third Warrant [Member]
Warrants to purchase of common stock, shares | shares						225,000
Warrants exercise price per share | $ / shares						$ 4.50
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Maximum [Member]
Convertible debt principal amount						$ 15,000
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | October 1, 2019 GW Note [Member]
Convertible debt principal amount				$ 131,000																		131,000
Proceeds from convertible debt				$ 125,000
Debt maturity date				Oct. 1, 2020
Debt instrument, interest rate, stated percentage				8.00%
Accrued interest																						2,606
Debt premium amount				$ 87,333
Debt instrument, default, interest rate				24.00%
Percentage of outstanding shares of common stock				4.99%
Debt instrument principal payment				$ 6,000
Debt instrument, description				The conversion price for the October 1, 2019 GW Holdings Note shall be equal to a 40% discount of the lowest closing bid price ("Lowest Trading Price") of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, GW Holdings shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by GW Holdings and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock which may be increased up to 9.99% upon 60 days prior written notice by the GW Holdings to the Company.
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | October 1, 2019 GW Note [Member] | Maximum [Member]
Debt instrument, default, interest rate				150.00%
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | October 1, 2019 GW Note [Member] | Minimum [Member]
Debt instrument, default, interest rate				110.00%
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member]
Original issue discount																						534,000
Debt premium amount																						539,000
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member]
Convertible debt principal amount			$ 108,000																			108,000
Original issue discount			5,000																			591,000
Proceeds from convertible debt			$ 100,000
Debt maturity date			Oct. 3, 2020
Debt instrument, interest rate, stated percentage			10.00%
Accrued interest																						2,626
Debt premium amount			$ 72,000																			698,000
Debt instrument, default, interest rate			15.00%
Percentage of outstanding shares of common stock			4.99%
Debt instrument principal payment			$ 3,000
Debt instrument, description			The conversion price for the October 3, 2019 Crown Bridge Note shall be equal to a 40% discount of the lowest closing bid price ("Lowest Trading Price") of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, Crown Bridge shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Crown Bridge and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock which may be increased up to 9.99% upon 60 days prior written notice by the Crown Bridge to the Company.
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member] | Maximum [Member]
Debt instrument, default, interest rate			150.00%
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member] | Minimum [Member]
Debt instrument, default, interest rate			110.00%
August 10, 2017 Consulting Agreement [Member]
Convertible debt principal amount																					$ 310,000	9,000		9,000
Debt maturity date																					Aug. 10, 2019
Debt instrument, interest rate, stated percentage																					10.00%
Accrued interest																						26,653		25,917
Common stock trading volume, percent																					65.00%
Common stock trading days | Integer																					10
Debt instrument, default, interest rate																					18.00%
Debt conversion of converted amount																					$ 750
Accrued expenses																								155,000	155,000					$ 155,000
Embedded derivative, fair value of embedded derivative liability																					$ 578,212
August 10, 2017 Consulting Agreement [Member] | Consultant [Member]
Convertible debt principal amount																								161,000	140,000
Accrued interest																								19,418	$ 10,764
Debt conversion of converted amount																								161,000
Redstart Holdings Corp Financing Agreement [Member]
Convertible debt principal amount																						46,600
Amortization of debt discount																						18,266
Redstart Holdings Corp Financing Agreement [Member] | Redstart Holdings Note [Member] | November 19, 2019 [Member]
Common stock trading volume, percent											65.00%
Debt instrument, default, interest rate											22.00%
Embedded derivative, fair value of embedded derivative liability											$ 166,564
Conversion price, per share | $ / shares											$ 32.50
Debt instrument market price per share | $ / shares											$ 50
Debt instrument, description											The Company had the right to prepay the May 2019 Redstart Holdings Note until November 19, 2019. If the May 2019 Redstart Holdings Note was prepaid within 90 days of the issuance date, then the prepayment premium shall be 115% of the face amount plus any accrued interest; if the May 2019 Redstart Holdings Note was prepaid after 91 days from the issuance date, but prior to 121 days from the issuance date, then the prepayment premium shall be 120% of the face amount plus any accrued interest; and if the May 2019 Redstart Holdings Note was prepaid after 121 days from the issuance date, but prior to 150 days from the issuance date, then the prepayment premium shall be 125% of the face amount plus any accrued interest; and if the May 2019 Redstart Holdings Note was prepaid after 151 days from the issuance date, but prior to 180 days from the issuance date, then the prepayment premium shall be 129% of the face amount plus any accrued interest.
Redstart Holdings Corp Financing Agreement [Member] | Redstart Holdings Corp [Member]
Convertible debt principal amount											$ 133,000											86,400		133,000
Proceeds from convertible debt											$ 130,000
Debt maturity date											May 23, 2020
Debt instrument, interest rate, stated percentage											8.00%
Accrued interest																						$ 6,322		$ 1,137
Legal fees											$ 3,000
Percentage of outstanding shares of common stock											4.99%
Redstart Holdings Corp Financing Agreement [Member] | Redstart Holdings Corp [Member] | Redstart Holdings Note [Member]
Debt maturity date											May 23, 2020
Debt instrument, interest rate, stated percentage											8.00%
Legal fees											$ 3,000

Convertible Notes (Details Na_2

Convertible Notes (Details Narrative) (10-K)	Jan. 02, 2020USD ($)$ / shares	May 23, 2019USD ($)$ / shares	Dec. 24, 2018USD ($)Integer	Nov. 30, 2018USD ($)Integer	Nov. 30, 2018USD ($)	Nov. 07, 2018USD ($)	Oct. 02, 2018USD ($)Integer	Sep. 12, 2018USD ($)	Sep. 06, 2018USD ($)	Aug. 29, 2018USD ($)Integer	Aug. 29, 2018USD ($)	Aug. 28, 2018USD ($)Integer$ / shares	Jul. 24, 2018USD ($)Integer	Jul. 19, 2018USD ($)	Jul. 16, 2018USD ($)	Jul. 13, 2018USD ($)Integer	Jun. 30, 2018USD ($)$ / shares	Jun. 29, 2018USD ($)	Jun. 26, 2018USD ($)Integer	Jun. 14, 2018USD ($)	May 31, 2018USD ($)	May 18, 2018USD ($)	May 15, 2018USD ($)Integer$ / shares	Apr. 13, 2018USD ($)Integer	Mar. 23, 2018USD ($)Integer	Mar. 12, 2018USD ($)	Mar. 05, 2018USD ($)Integer$ / shares	Feb. 27, 2018USD ($)	Jan. 29, 2018USD ($)	Jan. 25, 2018USD ($)	Jan. 22, 2018USD ($)Integer$ / shares	Jan. 02, 2018USD ($)$ / sharesshares	Dec. 29, 2017USD ($)Integer	Dec. 29, 2017USD ($)Integer	Dec. 06, 2017USD ($)	Nov. 03, 2017USD ($)Integer$ / shares	Sep. 21, 2017USD ($)Integer	Sep. 14, 2017USD ($)	Aug. 10, 2017USD ($)Integer	Aug. 09, 2017USD ($)Integer	Jul. 24, 2017USD ($)	Jul. 05, 2017USD ($)	Jun. 03, 2017USD ($)	May 26, 2017USD ($)	May 04, 2017USD ($)	Apr. 11, 2017USD ($)	Mar. 02, 2017USD ($)Integer	Feb. 16, 2017USD ($)Integer$ / shares	Jan. 27, 2017USD ($)Integer	Dec. 21, 2016USD ($)	Dec. 12, 2016USD ($)Integer	Nov. 18, 2016USD ($)Integer$ / shares	Sep. 13, 2016USD ($)	Oct. 28, 2015USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / shares	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)$ / shares	Dec. 31, 2018USD ($)	Jun. 30, 2019USD ($)$ / shares	Jun. 30, 2018USD ($)$ / shares	Sep. 10, 2019$ / sharesshares	Jun. 24, 2019$ / shares	Feb. 25, 2019USD ($)	Oct. 03, 2018USD ($)	Jun. 30, 2017USD ($)	Dec. 02, 2016USD ($)shares
Convertible debt principal amount	$ 267,187
Warrants to purchase of common stock, shares | shares																																																													1,000,000
Warrants exercise price per share | $ / shares																																																													$ 2
Convertible debenture																																																							$ 216,400		$ 216,400
Derivative liability of convertible debenture																	$ 371,532																																						924,744		924,744		$ 698,264	$ 371,532					$ 881,172
Debt conversion of converted amount																																																									318,768
Gain (loss) on extinguishment of debt, net	146,367																																																						20,176	$ (20,355)	20,176	$ 1,165,516	1,204,242	251,392
Long-term debt																	3,096,935																																						2,016,365		$ 2,016,365		$ 1,076,785	3,096,935
Common stock trading volume, percent																																																									4.99%		4.99%
Debt premium amount																	$ 1,731,167																																						$ 1,151,106		$ 1,151,106		$ 613,003	$ 1,731,167
Common stock, par value | $ / shares																	$ 0.001																																						$ 0.001		$ 0.001		$ 0.001	$ 0.001		$ 0.001
Additional paid in capital	$ 410,750																$ 38,214,213																																						$ 47,766,162		$ 47,766,162		$ 45,713,322	$ 38,214,213
Debt conversion price per share | $ / shares	$ 0.165
Proceeds from convertible debt																																																									1,130,000	1,054,089	1,369,000	2,890,080
Embedded derivative, fair value of embedded derivative liability																	371,532																																						924,744		924,744		698,264	371,532
Debt discount related to note issuance																																																											180,000	543,744
Amortization of debt discount																																																									307,085	$ 303,813	389,673	853,459
Eagle Equities, LLC [Member] | December 21 Note [Member]
Accrued interest																	7,773																																											7,773
Eagle Equities, LLC [Member] | December 21 Eagle Back End Note [Member]
Accrued interest																	5,656																																											5,656
Eagle Equities, LLC [Member] | December 2017 Eagle Note [Member]
Convertible debt principal amount																																																											360,470
Initial Securities Purchase Agreement and Debenture [Member] | Delafield Investments Limited [Member]
Purchaser for investment amount																																																						$ 4,000,000
Debt instrument, interest rate, stated percentage																																																						5.00%
Convertible debt principal amount																																																						$ 4,350,000
Warrant term																																																						4 years
Warrants to purchase of common stock, shares | shares																																																						104,762
Warrants exercise price per share | $ / shares																																																						$ 1,500
Convertible debenture																																$ 340,181																																	720,271
Derivative liability of convertible debenture																																																																	252,303
Accrued interest																	8,250																																											8,250
Debt conversion of converted amount																																																												380,090
Gain (loss) on extinguishment of debt, net																																$ 199,339
Additional Issuance Agreement [Member]
Long-term debt																																																					$ 150,000
Debt original issue discount, rate																																																					5.00%
Additional Issuance Debenture [Member]
Convertible debt principal amount																																																					$ 165,000
Convertible debenture																	165,000																																											165,000					165,000
Derivative liability of convertible debenture																																																																	54,727
Accrued interest																	8,250																																											8,250					8,250
December 2016 Letter Agreement [Member]
Debt instrument, interest rate, stated percentage																																																																		8.00%
Convertible debt principal amount																																																																		$ 150,000
Warrant term																																2 years
Warrants to purchase of common stock, shares | shares																																208																																		960,000
Warrants exercise price per share | $ / shares																																$ 6,250
Convertible debenture																																$ 150,000																																	150,000
Accrued interest																																$ 16,899																																	6,937
December 12, 2016 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Debt instrument, interest rate, stated percentage																																																			8.00%
Convertible debt principal amount																																																			$ 100,000
Debt maturity date																																																			Dec. 12, 2017
Debt instrument, term																																																			1 year
Common stock trading volume, percent																																																			60.00%
Common stock trading days | Integer																																																			10
Payment of notes receivable																																														$ 100,000
Legal fees																																														5,000
Proceed from note receivable net																																														$ 95,000
Debt premium amount																																																			$ 66,667
December 12, 2016 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 21 Note [Member]
Accrued interest																	8,296																																											8,296
December 12, 2016 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 12 Eagle Back-End Note [Member]
Convertible debt principal amount																																																											100,000
Accrued interest																																																											13,144
December 21, 2016 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Debt instrument, interest rate, stated percentage																																																		8.00%
Convertible debt principal amount																																																		$ 157,500
Debt maturity date																																																		Dec. 21, 2017
Common stock trading volume, percent																																																		60.00%
Payment of notes receivable																																													$ 157,500
Legal fees																																													7,500
Proceed from note receivable net																																													150,000
Debt premium amount																																													105,000
January 27, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Debt instrument, interest rate, stated percentage																																																	8.00%
Convertible debt principal amount																																											$ 190,000						$ 230,000
Debt maturity date																																																	Sep. 27, 2017
Debt instrument, term																																																	1 year
Common stock trading volume, percent																																																	60.00%
Common stock trading days | Integer																																																	10
Payment of notes receivable																																													$ 40,000
Legal fees																																											$ 11,250
Debt premium amount																																																	$ 153,333
January 27, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | January 2017 Eagle Note [Member]
Accrued interest																	14,988																																											14,988
January 27, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | January 2017 Eagle Back-End Note [Member]
Convertible debt principal amount																																																											230,000
Accrued interest																																																											33,356
March 1, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Debt instrument, interest rate, stated percentage																																															8.00%
Convertible debt principal amount																																															$ 220,500
Debt maturity date																																															Mar. 1, 2018
Common stock trading volume, percent																																															60.00%
Common stock trading days | Integer																																															10
Payment of notes receivable																																										$ 220,500
Legal fees																																										10,500
Proceed from note receivable net																																										$ 210,000
Debt premium amount																																															$ 147,000
March 1, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | March 2017 Eagle Note [Member]
Accrued interest																	20,061																																											20,061
March 1, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | March 2017 Eagle Back-End Note [Member]
Convertible debt principal amount																																																											220,500
Accrued interest																																																											19,526
August 9, 2017 Securities Purchase Agreement [Member] | August 2017 Eagle Back End Note [Member]
Convertible debt principal amount																																																											200,000
Accrued interest																																																											$ 30,568
August 9, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Debt instrument, interest rate, stated percentage																																								8.00%
Convertible debt principal amount																																								$ 200,000
Debt maturity date																																								Aug. 8, 2018
Debt instrument, term																																								1 year
Common stock trading volume, percent																																								60.00%
Common stock trading days | Integer																																								10
Payment of notes receivable																																						$ 200,000
Legal fees																																						10,000
Proceed from note receivable net																																						$ 190,000
Debt premium amount																																								$ 133,333
Debt instrument, default, interest rate																																																											24.00%
August 9, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | August 2017 Eagle Note [Member]
Convertible debt principal amount																	120,000																																										$ 80,000	120,000
Accrued interest																	5,273																																										6,850	5,273
October 25, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Debt instrument, interest rate, stated percentage																																				8.00%
Convertible debt principal amount																																				$ 200,000
Debt maturity date																																				Jun. 25, 2018
Debt instrument, term																																				1 year
Common stock trading volume, percent																																				60.00%
Common stock trading days | Integer																																				10
Payment of notes receivable																																			$ 200,000
Legal fees																																			10,000
Proceed from note receivable net																																			$ 190,000
Debt premium amount																																				$ 133,333
Common stock, par value | $ / shares																																				$ 0.001
October 25, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | October 2017 Eagle Note [Member]
Accrued interest																																																											14,653
December 29, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Convertible debt principal amount																																																							13,865		13,865		360,470
Accrued interest																																																							9,630		9,630		43,535
Additional paid in capital																																																											240,313
December 29, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 2017 Eagle Note [Member]
Debt instrument, interest rate, stated percentage																																	8.00%	8.00%
Convertible debt principal amount																																	$ 532,435	$ 532,435																					158,100		158,100		360,470
Accrued interest																																																							22,478		22,478		20,065
Debt maturity date																																		Dec. 29, 2018
Common stock trading volume, percent																																		60.00%
Common stock trading days | Integer																																		10
Debt premium amount																																	$ 354,956	$ 354,956
Additional paid in capital																																																											240,313
December 29, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 2017 Eagle Note [Member]
Debt maturity date																																	Dec. 29, 2018
Common stock trading volume, percent																																	60.00%
Common stock trading days | Integer																																	10
Debt instrument, default, interest rate																																	24.00%
Debt conversion of convertible debt amount																																	$ 25,354
Payment of purchase price																																	507,081
Proceeds from convertible debt																																	$ 507,081
June 14, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Convertible debt principal amount																				$ 105,000																																							105,000
Accrued interest																																																											$ 6,674
June 14, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | June 2018 Eagle Note [Member]
Debt instrument, interest rate, stated percentage																				8.00%
Convertible debt principal amount																				$ 5,000
Debt original issue discount, rate																				10.00%
Debt maturity date																				Jun. 14, 2019
Common stock trading volume, percent																				60.00%
Debt premium amount																				$ 70,000
Debt instrument, default, interest rate																																																											24.00%
Percentage of outstanding shares of common stock																				4.99%
June 14, 2018 Securities Purchase Agreement [Member] | Depository Trust Company [Member] | June 2018 Eagle Note [Member]
Common stock trading volume, percent																				50.00%
July 13, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Legal fees														$ 3,750	$ 71,250
July 13, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | July 2018 Eagle Note [Member]
Debt instrument, interest rate, stated percentage																8.00%
Convertible debt principal amount																$ 75,000																																											$ 75,000
Accrued interest																$ 5,786
Debt maturity date																Jul. 13, 2019
Common stock trading volume, percent																60.00%
Common stock trading days | Integer																10
Debt premium amount																$ 50,000
Debt instrument, default, interest rate																																																											24.00%
Percentage of outstanding shares of common stock																4.99%
August 29, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | August 2018 Eagle Note [Member]
Debt instrument, interest rate, stated percentage										8.00%	8.00%
Convertible debt principal amount										$ 105,000	$ 105,000																																												105,000		105,000		$ 105,000
Accrued interest																																																							19,746		$ 19,746		$ 7,042
Debt original issue discount, rate										10.00%
Debt maturity date										Aug. 31, 2019
Common stock trading volume, percent										60.00%
Common stock trading days | Integer										10
Legal fees										$ 5,000
Proceed from note receivable net										100,000
Debt premium amount										$ 70,000	$ 70,000
Debt instrument, default, interest rate																																																									24.00%		24.00%
Percentage of outstanding shares of common stock										4.99%
August 29, 2018 Securities Purchase Agreement [Member] | Depository Trust Company [Member] | August 29, 2018 Eagle Note [Member]
Common stock trading volume, percent										50.00%
October 2, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | October 2018 Eagle Note [Member]
Debt instrument, interest rate, stated percentage							8.00%
Convertible debt principal amount							$ 210,000																																																210,000		$ 210,000		$ 210,000
Accrued interest																																																							29,227		$ 29,227		$ 12,473
Debt maturity date							Oct. 2, 2019
Common stock trading volume, percent							60.00%
Common stock trading days | Integer							10
Debt premium amount							$ 140,000
Debt instrument, default, interest rate																																																									24.00%		24.00%
Percentage of outstanding shares of common stock							4.99%
Debt instrument principal payment							$ 10,000
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Note [Member]
Debt instrument, interest rate, stated percentage							8.00%
Convertible debt principal amount							$ 212,000																																																35,820		$ 35,820							$ 106,000
Accrued interest																																																							2,434		2,434
Debt maturity date							Oct. 2, 2019
Common stock trading volume, percent							61.00%
Common stock trading days | Integer							10
Debt premium amount							$ 67,771																																																22,901		$ 22,901		$ 44,690
Debt instrument, default, interest rate																																																									24.00%		24.00%
Percentage of outstanding shares of common stock							4.99%
Proceeds from convertible debt							$ 100,700
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Back End Note [Member]
Debt maturity date							Oct. 2, 2019
November 30, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | November 2018 Eagle Note [Member]
Debt instrument, interest rate, stated percentage				8.00%	8.00%
Convertible debt principal amount				$ 105,000	$ 105,000																																																		105,000		$ 105,000		$ 105,000
Accrued interest																																																							10,540		$ 10,540		$ 4,879
Debt original issue discount, rate				10.00%
Debt maturity date				Nov. 30, 2019
Common stock trading volume, percent				61.00%
Common stock trading days | Integer				10
Debt premium amount				$ 67,131	$ 67,131
Debt instrument, default, interest rate																																																									24.00%		24.00%
Percentage of outstanding shares of common stock				4.99%
Debt instrument principal payment				$ 5,000
November 30, 2018 Securities Purchase Agreement [Member] | Depository Trust Company [Member] | November 2018 Eagle Note [Member]
Common stock trading volume, percent				51.00%	51.00%
December 24, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 2018 Eagle Note [Member]
Debt instrument, interest rate, stated percentage			8.00%
Convertible debt principal amount			$ 126,000																																																				126,000		$ 126,000		$ 126,000
Accrued interest																																																							10,688		$ 10,688		$ 5,220
Debt original issue discount, rate			10.00%
Debt maturity date			Dec. 24, 2019
Common stock trading volume, percent			61.00%
Common stock trading days | Integer			10
Debt premium amount			$ 80,557
Debt instrument, default, interest rate																																																									24.00%		24.00%
Percentage of outstanding shares of common stock			4.99%
Debt instrument principal payment			$ 6,000
December 24, 2018 Securities Purchase Agreement [Member] | Depository Trust Company [Member] | December 2018 Eagle Note [Member]
Common stock trading volume, percent			51.00%
August 9, 2017, December 29, 2017, June 14, 2018, July 13, 2018, August 29, 2018, October 2, 2018, November 30, 2018 and December 24, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Convertible debt principal amount																	1,867,935																																						634,865		$ 634,865		$ 792,965	1,867,935
Accrued interest																	107,726																																						94,691		94,691		55,675	107,726
May 26, 2017 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | 8% Convertible Redeemable Junior Subordinated Promissory Note [Member]
Debt instrument, interest rate, stated percentage																																												8.00%
Convertible debt principal amount																																												$ 160,000
Accrued interest																	7,499																																											7,499
Debt maturity date																																												May 26, 2018
Common stock trading volume, percent																																												62.00%
Debt premium amount																																												$ 98,065
July 24, 2017 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]
Convertible debt principal amount																														$ 160,000
Debt maturity date																																									Mar. 24, 2018
Legal fees																														8,000
Proceed from note receivable net																														$ 152,000
July 24, 2017 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | July 2017 GS Note [Member]
Debt instrument, interest rate, stated percentage																																									8.00%
Convertible debt principal amount																																									$ 160,000
Accrued interest																	8,169																																											8,169
July 24, 2017 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | July 2017 GS Back-End Note [Member]
Debt instrument, interest rate, stated percentage																																									8.00%
Convertible debt principal amount																																									$ 160,000																		35,000
Accrued interest																																																											5,829
July 24, 2017 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | July 2017 GS Note and July 2017 GS Back-End Note [Member]
Debt maturity date													Jul. 24, 2018
Common stock trading volume, percent													62.00%
Common stock trading days | Integer													10
Debt premium amount													$ 98,065
July 24, 2017 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | July 2017 GS Back-End Note [Member]
Convertible debt principal amount																	125,000																																											125,000
Accrued interest																	3,420																																											3,420
September 21, 2017 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]
Convertible debt principal amount																												$ 160,000
Debt maturity date																																					Mar. 24, 2018
Legal fees																												8,000
Proceed from note receivable net																												152,000
September 21, 2017 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | September 2017 GS Note [Member]
Debt instrument, interest rate, stated percentage																																					8.00%
Convertible debt principal amount																																					$ 160,000																						130,000
Accrued interest																	1,289																																										9,695	1,289
Debt conversion of converted amount																	30,000
September 21, 2017 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | September 2017 Back-End Note [Member]
Debt instrument, interest rate, stated percentage																																					8.00%
Convertible debt principal amount																																					$ 160,000
September 21, 2017 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | September 2017 GS Note and September 2017 GS Back-End Note [Member]
Debt maturity date																																					Sep. 12, 2018
Common stock trading volume, percent																																					62.00%
Common stock trading days | Integer																																					10
Debt premium amount																												$ 98,065
September 21, 2017 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | September 2017 GS Back-End Note [Member]
Convertible debt principal amount																																																											160,000
Accrued interest																																																											7,119
March 23, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]
Convertible debt principal amount																					$ 106,000
Debt maturity date																									Nov. 23, 2018
Legal fees																					5,300
Proceed from note receivable net																					100,700
March 23, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | March 2018 GS Note [Member]
Debt instrument, interest rate, stated percentage																									8.00%
Convertible debt principal amount																									$ 106,000																																		106,000
Accrued interest																																																											2,765
March 23, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | March 2018 GS Back-End Note [Member]
Debt instrument, interest rate, stated percentage																									8.00%
Convertible debt principal amount																									$ 106,000																																		106,000
Accrued interest																																																											4,740
March 23, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | March 2018 GS Note and March 2018 GS Back-End Note [Member]
Debt maturity date																									Mar. 23, 2019
Common stock trading volume, percent																									62.00%
Common stock trading days | Integer																									10
Debt premium amount																					$ 64,968
April 13, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | April 2018 GS Note [Member]
Debt instrument, interest rate, stated percentage																								8.00%
Convertible debt principal amount								$ 150,000																$ 150,000																																			150,000
Accrued interest																																																											9,632
Legal fees								7,500
Proceed from note receivable net								$ 142,500
Debt premium amount																								$ 95,902
April 13, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | April 2018 GS Back-End Note [Member]
Debt instrument, interest rate, stated percentage																								8.00%
Convertible debt principal amount																								$ 150,000																																			150,000
Accrued interest																																																											1,606
Debt premium amount																								$ 95,902
April 13, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | April 2018 GS Note and April 2018 GS Back-End Note [Member]
Debt maturity date																								Apr. 13, 2019
Common stock trading volume, percent																								61.00%
Common stock trading days | Integer																								10
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]
Convertible debt principal amount																	687,000																																										35,820	687,000
Accrued interest																	19,877																																										7,813	19,877
November 2016 Consulting Agreement [Member]
Debt instrument, interest rate, stated percentage																																																				10.00%
Convertible debt principal amount																																																				$ 250,000
Debt instrument, term																																																				2 years
November 2016 Consulting Agreement [Member] | First Convertible Note [Member]
Convertible debt principal amount																	19,639																																			$ 250,000								19,639					27,500
Convertible debenture																																																				$ 1,250
Accrued interest																																																																	1,664
Common stock trading volume, percent																																																				65.00%
Common stock trading days | Integer																																																				10
Debt conversion price per share | $ / shares																																																				$ 2.50
Embedded derivative, fair value of embedded derivative liability																																																				$ 255,757
November 2016 Consulting Agreement [Member] | Second Convertible Note [Member]
Convertible debt principal amount																																																$ 250,000
Convertible debenture																																																$ 1,250
Accrued interest																	31,021																																											31,021
Common stock trading volume, percent																																																65.00%
Common stock trading days | Integer																																																10
Debt conversion price per share | $ / shares																																																$ 2.50
Embedded derivative, fair value of embedded derivative liability																																																$ 409,416
August 10, 2017 Consulting Agreement [Member]
Debt instrument, interest rate, stated percentage																																							10.00%
Convertible debt principal amount																																							$ 310,000																9,000		9,000		9,000
Accrued interest																																																							26,653		26,653		25,917
Debt conversion of converted amount																																							$ 750
Debt maturity date																																							Aug. 10, 2019
Common stock trading volume, percent																																							65.00%
Common stock trading days | Integer																																							10
Debt instrument, default, interest rate																																							18.00%
Accrued expenses																	155,000																																										155,000	155,000					$ 155,000
Embedded derivative, fair value of embedded derivative liability																																							$ 578,212
August 10, 2017 Consulting Agreement [Member] | Consultant [Member]
Convertible debt principal amount																	140,000																																										161,000	140,000
Accrued interest																	$ 10,764																																										19,418	$ 10,764
Debt conversion of converted amount																																																											161,000
January 22, 2018 Securities Purchase Agreement [Member] | Power Up Lending Group Ltd. [Member] | January 2018 Power Up Note [Member]
Debt instrument, interest rate, stated percentage																															8.00%
Convertible debt principal amount																															$ 153,000																												153,000
Derivative liability of convertible debenture																															$ 180,251
Accrued interest																																																											6,185
Debt maturity date																															Jan. 22, 2019
Common stock trading volume, percent																															65.00%
Common stock trading days | Integer																															10
Legal fees																													$ 2,500
Proceed from note receivable net																													153,000
Percentage of outstanding shares of common stock																															4.99%
Debt conversion price per share | $ / shares																															$ 50
Diligence fees																													500
Net cash proceeds from convertible promissory note																													$ 150,000
Debt instrument market price per share | $ / shares																															$ 0.10
Debt conversion price, description																															If the Market Price is greater than or equal to $50.00, the conversion price shall be the greater of 65% of the Market Price ("Variable Conversion Price") and $32.50. In the event Market Price is less than $50.00, the conversion price shall be the Variable Conversion Price.
January 22, 2018 Securities Purchase Agreement [Member] | Power Up Lending Group Ltd. [Member] | January 2018 Power Up Note [Member] | July 21, 2018 [Member]
Common stock trading volume, percent																															150.00%
March 5, 2018 Securities Purchase Agreement [Member] | Power Up Lending Group Ltd. [Member] | March 2018 Power Up Note [Member]
Debt instrument, interest rate, stated percentage																											8.00%
Convertible debt principal amount																											$ 53,000
Derivative liability of convertible debenture																											$ 65,231
Debt maturity date																											Mar. 5, 2019
Common stock trading volume, percent																											65.00%
Common stock trading days | Integer																											10
Legal fees																										$ 2,500
Proceed from note receivable net																										53,000
Percentage of outstanding shares of common stock																											4.99%
Debt conversion price per share | $ / shares																											$ 32.50
Diligence fees																										500
Net cash proceeds from convertible promissory note																										$ 50,000
Debt instrument market price per share | $ / shares																											$ 50
March 5, 2018 Securities Purchase Agreement [Member] | Power Up Lending Group Ltd. [Member] | March 2018 Power Up Note [Member] | September 1, 2018 [Member]
Common stock trading volume, percent																											150.00%
March 5, 2018 Securities Purchase Agreement [Member] | Power Up Lending Group Ltd. [Member] | March 5 2018 Power Up Note [Member]
Convertible debt principal amount												$ 53,000
Accrued interest												$ 2,033
Debt maturity date												Mar. 5, 2018
Debt penalty amount												$ 20,362
May 15, 2018 Securities Purchase Agreement [Member] | Power Up Lending Group Ltd. [Member] | May 2018 Power Up Note [Member]
Debt instrument, interest rate, stated percentage																							8.00%
Convertible debt principal amount						$ 53,000																	$ 53,000
Derivative liability of convertible debenture																							$ 33,744
Accrued interest						1,696
Debt maturity date																							May 5, 2019
Common stock trading volume, percent																							65.00%
Common stock trading days | Integer																							10
Legal fees																						$ 2,500
Proceed from note receivable net																						53,000
Percentage of outstanding shares of common stock																							4.99%
Debt conversion price per share | $ / shares																							$ 32.50
Diligence fees																						500
Net cash proceeds from convertible promissory note																						$ 50,000
Debt instrument market price per share | $ / shares																							$ 50
Debt penalty amount						$ 20,715
May 15, 2018 Securities Purchase Agreement [Member] | Power Up Lending Group Ltd. [Member] | May 2018 Power Up Note [Member] | November 11, 2018 [Member]
Common stock trading volume, percent																							150.00%
August 28, 2018 Securities Purchase Agreement [Member]
Debt Instrument, description												In the event that the Company fails to deliver to Power Up shares of common stock issuable upon conversion of principal or interest under the August 2018 Power Up Note within three business days of a notice of conversion by Power Up, the Company shall incur a penalty of $500, provided, however, that such fee shall not be due if the failure to deliver the shares is a result of a third party such as the transfer agent.
August 28, 2018 Securities Purchase Agreement [Member] | May 2018 Power Up Note [Member]
Debt instrument, interest rate, stated percentage												8.00%
Convertible debt principal amount												$ 53,000
Debt maturity date											Aug. 28, 2019
Legal fees											$ 2,500
Proceed from note receivable net											53,000
Debt instrument, default, interest rate												22.00%
Diligence fees											500
Net cash proceeds from convertible promissory note											$ 50,000
August 28, 2018 Securities Purchase Agreement [Member] | August 2018 Power Up Note [Member]
Convertible debt principal amount																																																															$ 53,000
Accrued interest																																																															$ 395
Penalty prepayment																																																											22,047
August 28, 2018 Securities Purchase Agreement [Member] | Power Up Lending Group Ltd. [Member] | February 24, 2019 [Member]
Common stock trading volume, percent												65.00%
Common stock trading days | Integer												10
Percentage of outstanding shares of common stock												4.99%
Debt conversion price per share | $ / shares												$ 32.50
Embedded derivative, fair value of embedded derivative liability												$ 396,380
Debt instrument market price per share | $ / shares												$ 50
Financing Agreement [Member] | JSJ Investments, Inc. [Member] | June 2018 JSJ Note [Member]
Debt instrument, interest rate, stated percentage																			8.00%
Convertible debt principal amount			$ 113,000																$ 113,000
Accrued interest			4,508
Debt maturity date																			Jun. 26, 2019
Legal fees																			$ 3,000
Debt premium amount																			60,846
Net cash proceeds from convertible promissory note																			$ 110,000
Debt penalty amount			$ 51,380
Debt Instrument, description																			The June 2018 JSJ Note may be prepaid until December 23, 2018. If the June 2018 JSJ Note is prepaid within 90 days of the issuance date, then the prepayment premium shall be 135% of the face amount plus any accrued interest; if the JSJ Note is prepaid after 90 days from the issuance date, but prior to 121 days from the issuance date, then the prepayment premium shall be 140% of the face amount plus any accrued interest; and if the June 2018 JSJ Note is prepaid after 120 days from the issuance date, but prior to 180 days from the issuance date, then the prepayment premium shall be 145% of the face amount plus any accrued interest.
Financing Agreement [Member] | JSJ Investments, Inc. [Member] | June 2018 JSJ Note [Member] | December 23, 2018 [Member]
Common stock trading days | Integer																			10
Coventry Enterprises LLC Financing Agreement [Member] | July 2018 Coventry Note [Member]
Convertible debt principal amount																																																											100,000
Accrued interest																																																											7,479
Coventry Enterprises LLC Financing Agreement [Member] | July 2018 Coventry Back-End Note [Member]
Convertible debt principal amount																																																											100,000
Accrued interest																																																											$ 8,137
Debt instrument, default, interest rate																																																											24.00%
Coventry Enterprises LLC Financing Agreement [Member] | July 2018 Coventry Enterprises Note [Member]
Payment of notes receivable									$ 100,000
Legal fees									5,000
Proceed from note receivable net									$ 95,000
Issuance on offsetting collateralized secured note																		$ 100,000
Coventry Enterprises LLC Financing Agreement [Member] | July 2018 Coventry Note and July 2018 Coventry Back-End Note [Member]
Debt maturity date																																																											Jun. 29, 2019
Common stock trading volume, percent																																																											61.00%
Debt Instrument, description																																																											Coventry Enterprises shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Coventry Enterprises and its affiliates, exceeds 9.9% of the outstanding shares of the Company's common stock.
Amortization of debt discount																																																											$ 63,934
Coventry Enterprises LLC Financing Agreement [Member] | Coventry Enterprises, LLC [Member]
Debt instrument, interest rate, stated percentage																		8.00%
Convertible debt principal amount																		$ 200,000
Coventry Enterprises LLC Financing Agreement [Member] | Coventry Enterprises, LLC [Member] | July 2018 Coventry Note [Member]
Convertible debt principal amount																		100,000
Proceeds from convertible debt																		95,000
Coventry Enterprises LLC Financing Agreement [Member] | Coventry Enterprises, LLC [Member] | July 2018 Coventry Back-End Note [Member]
Convertible debt principal amount																		$ 100,000
Debt maturity date																		Feb. 28, 2019
Redstart Holdings Corp Financing Agreement [Member]
Convertible debt principal amount																																																							46,600		46,600
Amortization of debt discount																																																									18,266
Redstart Holdings Corp Financing Agreement [Member] | Redstart Holdings Note [Member] | November 19, 2019 [Member]
Common stock trading volume, percent		65.00%
Debt instrument, default, interest rate		22.00%
Debt conversion price per share | $ / shares		$ 32.50
Embedded derivative, fair value of embedded derivative liability		$ 166,564
Debt instrument market price per share | $ / shares		$ 50
Debt Instrument, description		The Company had the right to prepay the May 2019 Redstart Holdings Note until November 19, 2019. If the May 2019 Redstart Holdings Note was prepaid within 90 days of the issuance date, then the prepayment premium shall be 115% of the face amount plus any accrued interest; if the May 2019 Redstart Holdings Note was prepaid after 91 days from the issuance date, but prior to 121 days from the issuance date, then the prepayment premium shall be 120% of the face amount plus any accrued interest; and if the May 2019 Redstart Holdings Note was prepaid after 121 days from the issuance date, but prior to 150 days from the issuance date, then the prepayment premium shall be 125% of the face amount plus any accrued interest; and if the May 2019 Redstart Holdings Note was prepaid after 151 days from the issuance date, but prior to 180 days from the issuance date, then the prepayment premium shall be 129% of the face amount plus any accrued interest.
Redstart Holdings Corp Financing Agreement [Member] | Redstart Holdings Corp [Member]
Debt instrument, interest rate, stated percentage		8.00%
Convertible debt principal amount		$ 133,000																																																					86,400		86,400		133,000
Accrued interest																																																							$ 6,322		$ 6,322		$ 1,137
Debt maturity date		May 23, 2020
Legal fees		$ 3,000
Percentage of outstanding shares of common stock		4.99%
Proceeds from convertible debt		$ 130,000
Redstart Holdings Corp Financing Agreement [Member] | Redstart Holdings Corp [Member] | Redstart Holdings Note [Member]
Debt instrument, interest rate, stated percentage		8.00%
Debt maturity date		May 23, 2020
Legal fees		$ 3,000
Proceed from note receivable net		$ 130,000

Convertible Notes - Schedule of

Convertible Notes - Schedule of Convertible Notes (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Debt Disclosure [Abstract]
Convertible notes and debenture	$ 2,016,365	$ 1,076,785	$ 3,096,935
Unamortized discounts	(415,712)	(131,893)	(277,733)
Accrued interest	182,581	99,842	148,930
Premiums	1,151,106	613,003	1,731,167
Convertible notes, net	$ 2,934,340	$ 1,657,377	$ 4,699,299

Income Taxes (Details Narrative

Income Taxes (Details Narrative) (10-K) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Income tax percentage description			On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act ("TCJA") was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for fiscal years beginning after December 31, 2017.		On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act ("TCJA") was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for fiscal years beginning after December 31, 2017.
Income tax percentage					21.00%
Income tax benefit	$ 143	$ (116,970)	$ (108,751)	$ (116,970)	$ (115,437)	$ (179,306)
Unrecognized tax benefits
Changes in unrecognized tax benefits
U.S [Member]
Net operating loss carry forwards					2,942,144
Federal [Member]
Net operating loss carry forwards					$ 2,900,000
Operating loss carryforward limitation					The remaining balance of $0.2 million is limited in annual usage of 80% of current years taxable income, but do not have an expiration.
Federal [Member] | Expire in 2030 [Member]
Net operating loss carry forwards					$ 2,700,000
Federal [Member] | No Expiration [Member]
Net operating loss carry forwards					200,000
Australia [Member]
Income tax benefit
Australia [Member] | No Expiration [Member]
Net operating loss carry forwards					$ 21,655,871
Tax Cuts and Jobs Act [Member]
Income tax percentage description					On December 22, 2017, the Tax Cuts and Jobs Act ("The Act"), was signed into law by President Trump. The Act includes a number of provisions, including the lowering of the U.S. corporate tax rate from 34 percent to 21 percent
Income tax percentage					21.00%
Changes in deferred tax assets					$ 416,339

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Provision (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income before Income taxes					$ (5,758,369)	$ (7,039,155)
Taxes under statutory US tax rates					(1,209,258)	(1,478,222)
Increase (decrease) in valuation allowance					1,394,444	1,418,349
Change in Federal tax rates						(99,013)
Foreign tax rate differential					(186,286)	(5,043)
Other					1,100	(114,391)
Income tax (expense) benefit	$ 143	$ (116,970)	$ (108,751)	$ (116,970)	$ (115,437)	$ (179,306)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Warrant Derivative Liability	$ 7,403	$ 7,403
Provision for Annual Leave	96,759	44,969
Superannuation	9,473	4,041
Prepaid Investor Services	414,396	353,553
Capital Raising Costs		23,559
Legal Costs	91,961	23,885
Intellectual Property	41,686	11,760
Patent Costs	171,195	171,195
Formation Expense	7,208	7,208
Net Operating Loss CF	6,573,215	5,668,743
Foreign Exchange Loss (OCI)	(39,379)	(39,379)
Revalue of derivative liability	519,151
Stock Based Compensation	51,481
Total Deferred tax assets	7,944,549	6,276,937
R&D	(139,833)
Capital Raising Costs	(133,335)
Total deferred tax liabilities	(273,168)
Net deferred tax assets (liabilities)	7,671,381	6,276,937
Valuation allowance	(7,671,381)	(6,276,937)
Net deferred tax assets (liabilities)

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Sep. 10, 2019	Jul. 19, 2019	Jun. 24, 2019	Apr. 14, 2016	May 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jan. 02, 2020	Aug. 31, 2019	Sep. 21, 2018	Sep. 20, 2018	Jan. 23, 2018	Jan. 22, 2018	Dec. 09, 2014
Reverse stock split			one-for-five hundred (1:500)
Common stock, par value			$ 0.001			$ 0.001		$ 0.001	$ 0.001
Common stock, shares authorized			100,000,000			100,000,000		100,000,000	100,000,000			4,000,000,000	400,000,000	400,000,000	100,000,000
Preferred stock, shares authorized						1,500,005		1,500,005	1,500,005							500,000
Preferred stock, par value						$ 0.01		$ 0.01	$ 0.01
Common stock issued during period		20,000				1,246,859
Debt conversion price per share										$ 0.165
Conversion price, decrease						$ 0.067
Conversion price, increase						$ 0.906
Conversion of principal and interest, aggregate amount						$ 318,768
Additional paid in capital						47,766,162		$ 45,713,322	$ 38,214,213	$ 410,750
Embedded derivative liability						$ 924,744		698,264	371,532
Common stock reserved for future issuances						77,292,139
Share issued price per share		$ 1.99
Proceeds from issuance of common stock		$ 39,800					$ 405,773	1,100,380
Consulting expenses						39,800
Number of restricted shares issued					78,000
Share based compensation arrangement by share based payment award options grant date fair value				$ 3,924,880
Share Based Compensation						$ 150,208
Warrants to purchase common stock	1,000,000
Warrant exercise price	$ 2
Warrant expiration date	Sep. 10, 2022
Fair value of warrants	$ 984,810
Share-based Payment Arrangement, Option [Member]
Granted exercise price						$ 76.37
Share Based Compensation					$ 41,437
Grant options to purchase						59,644
Exercise price					$ 4.65
Risk free rate					2.42%
Dividend yield					0.00%
Fair value term					10 years
Expected volatility					268.00%
Option granted value					$ 248,620
Common Stock [Member]
Amount recorded to equity						$ 343,179
Embedded conversion option derivatives						46,600
Fair market value of shares issued value						71,011
Loss on extinguishment						24,411
Gain on extinguishment						44,587
Additional paid in capital						160,205
First Warrant [Member]
Warrants to purchase common stock											450,000
Warrant exercise price											$ 2.25
Second Warrant [Member]
Warrants to purchase common stock											300,000
Warrant exercise price											$ 3.33
Third Warrant [Member]
Warrants to purchase common stock											225,000
Warrant exercise price											$ 4.50
Warrant [Member]
Share Based Compensation						$ 984,810
Warrants outstanding and exercisable						1,975,059
Warrants expiration term description						As of December 31, 2019, there were 1,975,059 warrants outstanding and exercisable with expiration dates commencing May 2020 and continuing through August 2024, with a weighted average exercise price per share of $2.69.		Expiration dates commencing May 2020 and continuing through November 2020
Restricted Stock Units (RSUs) [Member]
Number of restricted shares issued					117,000
Granted exercise price					$ 4.25
Share based compensation arrangement by share based payment award options grant date fair value					$ 497,240
Share Based Compensation						$ 108,771
Unrecognized restricted stock units expense						357,392
Restricted Stock [Member]
Unvested stock option recognized						$ 196,824
Chief Executive Officer [Member]
Common stock issued during period					58,500
Number of restricted shares issued					39,000
Granted exercise price				$ 3,750
Share based compensation arrangement by share based payment award options grant date fair value				$ 1,962,440
Grant options to purchase				572
Option Description					The total 58,500 options have a term of 10 years from the date of grant and exercise price ranging from $4.25 to $4.675 per share. 1/3rd of these options shall vest every successive one-year anniversary, provided, that on each such vesting date, the Chief Executive Officer and Chief Scientific Officer are employed by the Company and subject to the other provisions of the employment agreement. The 58,500 stock options were valued using a Black-Scholes model with the following assumptions: stock price at valuation date of $4.25 based on quoted trading price on date of grant, exercise price of $4.65, dividend yield of zero, years to maturity of 10.00, a risk free rate of 2.42%, and expected volatility 268% for a total value of $248,620.
Chief Executive Officer [Member] | Share-based Payment Arrangement, Option [Member]
Grant options to purchase					39,000
Chief Scientific Officer [Member] | Share-based Payment Arrangement, Option [Member]
Grant options to purchase					19,500
Convertible Debt [Member]
Debt conversion price per share						$ 0.3575
Embedded derivative liability						$ 343,179
Fair market value of shares						$ 343,179
Series A Preferred Stock [Member]
Preferred stock, shares authorized						500,000		500,000	500,000							500,000
Preferred stock, par value						$ 0.01		$ 0.01	$ 0.01
Preferred stock, shares issued						500,000		500,000	500,000
Preferred stock, shares outstanding						500,000		500,000	500,000

Stockholders' Deficit (Detail_2

Stockholders' Deficit (Details Narrative) (10-K) - USD ($)	Jan. 02, 2020	Jul. 19, 2019	Jun. 28, 2019	Jun. 26, 2019	Jun. 24, 2019	Jun. 16, 2019	May 24, 2019	May 17, 2019	May 06, 2019	May 02, 2019	Apr. 22, 2019	Apr. 18, 2019	Apr. 08, 2019	Mar. 26, 2019	Mar. 25, 2019	Mar. 15, 2019	Mar. 08, 2019	Mar. 07, 2019	Feb. 26, 2019	Feb. 25, 2019	Feb. 19, 2019	Feb. 08, 2019	Jan. 29, 2019	Jan. 16, 2019	Jan. 03, 2019	Dec. 31, 2018	Dec. 27, 2018	Dec. 20, 2018	Dec. 18, 2018	Dec. 13, 2018	Dec. 06, 2018	Dec. 04, 2018	Nov. 29, 2018	Nov. 28, 2018	Nov. 23, 2018	Nov. 16, 2018	Nov. 05, 2018	Oct. 25, 2018	Oct. 24, 2018	Oct. 19, 2018	Oct. 16, 2018	Oct. 08, 2018	Oct. 05, 2018	Sep. 27, 2018	Sep. 26, 2018	Sep. 21, 2018	Sep. 19, 2018	Sep. 14, 2018	Sep. 12, 2018	Sep. 11, 2018	Sep. 07, 2018	Sep. 06, 2018	Sep. 05, 2018	Sep. 04, 2018	Aug. 31, 2018	Aug. 29, 2018	Aug. 28, 2018	Aug. 27, 2018	Aug. 24, 2018	Aug. 22, 2018	Aug. 20, 2018	Aug. 13, 2018	Aug. 08, 2018	Aug. 07, 2018	Aug. 03, 2018	Aug. 02, 2018	Jul. 31, 2018	Jul. 30, 2018	Jul. 26, 2018	Jul. 25, 2018	Jul. 24, 2018	Jul. 23, 2018	Jul. 22, 2018	Jul. 17, 2018	Jul. 15, 2018	Jul. 13, 2018	Jul. 10, 2018	Jul. 06, 2018	Jul. 02, 2018	Jun. 23, 2018	Jun. 21, 2018	Jun. 20, 2018	Jun. 15, 2018	Jun. 08, 2018	Jun. 07, 2018	May 18, 2018	May 15, 2018	May 14, 2018	Apr. 30, 2018	Apr. 26, 2018	Apr. 18, 2018	Apr. 14, 2018	Apr. 12, 2018	Apr. 11, 2018	Apr. 05, 2018	Apr. 03, 2018	Apr. 02, 2018	Mar. 26, 2018	Mar. 21, 2018	Mar. 16, 2018	Mar. 14, 2018	Mar. 11, 2018	Mar. 08, 2018	Mar. 05, 2018	Mar. 04, 2018	Feb. 28, 2018	Feb. 23, 2018	Feb. 21, 2018	Feb. 15, 2018	Feb. 13, 2018	Feb. 04, 2018	Feb. 02, 2018	Jan. 31, 2018	Jan. 30, 2018	Jan. 26, 2018	Jan. 12, 2018	Jan. 09, 2018	Jan. 04, 2018	Jan. 03, 2018	Jan. 02, 2018	Dec. 29, 2017	Dec. 22, 2017	Dec. 21, 2017	Dec. 19, 2017	Dec. 18, 2017	Dec. 15, 2017	Dec. 11, 2017	Dec. 08, 2017	Dec. 06, 2017	Dec. 01, 2017	Nov. 27, 2017	Nov. 26, 2017	Nov. 17, 2017	Nov. 15, 2017	Nov. 13, 2017	Nov. 08, 2017	Nov. 06, 2017	Nov. 02, 2017	Oct. 30, 2017	Oct. 27, 2017	Oct. 24, 2017	Oct. 23, 2017	Oct. 19, 2017	Oct. 18, 2017	Oct. 16, 2017	Oct. 11, 2017	Oct. 10, 2017	Oct. 09, 2017	Oct. 05, 2017	Oct. 04, 2017	Oct. 02, 2017	Sep. 26, 2017	Sep. 25, 2017	Sep. 18, 2017	Sep. 14, 2017	Sep. 08, 2017	Sep. 06, 2017	Sep. 03, 2017	Aug. 29, 2017	Aug. 25, 2017	Aug. 22, 2017	Aug. 17, 2017	Aug. 16, 2017	Aug. 02, 2017	Aug. 01, 2017	Jul. 28, 2017	Jul. 20, 2017	Jul. 17, 2017	Jul. 13, 2017	Jul. 05, 2017	Apr. 14, 2017	Apr. 14, 2016	May 31, 2019	May 31, 2019	Mar. 31, 2019	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Dec. 02, 2018	Nov. 20, 2018	Sep. 20, 2018	Jan. 23, 2018	Jan. 22, 2018	Jun. 16, 2015	Dec. 09, 2014
Common stock, shares authorized					100,000,000																																									4,000,000,000																																																																																																																																		100,000,000			100,000,000		100,000,000	100,000,000				400,000,000	400,000,000	100,000,000
Reverse stock split					one-for-five hundred (1:500)
Common stock, par value					$ 0.001																																																																																																																																																																											$ 0.001			$ 0.001		$ 0.001	$ 0.001
Stock split, description					The Company effected a one-for-five hundred (1:500) reverse stock split whereby the Company (i) decreased the number of authorized shares of common stock, $0.001 par value per share, to 100,000,000 and (ii) decreased by a ratio of one-for-five hundred (1:500) the number of retroactively issued and outstanding shares of common stock.
Preferred stock, shares authorized																																																																																																																																																																																1,500,005			1,500,005		1,500,005	1,500,005								500,000
Preferred stock, par value																																																																																																																																																																																$ 0.01			$ 0.01		$ 0.01	$ 0.01
Consulting expense																																																																																																																																																																																			$ 39,800
Loss on settlement of debt	$ 146,367																																																																																																																																																																															$ 20,176		$ (20,355)	$ 20,176	$ 1,165,516	$ 1,204,242	$ 251,392
Share issued price per share		$ 1.99
Number of restricted shares issued																																																																																																																																																																														78,000
Number of common shares issued during period		20,000																																																																																																																																																																																	1,246,859
Number of common stock for services, value																																																																																																																																																																																	$ 39,800	$ 69,000			169,000	130,000
Proceeds from issuance of common stock		$ 39,800																																																																																																																																																																																		405,773	1,100,380
Number of common shares reserved for future issuance																																																																																																																																																																																77,292,139			77,292,139
Debt conversion price per share	$ 0.165
Shares issued for conversion of convertible debt	2,804,424
Number of shares vested																																																																																																																																																																												191
Stock option expire date																																																																																																																																																																												Apr. 14, 2021
Share based compensation arrangement by share based payment award options grant date fair value																																																																																																																																																																												$ 3,924,880
Stock option expense																																																																																																																																																																																						516,148
Option term																																																																																																																																																																																					9 years 8 months 19 days
Stock price																																																																																																																																																																																$ 0.38			$ 0.38		$ 6
2019 Equity Incentive Plan [Member]
Number of common shares reserved for future issuance																																																																																																																																																																																					234,000
Shares Issued One [Member]
Debt principal balance																																																																															$ 35,000																																																																																											$ 26,000
Debt interest amount																																																																															$ 2,808																																																																																											$ 1,121
Debt conversion price per share																																																																															$ 14.97																																																																																											$ 270
Shares issued for conversion of convertible debt																																																																															2,526																																																																																											100
Shares Issued Two [Member]
Debt principal balance																																																																														$ 40,000																																																																																											$ 42,500
Debt interest amount																																																																														$ 4,570
Debt conversion price per share																																																																														$ 13.80																																																																																											$ 315
Shares issued for conversion of convertible debt																																																																														3,230																																																																																											135
Shares Issued Three [Member]
Debt principal balance																																																																													$ 25,000																																																																																											$ 16,000
Debt interest amount																																																																													$ 2,050																																																																																											$ 732
Debt conversion price per share																																																																													$ 13.20																																																																																											$ 200
Shares issued for conversion of convertible debt																																																																													2,049																																																																																											83
Shares Issued Four [Member]
Debt principal balance																																																																													$ 35,000																																																																																										$ 28,000
Debt interest amount																																																																													$ 1,281																																																																																										$ 1,300
Debt conversion price per share																																																																													$ 13.64																																																																																										$ 145
Shares issued for conversion of convertible debt																																																																													2,660																																																																																										203
Shares Issued Five [Member]
Debt principal balance																																																																												$ 30,000																																																																																										$ 22,500
Debt interest amount																																																																												$ 2,480																																																																																										$ 1,593
Debt conversion price per share																																																																												$ 10.26																																																																																										$ 130
Shares issued for conversion of convertible debt																																																																												3,166																																																																																										187
Shares Issued Six [Member]
Debt principal balance																																																																											$ 30,000																																																																																									$ 20,000
Debt interest amount																																																																											$ 3,484
Debt conversion price per share																																																																											$ 10.80																																																																																									$ 140
Shares issued for conversion of convertible debt																																																																											3,100																																																																																									142
Shares Issued Seven [Member]
Debt principal balance																																																																										$ 20,000																																																																																										$ 25,000
Debt interest amount																																																																										$ 1,671																																																																																										$ 1,233
Debt conversion price per share																																																																										$ 9.60																																																																																										$ 105
Shares issued for conversion of convertible debt																																																																										2,257																																																																																										250
Shares Issued Eight [Member]
Debt principal balance																																																																									$ 30,000																																																																																										$ 25,000
Debt interest amount																																																																									$ 3,529																																																																																										$ 1,311
Debt conversion price per share																																																																									$ 8.15																																																																																										$ 115
Shares issued for conversion of convertible debt																																																																									4,114																																																																																										224
Shares Issued Nine [Member]
Debt principal balance																																																																								$ 30,000																																																																																										$ 20,000
Debt interest amount																																																																								$ 1,959
Debt conversion price per share																																																																								$ 9.30																																																																																										$ 150
Shares issued for conversion of convertible debt																																																																								3,437																																																																																										132
Shares Issued Ten [Member]
Debt principal balance																																																																							$ 30,000																																																																																										$ 20,000
Debt interest amount																																																																							$ 2,553																																																																																										$ 1,500
Debt conversion price per share																																																																							$ 7.50																																																																																										$ 125
Shares issued for conversion of convertible debt																																																																							4,340																																																																																										170
Shares Issued Eleven [Member]
Debt principal balance																																																																						$ 20,000																																																																																										$ 25,000
Debt interest amount																																																																																																																																																																$ 1,361
Debt conversion price per share																																																																						$ 8.99																																																																																										$ 115
Shares issued for conversion of convertible debt																																																																						2,225																																																																																										225
Shares Issued Twelve [Member]
Debt principal balance																																																																					$ 20,000																																																																																										$ 20,000
Debt interest amount
Debt conversion price per share																																																																					$ 7.85																																																																																										$ 120
Shares issued for conversion of convertible debt																																																																					2,548																																																																																										164
Shares Issued Thirteen [Member]
Debt principal balance																																																																				$ 20,000																																																																																										$ 20,000
Debt interest amount																																																																																																																																																														$ 1,661
Debt conversion price per share																																																																				$ 7.20																																																																																										$ 100
Shares issued for conversion of convertible debt																																																																				2,778																																																																																										213
Shares Issued Fourteen [Member]
Debt principal balance																																																																			$ 20,000																																																																																										$ 12,500
Debt interest amount																																																																			$ 1,733																																																																																										$ 714
Debt conversion price per share																																																																			$ 5.85																																																																																										$ 95
Shares issued for conversion of convertible debt																																																																			3,715																																																																																										142
Shares Issued Fifteen [Member]
Debt principal balance																																																																			$ 15,000																																																																																									$ 20,000
Debt interest amount
Debt conversion price per share																																																																			$ 7.20																																																																																									$ 120
Shares issued for conversion of convertible debt																																																																			2,083																																																																																									166
Shares Issued Sixteen [Member]
Debt principal balance																																																																		$ 20,000																																																																																									$ 15,000
Debt interest amount																																																																		$ 1,742																																																																																									$ 450
Debt conversion price per share																																																																		$ 5.13																																																																																									$ 75
Shares issued for conversion of convertible debt																																																																		4,238																																																																																									206
Shares Issued Seventeen [Member]
Debt principal balance																																																																		$ 15,000																																																																																									$ 20,000
Debt interest amount																																																																																																																																																											$ 1,665
Debt conversion price per share																																																																		$ 5.95																																																																																									$ 80
Shares issued for conversion of convertible debt																																																																		2,521																																																																																									278
Shares Issued Eighteen [Member]
Debt principal balance																																																																	$ 10,000																																																																																									$ 20,000
Debt interest amount																																																																	$ 873
Debt conversion price per share																																																																	$ 4.59																																																																																									$ 95
Shares issued for conversion of convertible debt																																																																	2,369																																																																																									215
Shares Issued Nineteen [Member]
Debt principal balance																																																																	$ 25,000																																																																																								$ 20,000
Debt interest amount																																																																	$ 1,693																																																																																								$ 649
Debt conversion price per share																																																																	$ 5.30																																																																																								$ 70
Shares issued for conversion of convertible debt																																																																	5,035																																																																																								299
Shares Issued Twenty [Member]
Debt principal balance																																																																$ 20,000																																																																																								$ 30,000
Debt interest amount
Debt conversion price per share																																																																$ 4.60																																																																																								$ 90
Shares issued for conversion of convertible debt																																																																4,348																																																																																								337
Shares Issued Twenty One [Member]
Debt principal balance																																																															$ 15,000																																																																																									$ 20,000
Debt interest amount																																																															$ 1,871																																																																																									$ 1,716
Debt conversion price per share																																																															$ 3.90																																																																																									$ 75
Shares issued for conversion of convertible debt																																																															4,326																																																																																									291
Shares Issued Twenty Two [Member]
Debt principal balance																																																															$ 18,000																																																																																								$ 25,000
Debt interest amount																																																															$ 2,195																																																																																								$ 850
Debt conversion price per share																																																															$ 2.80																																																																																								$ 70
Shares issued for conversion of convertible debt																																																															7,225																																																																																								375
Shares Issued Twenty Three [Member]
Debt principal balance																																																														$ 15,000																																																																																								$ 40,000
Debt interest amount																																																														$ 1,343
Debt conversion price per share																																																														$ 2.85																																																																																								$ 90
Shares issued for conversion of convertible debt																																																														5,735																																																																																								449
Shares Issued Twenty Four [Member]
Debt principal balance																																																														$ 15,000																																																																																							$ 20,000
Debt interest amount																																																														$ 1,049																																																																																							$ 1,716
Debt conversion price per share																																																														$ 2.95																																																																																							$ 75
Shares issued for conversion of convertible debt																																																														5,449																																																																																							291
Shares Issued Twenty Five [Member]
Debt principal balance																																																														$ 20,000																																																																																						$ 30,000
Debt interest amount																																																																																																																																																				$ 1,067
Debt conversion price per share																																																														$ 3.20																																																																																						$ 70
Shares issued for conversion of convertible debt																																																														6,250																																																																																						431
Shares Issued Twenty Six [Member]
Debt principal balance																																																													$ 10,000																																																																																						$ 45,000
Debt interest amount																																																													$ 647
Debt conversion price per share																																																													$ 1.59																																																																																						$ 95
Shares issued for conversion of convertible debt																																																													6,696																																																																																						484
Shares Issued Twenty Seven [Member]
Debt principal balance																																																													$ 12,430																																																																																					$ 20,000
Debt interest amount																																																																																																																																																		$ 1,812
Debt conversion price per share																																																													$ 1.90																																																																																					$ 80
Shares issued for conversion of convertible debt																																																													6,542																																																																																					280
Shares Issued Twenty Eight [Member]
Debt principal balance																																																												$ 14,000																																																																																					$ 20,000
Debt interest amount																																																												$ 1,006																																																																																					$ 1,834
Debt conversion price per share																																																												$ 1.64																																																																																					$ 80
Shares issued for conversion of convertible debt																																																												9,134																																																																																					269
Shares Issued Twenty Nine [Member]
Debt principal balance																																																												$ 10,570																																																																																				$ 25,000
Debt interest amount																																																												$ 885																																																																																				$ 939
Debt conversion price per share																																																												$ 1.75																																																																																				$ 65
Shares issued for conversion of convertible debt																																																												6,546																																																																																				393
Shares Issued Thirty [Member]
Debt principal balance																																																											$ 10,000																																																																																				$ 30,000
Debt interest amount																																																											$ 656
Debt conversion price per share																																																											$ 1.38																																																																																				$ 80
Shares issued for conversion of convertible debt																																																											7,721																																																																																				387
Shares Issued Thirty One [Member]
Debt principal balance																																																																																																																																														$ 20,000
Debt interest amount																																																										$ 5,235																																																																																				$ 1,884
Debt conversion price per share																																																										$ 1.48																																																																																				$ 55
Shares issued for conversion of convertible debt																																																										3,537																																																																																				396
Shares Issued Thirty Two [Member]
Debt principal balance																																																									$ 8,500																																																																																				$ 21,000
Debt interest amount																																																									$ 565																																																																																				$ 817
Debt conversion price per share																																																									$ 1.17																																																																																				$ 55
Shares issued for conversion of convertible debt																																																									7,748																																																																																				404
Shares Issued Thirty Three [Member]
Debt principal balance																																																									$ 10,250																																																																																			$ 15,000
Debt interest amount																																																									$ 750
Debt conversion price per share																																																									$ 1.21																																																																																			$ 45
Shares issued for conversion of convertible debt																																																									9,099																																																																																			320
Shares Issued Thirty Four [Member]
Debt principal balance																																																								$ 8,450																																																																																			$ 8,750
Debt interest amount																																																								$ 563																																																																																			$ 352
Debt conversion price per share																																																								$ 1.17																																																																																			$ 35
Shares issued for conversion of convertible debt																																																								7,704																																																																																			289
Shares Issued Thirty Five [Member]
Debt principal balance																																																							$ 9,000																																																																																				$ 20,000
Debt interest amount																																																							$ 1,159																																																																																				$ 1,902
Debt conversion price per share																																																							$ 1.28																																																																																				$ 35
Shares issued for conversion of convertible debt																																																							7,946																																																																																				602
Shares Issued Thirty Six [Member]
Debt principal balance																																																						$ 3,000																																																																																				$ 5,000
Debt interest amount																																																						$ 237																																																																																				$ 8,250
Debt conversion price per share																																																						$ 1.17																																																																																				$ 45
Shares issued for conversion of convertible debt																																																						2,766																																																																																				311
Shares Issued Thirty Seven [Member]
Debt principal balance																																																					$ 3,000																																																																																				$ 12,750
Debt interest amount																																																					$ 237																																																																																				$ 533
Debt conversion price per share																																																					$ 1.17																																																																																				$ 25
Shares issued for conversion of convertible debt																																																					2,767																																																																																				490
Shares Issued Thirty Eight [Member]
Debt principal balance																																																				$ 28,750																																																																																					$ 17,500
Debt interest amount
Debt conversion price per share																																																				$ 1.15																																																																																					$ 35
Shares issued for conversion of convertible debt																																																				25,000																																																																																					502
Shares Issued Thirty Nine [Member]
Debt principal balance																																																				$ 7,250																																																																																				$ 20,000
Debt interest amount																																																				$ 545																																																																																				$ 2,356
Debt conversion price per share																																																				$ 1.21																																																																																				$ 30
Shares issued for conversion of convertible debt																																																				6,448																																																																																				764
Shares Issued Forty [Member]
Debt principal balance																																																				$ 9,000																																																																																			$ 11,000
Debt interest amount																																																				$ 1,194																																																																																			$ 623
Debt conversion price per share																																																				$ 1.28																																																																																			$ 25
Shares issued for conversion of convertible debt																																																				7,973																																																																																			430
Shares Issued Forty One [Member]
Debt principal balance																																																			$ 5,000																																																																																			$ 20,000
Debt interest amount																																																			$ 343																																																																																			$ 2,443
Debt conversion price per share																																																			$ 1.17																																																																																			$ 30
Shares issued for conversion of convertible debt																																																			4,567																																																																																			767
Shares Issued Forty Two [Member]
Debt principal balance																																																		$ 28,500																																																																																			$ 15,000
Debt interest amount																																																		$ 2,174
Debt conversion price per share																																																		$ 7.75																																																																																			$ 35
Shares issued for conversion of convertible debt																																																		3,958																																																																																			430
Shares Issued Forty Three [Member]
Debt principal balance																																																	$ 25,000																																																																																			$ 20,000
Debt interest amount																																																	$ 3,288																																																																																			$ 2,568
Debt conversion price per share																																																	$ 6.60																																																																																			$ 30
Shares issued for conversion of convertible debt																																																	4,289																																																																																			772
Shares Issued Forty Four [Member]
Debt principal balance																																																$ 50,000																																																																																			$ 20,000
Debt interest amount																																																$ 4,056																																																																																			$ 1,196
Debt conversion price per share																																																$ 13.95																																																																																			$ 25
Shares issued for conversion of convertible debt																																																3,875																																																																																			785
Shares Issued Forty Five [Member]
Debt principal balance																																																$ 131,500																																																																																		$ 20,000
Debt interest amount																																																$ 5,707																																																																																		$ 802
Debt conversion price per share																																																$ 14.42																																																																																		$ 30
Shares issued for conversion of convertible debt																																																9,518																																																																																		746
Shares Issued Forty Six [Member]
Debt principal balance																																															$ 28,500																																																																																		$ 21,000
Debt interest amount																																															$ 1,268																																																																																		$ 1,297
Debt conversion price per share																																															$ 17.86																																																																																		$ 25
Shares issued for conversion of convertible debt																																															1,667																																																																																		826
Shares Issued Forty Seven [Member]
Debt principal balance																																														$ 30,000																																																																																		$ 9,900
Debt interest amount																																														$ 2,153																																																																																		$ 792
Debt conversion price per share																																														$ 17.28																																																																																		$ 25
Shares issued for conversion of convertible debt																																														1,861																																																																																		396
Shares Issued Forty Eight [Member]
Debt principal balance																																													$ 128,500																																																																																			$ 42,666
Debt interest amount																																													$ 9,333
Debt conversion price per share																																													$ 16.80																																																																																			$ 35
Shares issued for conversion of convertible debt																																													8,178																																																																																			1,223
Shares Issued Forty Nine [Member]
Debt principal balance																																													$ 106,000																																																																																		$ 9,900
Debt interest amount																																													$ 2,765																																																																																		$ 799
Debt conversion price per share																																													$ 17.36																																																																																		$ 25
Shares issued for conversion of convertible debt																																													6,265																																																																																		396
Shares Issued Fifty [Member]
Debt principal balance																																												$ 75,000																																																																																			$ 27,000
Debt interest amount																																												$ 4,917																																																																																			$ 1,142
Debt conversion price per share																																												$ 16.80																																																																																			$ 30
Shares issued for conversion of convertible debt																																												4,757																																																																																			1,009
Shares Issued Fifty One [Member]
Debt principal balance																																										$ 125,000																																																																																					$ 42,666
Debt interest amount																																										$ 8,500
Debt conversion price per share																																										$ 16.80																																																																																					$ 35
Shares issued for conversion of convertible debt																																										7,946																																																																																					1,223
Shares Issued Fifty Two [Member]
Debt principal balance																																										$ 65,000																																																																																				$ 56,758
Debt interest amount																																										$ 6,110
Debt conversion price per share																																										$ 16.80																																																																																				$ 40
Shares issued for conversion of convertible debt																																										4,233																																																																																				1,465
Shares Issued Fifty Three [Member]
Debt principal balance																																									$ 106,000																																																																																				$ 30,000
Debt interest amount																																									$ 4,740																																																																																				$ 2,467
Debt conversion price per share																																									$ 21.70																																																																																				$ 35
Shares issued for conversion of convertible debt																																									5,103																																																																																				958
Shares Issued Fifty Four [Member]
Debt principal balance																																								$ 50,000																																																																																				$ 23,000
Debt interest amount																																								$ 6,956																																																																																				$ 1,013
Debt conversion price per share																																								$ 21																																																																																				$ 35
Shares issued for conversion of convertible debt																																								2,712																																																																																				738
Shares Issued Fifty Five [Member]
Debt principal balance																																							$ 100,000																																																																																				$ 63,000
Debt interest amount																																							$ 14,022
Debt conversion price per share																																							$ 20.40																																																																																				$ 40
Shares issued for conversion of convertible debt																																							5,589																																																																																				1,578
Shares Issued Fifty Six [Member]
Debt principal balance																																						$ 85,000																																																																																				$ 25,000
Debt interest amount																																						$ 820																																																																																				$ 2,078
Debt conversion price per share																																						$ 20.74
Shares issued for conversion of convertible debt																																						4,138																																																																																				860
Shares Issued Fifty Seven [Member]
Debt principal balance																																					$ 65,000																																																																																			$ 25,000
Debt interest amount																																					$ 784																																																																																			$ 1,178
Debt conversion price per share																																					$ 13.76																																																																																			$ 35
Shares issued for conversion of convertible debt																																					4,782																																																																																			804
Shares Issued Fifty Eight [Member]
Debt principal balance																																				$ 50,000																																																																																			$ 25,200
Debt interest amount																																				$ 6,500																																																																																			$ 2,162
Debt conversion price per share																																				$ 8.40																																																																																			$ 30
Shares issued for conversion of convertible debt																																				6,726																																																																																			869
Shares Issued Fifty Nine [Member]
Debt principal balance																																			$ 24,000																																																																																			$ 25,200
Debt interest amount																																			$ 2,320																																																																																			$ 1,372
Debt conversion price per share																																			$ 7.53																																																																																			$ 35
Shares issued for conversion of convertible debt																																			3,495																																																																																			798
Shares Issued Sixty [Member]
Debt principal balance																																	$ 50,000																																																																																				$ 40,000
Debt interest amount																																	$ 6,644																																																																																				$ 4,581
Debt conversion price per share																																	$ 7.53																																																																																				$ 35
Shares issued for conversion of convertible debt																																	7,523																																																																																				1,261
Shares Issued Sixty One [Member]
Debt principal balance																																$ 28,000																																																																																				$ 25,000
Debt interest amount																																$ 1,405																																																																																				$ 1,233
Debt conversion price per share																																$ 7.32																																																																																				$ 40
Shares issued for conversion of convertible debt																																4,017																																																																																				691
Shares Issued Sixty Two [Member]
Debt principal balance																														$ 30,000																																																																																						$ 7,500
Debt interest amount																														$ 3,260																																																																																						$ 875
Debt conversion price per share																														$ 5.10																																																																																						$ 35
Shares issued for conversion of convertible debt																														6,522																																																																																						232
Shares Issued Sixty Three [Member]
Debt principal balance																													$ 40,000																																																																																						$ 30,000
Debt interest amount																													$ 4,391																																																																																						$ 1,793
Debt conversion price per share																													$ 3.90																																																																																						$ 45
Shares issued for conversion of convertible debt																													11,382																																																																																						707
Shares Issued Sixty Four [Member]
Debt principal balance																													$ 37,000																																																																																					$ 40,000
Debt interest amount																													$ 1,971																																																																																					$ 2,130
Debt conversion price per share																													$ 3.97																																																																																					$ 45
Shares issued for conversion of convertible debt																													9,829																																																																																					985
Shares Issued Sixty Five [Member]
Debt principal balance																												$ 20,000																																																																																			$ 22,500
Debt interest amount																												$ 3,058																																																																																			$ 2,650
Debt conversion price per share																												$ 3.90																																																																																			$ 40
Shares issued for conversion of convertible debt																												5,912																																																																																			629
Shares Issued Sixty Six [Member]
Debt principal balance																										$ 75,000																																																																																				$ 20,000
Debt interest amount																										$ 4,300																																																																																				$ 1,276
Debt conversion price per share																										$ 3.97																																																																																				$ 35																																																																				$ 3.97		$ 3.97
Shares issued for conversion of convertible debt																										20,000																																																																																				572
Shares Issued Sixty Seven [Member]
Debt principal balance																										$ 60,000																																																																																		$ 40,000
Debt interest amount																										$ 9,320																																																																																		$ 4,986
Debt conversion price per share																										$ 3.90																																																																																		$ 40																																																																						$ 3.90		$ 3.90
Shares issued for conversion of convertible debt																										17,774																																																																																		1,144
Shares Issued Sixty Eight [Member]
Debt principal balance																									$ 45,000																																																																																		$ 25,000
Debt interest amount																									$ 2,555																																																																																		$ 1,173
Debt conversion price per share																									$ 5.52																																																																																		$ 35
Shares issued for conversion of convertible debt																									8,614																																																																																		704
Shares Issued Sixty Nine [Member]
Debt principal balance																								$ 50,000																																																																																			$ 20,000
Debt interest amount																								$ 2,400																																																																																			$ 1,320
Debt conversion price per share																								$ 4.26																																																																																			$ 35
Shares issued for conversion of convertible debt																								12,300																																																																																			592
Shares Issued Seventy [Member]
Debt principal balance																							$ 25,000																																																																																			$ 60,000
Debt interest amount																																																																																																										$ 4,027
Debt conversion price per share																							$ 4.33																																																																																			$ 30
Shares issued for conversion of convertible debt																							5,772																																																																																			2,023
Shares Issued Seventy One [Member]
Debt principal balance																							$ 55,000																																																																																		$ 40,000
Debt interest amount																							$ 2,799																																																																																		$ 5,012
Debt conversion price per share																							$ 4.26																																																																																		$ 30
Shares issued for conversion of convertible debt																							13,568																																																																																		1,522
Shares Issued Seventy Two [Member]
Debt principal balance																							$ 40,000																																																																																	$ 28,000
Debt interest amount																							$ 2,499																																																																																	$ 1,375
Debt conversion price per share																							$ 4.33																																																																																	$ 30
Shares issued for conversion of convertible debt																							9,813																																																																																	987
Shares Issued Seventy Three [Member]
Debt principal balance																						$ 49,990																																																																																	$ 27,000
Debt interest amount																						$ 4,466																																																																																	$ 1,343
Debt conversion price per share																						$ 4.53																																																																																	$ 30
Shares issued for conversion of convertible debt																						12,021																																																																																	1,016
Shares Issued Seventy Four [Member]
Debt principal balance																					$ 40,000																																																																																		$ 50,000
Debt interest amount																					$ 3,671																																																																																		$ 3,444
Debt conversion price per share																					$ 4.26																																																																																		$ 25
Shares issued for conversion of convertible debt																					10,251																																																																																		1,979
Shares Issued Seventy Five [Member]
Debt principal balance																			$ 60,000																																																																																			$ 60,000
Debt interest amount																			$ 5,600																																																																																			$ 7,906
Debt conversion price per share																			$ 4.20																																																																																			$ 30
Shares issued for conversion of convertible debt																			15,619																																																																																			2,348
Shares Issued Seventy Six [Member]
Debt principal balance																		$ 25,000																																																																																			$ 25,000
Debt interest amount																																																																																																					$ 1,756
Debt conversion price per share																		$ 3.97																																																																																			$ 25
Shares issued for conversion of convertible debt																		6,305																																																																																			991
Shares Issued Seventy Seven [Member]
Debt principal balance																	$ 60,000																																																																																			$ 28,000
Debt interest amount																	$ 5,733																																																																																			$ 1,442
Debt conversion price per share																	$ 3.90																																																																																			$ 30
Shares issued for conversion of convertible debt																	16,855																																																																																			1,055
Shares Issued Seventy Eight [Member]
Debt principal balance																$ 40,000																																																																																			$ 50,000
Debt interest amount																$ 3,884																																																																																			$ 2,089
Debt conversion price per share																$ 3.60																																																																																			$ 25
Shares issued for conversion of convertible debt																12,190																																																																																			1,929
Shares Issued Seventy Nine [Member]
Debt principal balance															$ 21,250																																																																																			$ 27,000
Debt interest amount																																																																																																		$ 1,450
Debt conversion price per share															$ 3.48																																																																																			$ 30
Shares issued for conversion of convertible debt															6,112																																																																																			1,009
Shares Issued Eighty [Member]
Debt principal balance														$ 35,000																																																																																			$ 50,000
Debt interest amount														$ 3,484																																																																																			$ 2,916
Debt conversion price per share														$ 3.42																																																																																			$ 30
Shares issued for conversion of convertible debt														11,253																																																																																			1,825
Shares Issued Eighty One [Member]
Debt principal balance													$ 25,000																																																																																			$ 25,000
Debt interest amount													$ 2,561																																																																																			$ 1,386
Debt conversion price per share													$ 3																																																																																			$ 30
Shares issued for conversion of convertible debt													9,187																																																																																			1,013
Shares Issued Eighty Two [Member]
Debt principal balance												$ 30,000																																																																																			$ 50,000
Debt interest amount												$ 3,140																																																																																			$ 2,256
Debt conversion price per share												$ 2.79																																																																																			$ 25
Shares issued for conversion of convertible debt												11,878																																																																																			2,177
Shares Issued Eighty Three [Member]
Debt principal balance											$ 26,000																																																																																			$ 20,000
Debt interest amount											$ 1,111																																																																																			$ 929
Debt conversion price per share											$ 2.84																																																																																			$ 20
Shares issued for conversion of convertible debt											9,558																																																																																			1,163
Shares Issued Eighty Four [Member]
Debt principal balance										$ 24,700																																																																																			$ 30,000
Debt interest amount																																																																																													$ 1,289
Debt conversion price per share										$ 2.44																																																																																			$ 20
Shares issued for conversion of convertible debt										10,123																																																																																			1,682
Shares Issued Eighty Five [Member]
Debt principal balance									$ 30,000																																																																																		$ 50,000
Debt interest amount									$ 4,220																																																																																		$ 3,750
Debt conversion price per share									$ 2.40																																																																																		$ 15
Shares issued for conversion of convertible debt									14,258																																																																																		3,120
Shares Issued Eighty Six [Member]
Debt principal balance								$ 23,700																																																																																		$ 35,000
Debt interest amount								$ 1,143																																																																																		$ 3,259
Debt conversion price per share								$ 2.20																																																																																		$ 20
Shares issued for conversion of convertible debt								11,313																																																																																		2,125
Shares Issued Eighty Seven [Member]
Debt principal balance							$ 20,000																																																																																		$ 25,000
Debt interest amount							$ 2,893																																																																																		$ 526
Debt conversion price per share							$ 1.80																																																																																		$ 20
Shares issued for conversion of convertible debt							12,719																																																																																		1,372
Shares Issued Eighty Eight [Member]
Debt principal balance						$ 15,000																																																																																		$ 30,000
Debt interest amount						$ 2,240																																																																																		$ 723
Debt conversion price per share						$ 1.98																																																																																		$ 20
Shares issued for conversion of convertible debt						8,707																																																																																		1,537
Shares Issued Eighty Nine [Member]
Debt principal balance																																																																																							$ 20,000
Debt interest amount				$ 2,723																																																																																			$ 2,000
Debt conversion price per share				$ 0.15																																																																																			$ 20
Shares issued for conversion of convertible debt				17,855																																																																																			1,055
Shares Issued Ninety [Member]
Debt principal balance			$ 20,480																																																																																			$ 33,500
Debt interest amount			$ 2,467																																																																																			$ 3,283
Debt conversion price per share			$ 0.61																																																																																			$ 20
Shares issued for conversion of convertible debt			37,348																																																																																			1,916
Shares Issued Ninety One [Member]
Debt principal balance			$ 20,480																																																																																		$ 33,000
Debt interest amount			$ 1,176																																																																																		$ 3,381
Debt conversion price per share			$ 0.62																																																																																		$ 15
Shares issued for conversion of convertible debt			34,669																																																																																		2,091
Shares Issued Ninety Two [Member]
Debt principal balance																																																																																				$ 35,000
Debt interest amount																																																																																				$ 1,035
Debt conversion price per share																																																																																				$ 20
Shares issued for conversion of convertible debt																																																																																				2,004
Shares Issued Ninety Three [Member]
Debt principal balance																																																																																			$ 32,000
Debt interest amount																																																																																			$ 3,335
Debt conversion price per share																																																																																			$ 15
Shares issued for conversion of convertible debt																																																																																			2,031
Shares Issued Ninety Four [Member]
Debt principal balance																																																																																		$ 35,000
Debt interest amount																																																																																		$ 3,687
Debt conversion price per share																																																																																		$ 15
Shares issued for conversion of convertible debt																																																																																		2,223
Shares Issued Ninety Five [Member]
Debt principal balance																																																																																	$ 35,000
Debt interest amount																																																																																	$ 1,135
Debt conversion price per share																																																																																	$ 20
Shares issued for conversion of convertible debt																																																																																	2,006
Shares Issued Ninety Six [Member]
Debt principal balance																																																																																$ 20,000
Debt interest amount																																																																																$ 2,098
Debt conversion price per share																																																																																$ 15
Shares issued for conversion of convertible debt																																																																																1,408
Warrants [Member]
Number of warrants outstanding																																																								24																																																																																																																													59
Number of warrant expired shares																																																																																																																																																																																								208
Warrants expiration term description																																																																																																																																																																																			As of December 31, 2019, there were 1,975,059 warrants outstanding and exercisable with expiration dates commencing May 2020 and continuing through August 2024, with a weighted average exercise price per share of $2.69.		Expiration dates commencing May 2020 and continuing through November 2020
Weighted average exercise price per share																																																																																																																																																																																					$ 4,765
Warrants [Member] | AUD Currency [Member]
Amount received from warrant																																																								$ 39
Maximum [Member]
Debt conversion price per share	$ 0.75
Minimum [Member]
Debt conversion price per share	$ 0.0672
First Anniversary [Member]
Number of shares vested																																																																																																																																																																											191
Stock option expire date																																																																																																																																																																											Apr. 14, 2021
Second Anniversary [Member]
Number of shares vested																																																																																												191
Stock option expire date																																																																																												Apr. 14, 2021
Consulting Agreement [Member]
Consulting expense																																																																																																																									$ 70,000																																																													35,287
Share issued price per share																																																																																																																									$ 70
Preparation for certain marketing materials																																																																																																																									$ 9,772
Number of restricted shares issued																																																																																																																									1,000
Bonus percentage																																																																																																																									6.00%
Agreement description																																																																																																																									The Company agreed to pay the consultant (i) an hourly fee of $950 per hour, for up to $71,250 of time-based services; (ii) $9,772 for the preparation of certain marketing materials; (iii) an upfront fee of 1,000 restricted shares of the Company's common stock, with up to 1,500 additional shares to be issued on the six month anniversary of the date of the consulting agreement at the Company's sole discretion, and (iv) a marketing bonus equal to 6% of the value of any: (x) business collaboration with the Company which is identified or introduced by the Consultant; or (y) joint venture, licensing, collaboration or similar monetization or strategic transaction (other than any capital-raising transaction) which is identified or introduced by the Consultant.
Number of common shares issued during period																																																																																																																									1,000
Consulting Agreement [Member] | Six Month Anniversary [Member]
Number of restricted shares issued																																																																																																																									1,500
Consulting Agreement [Member] | Maximum [Member]
Consulting expense																																																																																																																									$ 71,250
Consulting Agreement [Member] | Per Hour [Member]
Consulting expense																																																																																																																									$ 950
Consulting Services Agreement with Certain Consultant Between December 21, 2018 and March 20, 2019 [Member]
Consulting expense																																																																																																																																																																																					$ 100,000
Share issued price per share																																																																																																																																																																															$ 10
Consulting Services Agreement with Certain Consultant Between December 21, 2018 and March 20, 2019 [Member] | First Tranche [Member]
Stock issued for the services, shares																																																																																																																																																																															10,000
Consulting Services Agreement with Certain Consultant Between December 21, 2018 and March 20, 2019 [Member] | Second Tranche [Member]
Stock issued for the services, shares																																																																																																																																																																															10,000
Consulting Services Agreement with Consultant Between March 21, 2019 and December 20, 2019 [Member]
Stock issued for the services, shares																																																																																																																																																																															6,000
Number of common stock for services, value																																																																																																																																																																															$ 100,000
Employment Agreements [Member]
Share issued price per share																																																																																																																																																																													$ 4.25	$ 4.25
Number of restricted shares issued																																																																																																																																																																													117,000
Number of restricted stock issued, value																																																																																																																																																																													$ 497,240
Stock-based compensation related to restricted stock																																																																																																																																																																																					31,077
Unrecognized restricted stock units expense																																																																																																																																																																																					466,163
Number of options granted																																																																																																																																																																													58,500
Stock option expense																																																																																																																																																																																					10,360
Option term																																																																																																																																																																													10 years
Stock price																																																																																																																																																																													$ 4.25	4.25
Exercise price																																																																																																																																																																													$ 4.65	$ 4.65
Dividend yield																																																																																																																																																																													0.00%
Years to maturity																																																																																																																																																																													10 years
Risk free rate																																																																																																																																																																													2.42%
Expected volatility																																																																																																																																																																													268.00%
Fair value of options																																																																																																																																																																													$ 248,620
Unvested stock options expense																																																																																																																																																																																					$ 238,261
Employment Agreements [Member] | Maximum [Member]
Granted exercise price																																																																																																																																																																													$ 4.675
Employment Agreements [Member] | Minimum [Member]
Granted exercise price																																																																																																																																																																													$ 4.25
October 5, 2018 Equity Purchase Agreement [Member]
Share issued price per share																																																																																																																																																																																					$ 8.50
Number of common shares issued during period																																																																																																																																																																																					113,200
Proceeds from issuance of common stock																																																																																																																																																																																					$ 964,009
Amortization expense																																																																																																																																																																																					$ 333,059
October 5, 2018 Equity Purchase Agreement [Member] | Maximum [Member]
Share issued price per share																																																																																																																																																																																					$ 20
Proceeds from issuance of common stock																																											$ 10,000,000
October 5, 2018 Equity Purchase Agreement [Member] | Minimum [Member]
Share issued price per share																																																																																																																																																																																					6.50
Equity Purchase Agreement [Member]
Share issued price per share																																											$ 0.05
Equity purchase agreement description																																											Upon filing and effectiveness of the Company's Registration Statement on Form S-1, which was declared effective by the SEC on October 30, 2018, and provided other closing conditions are met, from time to time over the term of the Purchase Agreement, the Company had the right, but not the obligation, to direct the Investor to purchase shares of the Company's common stock (the "L2 Put Shares") in a maximum amount of $1,000,000, provided that the number of L2 Put Shares did not exceed 250% of the Average Daily Trading Volume (as defined in the L2 Purchase Agreement). At any time and from time to time during the 3-year term of the L2 Purchase Agreement (the "Commitment Period"), the Company had the right to deliver a notice L2 Capital (the "L2 Put Notice") and was obligated to deliver the Put Shares to Investor via DWAC (as defined in the L2 Purchase Agreement) within two trading days. The purchase price (the "L2 Purchase Price") for the Put Shares was 87.5% of the one lowest daily volume weighted average price on the Principal Market (as defined in the L2 Purchase Agreement) (as reported by Bloomberg Finance L.P.) during the five trading days immediately following the date L2 Capital receives the L2 Put Shares via DWAC associated with the applicable Put Notice (the "L2 Valuation Period"). The closing of a Put Notice occurred within one trading day following the end of the respective L2 Valuation Period, whereby (i) L2 Capital was obligated to deliver the L2 Investment Amount (as defined below) to the Company by wire transfer of immediately available funds and (ii) L2 Capital was obligated to return surplus L2 Put Shares if the value of the L2 Put Shares delivered to L2 Capital caused the Company to exceed the maximum commitment amount. The Company could not deliver another L2 Put Notice to L2 Capital within ten trading days of a prior Put Notice. The "L2 Investment Amount" means the aggregate L2 Purchase Price for the L2 Put Shares purchased by L2 Capital, minus clearing costs due to L2 Capital's broker or to the Company's transfer agent for the issuance of the L2 Put Shares (the "L2 Clearing Costs").The right of the Company to issue and sell the L2 Put Shares to L2 Capital was subject to the satisfaction of certain closing conditions, including, but not limited to, (i) the Company's Registration Statement on Form S-1 registering for resale by the Investor of the L2 Put Shares and Commitment Shares continuing to be effective as was declared by the U.S. Securities and Exchange Commission (the "SEC") on October 30, 2018, (ii) accuracy of the Company's representations and warranties, (iii) the Company's performance under the L2 Purchase Agreement in all material respects, (iv) no suspension of trading or delisting of the Company's common stock, (v) limitation of L2 Capital's beneficial ownership to no more than 9.99%, (vi) the Company maintaining its DWAC-eligible status, (vii) the Company maintaining a sufficient share reserve, and (viii) the minimum pricing for the L2 Put Shares must exceed $.05.
Equity ownership percentage																																											9.99%
Average trading percentage of common stock																																											5.00%
Divided stock value																																											$ 5,000
Number of common shares reserved for future issuance																																											924,143
February 25, 2019 Equity Purchase Agreement [Member]
Share issued price per share																				$ 0.05																																																																																																																																																																	$ 4.01
Number of common shares issued during period																																																																																																																																																																																					34,000
Proceeds from issuance of common stock																				$ 10,000,000																																																																																																																																																																	$ 136,371
Equity purchase agreement description																				Upon filing and effectiveness of the Company's Registration Statement on Form S-1, which was declared effective by the SEC on March 7, 2019, and provided other closing conditions are met, from time to time over the term of the Purchase Agreement, the Company has the right, but not the obligation, to direct the Investor to purchase shares of the Company's common stock (the "Put Shares") in a maximum amount of $1,000,000, provided that the number of Put Shares did not exceed 250% of the Average Daily Trading Volume (as defined in the Purchase Agreement). At any time and from time to time during the 3-year term of the Purchase Agreement (the "Commitment Period"), the Company has the right to deliver a notice to the Investor (the "Put Notice") and is obligated to deliver the Put Shares to Investor via DWAC (as defined in the Purchase Agreement) within two trading days. The purchase price (the "Purchase Price") for the Put Shares was 87.5% of the one lowest daily volume weighted average price on the Principal Market (as defined in the Purchase Agreement) (as reported by Bloomberg Finance L.P.) during the five trading days immediately following the date the Investor receives the Put Shares via DWAC associated with the applicable Put Notice (the "Valuation Period"). The closing of a Put Notice occurs within one trading day following the end of the respective Valuation Period, whereby (i) the Investor is obligated to deliver the Investment Amount (as defined below) to the Company by wire transfer of immediately available funds and (ii) the Investor is obligated to return surplus Put Shares if the value of the Put Shares delivered to the Investor causes the Company to exceed the maximum commitment amount. The Company cannot deliver another Put Notice to the Investor within ten trading days of a prior Put Notice. The "Investment Amount" means the aggregate Purchase Price for the Put Shares purchased by the Investor, minus clearing costs due to the Investor's broker or to the Company's transfer agent for the issuance of the Put Shares (the "Clearing Costs"). The right of the Company to issue and sell the Put Shares to the Investor is subject to the satisfaction of certain closing conditions, including, but not limited to, (i) the Company's Registration Statement on Form S-1 registering for resale by the Investor of the Put Shares continuing to be effective as was declared by the SEC on March 7, 2019, (ii) accuracy of the Company's representations and warranties, (iii) the Company's performance under the Purchase Agreement in all material respects, (iv) no suspension of trading or delisting of the Company's common stock, (v) limitation of the Investor's beneficial ownership to no more than 9.99%, (vi) the Company maintaining its DWAC-eligible status, (vii) the Company maintaining a sufficient share reserve, and (viii) the minimum pricing for the Put Shares must exceed $0.05.
Equity ownership percentage																				9.99%
Number of common shares reserved for future issuance																				1,333,333
February 25, 2019 Equity Purchase Agreement [Member] | Maximum [Member]
Share issued price per share																																																																																																																																																																																					$ 4.90
February 25, 2019 Equity Purchase Agreement [Member] | Minimum [Member]
Share issued price per share																																																																																																																																																																																					$ 3.06
Financing Agreements [Member]
Number of common shares reserved for future issuance																																																																																																																																																																																					6,819
Third Party [Member] | Consulting Services [Member]
Consulting expense																																																																																																																$ 30,000																																																					$ 30,000																	$ 30,000	$ 25,000
Stock issued for the services, shares																																																																																																													469
Loss on settlement of debt																																																																																																													$ 68,438				$ 2,813
Share issued price per share																																																																																																													$ 210				$ 70
Consultant [Member]
Consulting expense																																																																																																																																																																																					$ 39,000
Stock issued for the services, shares																											4,000
Share issued price per share																											$ 10
Number of common stock for services, value																											$ 39,000
Consultant [Member] | Beginning November 1, 2018 and Ending May 1, 2019 [Member]
Conversion of common stock																															4,000
Consultant [Member] | Consulting Agreement [Member]
Number of common shares issued during period																																																																																																													1,000
Board of Directors [Member]
Common stock, shares authorized																																																																																																																																																																																									2,000
Share issued price per share																																		$ 15
Number of common shares issued during period																																		2,000
Number of common shares issued during period, value																																		$ 30,000
Chief Executive Officer [Member]
Number of restricted shares issued																																																																																																																																																																														39,000
Number of common shares issued during period																																																																																																																																																																														58,500
Number of options granted																																																																																																																																																																												572
Granted exercise price																																																																																																																																																																												$ 3,750
Share based compensation arrangement by share based payment award options grant date fair value																																																																																																																																																																												$ 1,962,440
Chief Executive Officer [Member] | Employment Agreements [Member]
Number of restricted shares issued																																																																																																																																																																													78,000
Number of options granted																																																																																																																																																																													39,000
Chief Scientific Officer [Member] | Employment Agreements [Member]
Number of restricted shares issued																																																																																																																																																																													39,000
Number of options granted																																																																																																																																																																													19,500
Investor [Member] | October 5, 2018 Equity Purchase Agreement [Member]
Common stock, shares authorized																																											10,000,000
Share issued price per share																																											$ 41.30
Number of common shares issued during period																																											7,701
Deferred offing costs																																											$ 318,059
Legal fees																																											$ 15,000
Non-executive Director [Member]
Number of options granted																																																																																																																																																																												572
Granted exercise price																																																																																																																																																																												$ 3,750
Series A Preferred Stock [Member]
Preferred stock, shares authorized																																																																																																																																																																																500,000			500,000		500,000	500,000								500,000
Preferred stock, par value																																																																																																																																																																																$ 0.01			$ 0.01		$ 0.01	$ 0.01
Preferred stock voting rights description																																																																																																																																																																																					Series A Preferred Stock entitles him to two votes per share of Series A Preferred Stock.
Preferred stock, shares issued																																																																																																																																																																																500,000			500,000		500,000	500,000
Preferred stock, shares outstanding																																																																																																																																																																																500,000			500,000		500,000	500,000
Stock issued for the services, shares
Number of common stock for services, value
Series B Preferred Stock [Member]
Preferred stock, shares authorized																																																																																																																																																																																5			5		5	5							5
Preferred stock, par value																																																																																																																																																																																$ 0.01			$ 0.01		$ 0.01	$ 0.01
Preferred stock voting rights description																																																																																																																																																																																					Each holder of outstanding shares of Series B Preferred Stock is entitled to voting power equivalent to the number of votes equal to the total number of shares of common stock outstanding as of the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company and entitled to vote on all matters submitted or required to be submitted to a vote of the stockholders of the Company.
Preferred stock, shares issued																																																																																																																																																																																1			1		1	1
Preferred stock, shares outstanding																																																																																																																																																																																1			1		1	1
Stock issued for the services, shares
Number of common stock for services, value

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Equity [Abstract]
Number of shares Outstanding, Beginning	1,144	1,144
Number of shares Issued	58,500
Number of shares Exercised
Number of shares Expired
Number of shares Forfeited
Number of shares Outstanding, Ending	59,644	1,144
Number of shares Exercisable, Ending	1,144
Weighted Average Price Per Share Outstanding, Beginning	$ 3,750	$ 3,750
Weighted Average Price Per Share Issued	4.53
Weighted Average Price Per Share Exercised
Weighted Average Price Per Share Expired
Weighted Average Price Per Share Forfeited
Weighted Average Price Per Share Outstanding, Ending	76.37	$ 3,750
Weighted Average Price Per Share Exercisable, Ending	$ 3,750
Weighted average remaining contractual term	9 years 8 months 19 days
Weighted average fair value of options granted during the period	4 years 2 months 30 days
Aggregate intrinsic value	$ 85,800

Stockholders' Deficit - Sched_2

Stockholders' Deficit - Schedule of Option Exercise Price Range (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Number of shares options outstanding	59,644	1,144	1,144
Weighted average remaining contractual life, options	9 years 8 months 19 days
Weighted average exercise price, options	$ 76.37	$ 3,750	$ 3,750
Aggregate intrinsic value, options	$ 85,800
Number of shares options exercisable	1,144
Weighted average exercise price, options exercisable	$ 3,750
Aggregate intrinsic value, options exercisable
Exercise Price Range One [Member]
Range of exercise price, minimum	$ 4.25
Range of exercise price, maximum	$ 4.68
Number of shares options outstanding	58,500
Weighted average remaining contractual life, options	9 years 10 months 17 days
Weighted average exercise price, options	$ 4.53
Aggregate intrinsic value, options	$ 85,800
Number of shares options exercisable
Weighted average exercise price, options exercisable
Aggregate intrinsic value, options exercisable
Exercise Price Range Two [Member]
Range of exercise price, maximum	$ 3,750
Number of shares options outstanding	1,144
Weighted average remaining contractual life, options	1 year 9 months 14 days
Weighted average exercise price, options	$ 3,750
Aggregate intrinsic value, options
Number of shares options exercisable	1,144
Weighted average exercise price, options exercisable	$ 3,750
Aggregate intrinsic value, options exercisable

Stockholders' Deficit - Sched_3

Stockholders' Deficit - Schedule of Warrant Activity (Details) - Warrant [Member] - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Number of shares Outstanding, Beginning	291	299
Number of shares Issued
Number of shares Exercised	(24)
Number of shares Forfeited
Number of shares Expired	(208)	(8)
Number of shares Outstanding, Ending	59	291
Number of shares Outstanding Exercisable, Ending	59
Weighted Average Price Per Share Outstanding, Beginning	$ 5,555	$ 5,625
Weighted Average Price Per Share Issued
Weighted Average Price Per Share Exercised
Weighted Average Price Per Share Expired
Weighted Average Price Per Share Forfeited
Weighted Average Price Per Share Outstanding, Ending	4,765	$ 5,555
Weighted Average Price Per Share Outstanding Exercisable, Ending	$ 4,765
Weighted average remaining contractual term	6 months
Aggregate intrinsic value

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)

Sep. 26, 2019USD ($)

Sep. 13, 2018USD ($)

Sep. 13, 2018EUR (€)

Aug. 12, 2016USD ($)

May 05, 2016USD ($)

May 05, 2016AUD ($)

May 04, 2016USD ($)

Jun. 30, 2012

Jun. 30, 2018USD ($)

Dec. 31, 2019USD ($)shares

Jun. 30, 2019USD ($)

Jun. 30, 2018USD ($)

Dec. 31, 2014USD ($)

Penalty amount

$ 30,000

Operating lease term

5 years

Rent expense

$ 28,062

$ 30,521

Contract cost

49,854

Royalties percentage

2.00%

2.00%

Royalty Agreement Terms [Member]

Operating leases income statement revenue percentage

2.00%

License Agreement Terms [Member]

Operating leases income statement revenue percentage

5.00%

New Five-Year Operating Lease Agreement [Member]

Operating lease term

5 years

5 years

Payments for rent

$ 2,469

$ 2,325

New Five-Year Operating Lease Agreement [Member] | AUD Currency [Member]

Payments for rent

$ 3,606

Manufacturing Services Agreement [Member] | Minimum [Member]

Anticipated milestone payment

$ 2,500,000

Manufacturing Services Agreement [Member] | Maximum [Member]

Anticipated milestone payment

$ 5,000,000

Amatsigroup Agreement [Member]

Payments description

The Company anticipates that its payments to Amatsigroup under the MSA will range between $2.5 million and $5.0 million over three years, when the finished drug product is manufactured and released for clinical trials. The Company has spent a total of $1,689,146 of costs to date under this contract of which $1,689,146 was expensed in prior years. The MSA shall continue for a term of three years unless extended by mutual agreement in writing.

Contract cost

$ 1,689,146

$ 1,689,146

$ 1,689,146

One-Year Collaboration Agreement [Member]

Payment for services

$ 59,508

One-Year Collaboration Agreement [Member] | Euros [Member]

Payment for services | €

€ 52,000

Two-Year Collaboration Agreement [Member]

Payment for services

$ 45,775

Two-Year Collaboration Agreement [Member] | Euros [Member]

Payment for services | €

€ 40,000

From 2012 through the 2014 [Member]

Penalty amount

$ 10,000

10,000

Regal Consulting, LLC [Member]

Loss contingency amount

$ 400,000

Stock issued for the services, shares | shares

60,000

Foley Shechter [Member]

Legal fees

$ 151,032

Commitments and Contingencies_3

Commitments and Contingencies (Details Narrative) (10-K)	Sep. 13, 2018USD ($)	Sep. 13, 2018EUR (€)	Aug. 12, 2016USD ($)	May 05, 2016USD ($)	May 04, 2016USD ($)	Jun. 30, 2012	Jun. 30, 2018USD ($)	Dec. 31, 2019USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Dec. 31, 2014USD ($)
Penalty amount											$ 30,000
Operating lease term									5 years
Rent expense									$ 28,062	$ 30,521
Contract cost									49,854
Royalties percentage	2.00%	2.00%
Royalty Agreement Terms [Member]
Operating leases income statement revenue percentage						2.00%
License Agreement Terms [Member]
Operating leases income statement revenue percentage						5.00%
New Five-Year Operating Lease Agreement [Member]
Operating lease term				5 years
Payments for rent				$ 2,469	$ 2,325
New Five-Year Operating Lease Agreement [Member] | AUD Currency [Member]
Payments for rent					$ 3,300
Manufacturing Services Agreement [Member] | Minimum [Member]
Anticipated milestone payment			$ 2,500,000
Manufacturing Services Agreement [Member] | Maximum [Member]
Anticipated milestone payment			$ 5,000,000
Amatsigroup Agreement [Member]
Payments description			The Company anticipates that its payments to Amatsigroup under the MSA will range between $2.5 million and $5.0 million over three years, when the finished drug product is manufactured and released for clinical trials. The Company has spent a total of $1,689,146 of costs to date under this contract of which $1,689,146 was expensed in prior years. The MSA shall continue for a term of three years unless extended by mutual agreement in writing.
Contract cost								$ 1,689,146	$ 1,689,146	$ 1,689,146
One-Year Collaboration Agreement [Member]
Payment for services	$ 59,508
One-Year Collaboration Agreement [Member] | Euros [Member]
Payment for services | €		€ 52,000
Two-Year Collaboration Agreement [Member]
Payment for services	$ 45,775
Two-Year Collaboration Agreement [Member] | Euros [Member]
Payment for services | €		€ 40,000
From 2012 through the 2014 [Member]
Penalty amount							$ 10,000	$ 10,000

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Right Use of Asset (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Office lease ROU	$ 48,662
Less accumulated reduction	(13,271)
Balance of ROU asset	$ 35,391

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Operating Lease Liability (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Office lease liability	$ 48,662
Reduction of lease liability	(11,352)
Total	37,310
Less: current portion	(14,216)
Long term portion of lease liability	$ 23,094

Commitments and Contingencies_5

Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Remainder Fiscal Year 2020	$ 15,120
Year 2021	23,119
Total	38,239
Imputed interest	(929)
Total operating lease liability	$ 37,310
Fiscal Year Ended June 30, 2020		$ 28,325
Fiscal Year Ended June 30, 2021		$ 28,325

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	May 14, 2019USD ($)$ / sharesshares	May 14, 2019AUD ($)shares	Mar. 14, 2019USD ($)	Mar. 16, 2018USD ($)	Mar. 16, 2018AUD ($)	Feb. 01, 2018USD ($)	May 05, 2016USD ($)	May 05, 2016AUD ($)	Apr. 14, 2016$ / shares	Feb. 25, 2016USD ($)	Feb. 25, 2016AUD ($)	Feb. 25, 2015AUD ($)	May 31, 2019shares	Dec. 31, 2019USD ($)$ / shares	Dec. 31, 2019AUD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2019AUD ($)	Jun. 30, 2019USD ($)$ / shares	Jun. 30, 2019AUD ($)	Jun. 30, 2018USD ($)$ / shares	Jun. 30, 2018AUD ($)	Dec. 31, 2019AUD ($)
Loans from related party														$ 52,022				$ 51,867		$ 54,753
Due to related parties														$ 31,257				$ 31,164		$ 32,898
Excercise price | $ / shares
Restricted stock shares of common stock | shares													78,000
Stock price | $ / shares														$ 0.38				$ 6
Board of Directors [Member]
Payments form related party																				$ 56,056
Chief Executive Officer [Member]
Payments form related party														$ 94,228				$ 64,377
Bonus payable amount																		137,120
Remaining bonus amount																		178,256
Remaining due and payable														163,363
Granted exercise price | $ / shares									$ 3,750
Restricted stock shares of common stock | shares													39,000
Nathanielsz Employment Agreement [Member]
Expired date												Feb. 25, 2019
Annual salary														$ 205,680				$ 214,590
Percentage of pension of monthly salary														9.50%	9.50%			9.50%	9.50%
Percentage of bonus of annual base salary														200.00%	200.00%			200.00%	200.00%
Nathanielsz Employment Agreement [Member] | Minimum [Member]
Annual salary				$ 205,680
Nathanielsz Employment Agreement [Member] | Maximum [Member]
Annual salary				274,240
AUD Currency [Member] | Board of Directors [Member]
Payments form related party																					$ 80,046
AUD Currency [Member] | Chief Executive Officer [Member]
Payments form related party															$ 137,620				$ 90,000
Bonus payable amount																			200,000
Remaining bonus amount																			$ 260,000
Remaining due and payable															232,380
AUD Currency [Member] | Nathanielsz Employment Agreement [Member]
Annual salary												$ 25,000			300,000			$ 300,000
AUD Currency [Member] | Nathanielsz Employment Agreement [Member] | Minimum [Member]
Annual salary					$ 300,000
AUD Currency [Member] | Nathanielsz Employment Agreement [Member] | Maximum [Member]
Annual salary					400,000
Initial Nathanielsz RSUs [Member] | Employment Agreement [Member]
Restricted stock shares of common stock | shares	39,000	39,000
Additional Nathanielsz RSUs [Member] | Employment Agreement [Member]
Restricted stock shares of common stock | shares	39,000	39,000
RSUS vest, shares | shares	7,800	7,800
Gross proceeds from equity financing	$ 4,000,000
Restricted Stock Units [Member] | Employment Agreement [Member]
Restricted stock shares of common stock | shares	78,000	78,000
Stock price | $ / shares	$ 4.25
Restricted stock value	$ 331,500
Fair value of restricted stock	$ 165,747
Initial Kenyon RSUs [Member] | Services Agreement [Member]
Restricted stock shares of common stock | shares	19,500	19,500
Additional Kenyon RSUs [Member] | Services Agreement [Member]
Restricted stock shares of common stock | shares	19,500	19,500
RSUS vest, shares | shares	4,875	4,875
Gross proceeds from equity financing	$ 4,000,000
North Horizon Pty Ltd [Member]
Lease term							5 years
Annual rental payments							$ 28,790
Goods and service tax							2,618
Future minimum payments due														$ 41,044				54,291
North Horizon Pty Ltd [Member] | AUD Currency [Member]
Annual rental payments								$ 42,048
Goods and service tax								$ 3,823
North Horizon Pty Ltd [Member] | AUD Currency [Member]
Annual rental payments							39,600
Goods and service tax							3,600
Future minimum payments due																		75,900				$ 59,943
Current and Former Director [Member]
Loans from related party														52,022				51,867		54,753
Former Director [Member]
Due to related parties														31,257				31,164		$ 32,898
Nathanielsz [Member] | North Horizon Pty Ltd [Member]
Future minimum payments due							143,953
Nathanielsz [Member] | North Horizon Pty Ltd [Member] | AUD Currency [Member]
Future minimum payments due							$ 210,242
Mr. Nathanielsz [Member]
Annual salary						$ 82,272
Payments form related party														$ 14,638				38,463
Mr. Nathanielsz [Member] | Board of Directors [Member]
Payments form related party																$ 154,100
Mr. Nathanielsz [Member] | AUD Currency [Member]
Annual salary						$ 75,000
Payments form related party															$ 21,378			$ 53,772
Mr. Nathanielsz [Member] | AUD Currency [Member] | Board of Directors [Member]
Payments form related party																	$ 219,954
James Nathanielsz [Member]
Payments form related party										$ 3,205
James Nathanielsz [Member] | AUD Currency [Member]
Payments form related party											$ 4,481
Mr. Nathanielsz [Member] | Board of Directors [Member]
Officers' compensation	$ 315,376		$ 329,038	$ 210,090
Mr. Nathanielsz [Member] | Employment Agreement [Member]
Agreement term	3 years	3 years
Agreement renewal term	1 year	1 year
Option purchase shares | shares	39,000	39,000
Excercise price | $ / shares	$ 4.675
Market price	110.00%	110.00%
Granted exercise price | $ / shares	$ 4.25
Restricted stock shares of common stock | shares	39,000	39,000
Option term	10 years	10 years
Options vested, description	The Nathanielsz Options have a term of 10 years from the date of grant. 1/3rd of the Nathanielsz Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Mr. Nathanielsz is employed by the Company and subject to the other provisions of the Employment Agreement. The Initial Nathanielsz RSUs shall vest on the one-year anniversary of the Effective Date, subject to Mr. Nathanielsz's continued employment with the Company through such vesting date. The Additional Nathanielsz RSUs will vest as follows, subject to Mr. Nathanielsz's continued employment with the Company through the applicable vesting date: (i) 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company submitting Clinical Trial Application (the "CTA") for PRP, the Company's lead product candidate ("PRP"), for a First-In-Human study for PRP (the "Study") in an applicable jurisdiction to be selected by the Company, (ii) 7,800 of the Additional Nathanielsz RSUs shall vest upon the CTA being approved in an applicable jurisdiction, (iii) 7,800 of the Additional RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iv) 7,800 of the Additional Nathanielsz RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (v) the remaining 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested restricted stock unit shall be settled by delivery to Mr. Nathanielsz of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the 2019 Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Employment Agreement), (ii) the date that is ten business days following the vesting of such restricted stock unit, (iii) the date of Mr. Nathanielsz's death or Disability (as defined in the Employment Agreement), and (iv) Mr. Nathanielsz's employment being terminated either by the Company without Cause or by Mr. Nathanielsz for Good Reason (each as defined in the Employment Agreement). In the event of a Change of Control, any unvested portion of the Nathanielsz Options and such restricted stock units shall vest immediately prior to such event.	The Nathanielsz Options have a term of 10 years from the date of grant. 1/3rd of the Nathanielsz Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Mr. Nathanielsz is employed by the Company and subject to the other provisions of the Employment Agreement. The Initial Nathanielsz RSUs shall vest on the one-year anniversary of the Effective Date, subject to Mr. Nathanielsz's continued employment with the Company through such vesting date. The Additional Nathanielsz RSUs will vest as follows, subject to Mr. Nathanielsz's continued employment with the Company through the applicable vesting date: (i) 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company submitting Clinical Trial Application (the "CTA") for PRP, the Company's lead product candidate ("PRP"), for a First-In-Human study for PRP (the "Study") in an applicable jurisdiction to be selected by the Company, (ii) 7,800 of the Additional Nathanielsz RSUs shall vest upon the CTA being approved in an applicable jurisdiction, (iii) 7,800 of the Additional RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iv) 7,800 of the Additional Nathanielsz RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (v) the remaining 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested restricted stock unit shall be settled by delivery to Mr. Nathanielsz of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the 2019 Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Employment Agreement), (ii) the date that is ten business days following the vesting of such restricted stock unit, (iii) the date of Mr. Nathanielsz's death or Disability (as defined in the Employment Agreement), and (iv) Mr. Nathanielsz's employment being terminated either by the Company without Cause or by Mr. Nathanielsz for Good Reason (each as defined in the Employment Agreement). In the event of a Change of Control, any unvested portion of the Nathanielsz Options and such restricted stock units shall vest immediately prior to such event.
Stock price | $ / shares	$ 4.25
Restricted stock value	$ 165,747
Exercise price | $ / shares	$ 4.65
Dividend yield	0.00%	0.00%
Years to maturity	10 years	10 years
Risk free rate	2.42%	2.42%
Expected volatility	268.00%	268.00%
Mr. Nathanielsz [Member] | AUD Currency [Member] | Board of Directors [Member]
Officers' compensation		$ 460,000	$ 460,000		$ 300,000
Mr. Nathanielsz [Member] | AUD Currency [Member] | Employment Agreement [Member]
Annual salary		400,000
Dr Kenyon [Member] | AUD Currency [Member] | Services Agreement [Member]
Annual salary		$ 54,000
Dr Kenyon [Member] | Services Agreement [Member]
Agreement term	3 years	3 years
Agreement renewal term	1 year	1 year
Option purchase shares | shares	19,500	19,500
Excercise price | $ / shares	$ 4.25
Market price	100.00%	100.00%
Granted exercise price | $ / shares	$ 19,500
Option term	10 years	10 years
Options vested, description	The Kenyon Options have a term of 10 years from the date of grant. 1/3rd of the Kenyon Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Dr. Kenyon is employed by the Company and subject to the other provisions of the Services Agreement. The Initial Kenyon RSUs shall vest on the one-year anniversary of the Effective Date, subject to Dr. Kenyon's continued employment with the Company through such vesting date. The Additional Kenyon RSUs will vest as follows, subject to Dr. Kenyon's continued employment with the Company through the applicable vesting date: (i) 4,875 of the Additional Kenyon RSUs shall vest upon the Company submitting the CTA for PRP for the Study in an applicable jurisdiction to be selected by the Company, (ii) 4,875 of the Additional Kenyon RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iii) 4,875 of the Additional Kenyon RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (iv) the remaining 4,875 of the Additional Kenyon RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested Kenyon RSU shall be settled by delivery to Mr. Kenyon of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Services Agreement), (ii) the date that is ten business days following the vesting of such Kenyon RSU, (iii) the date of Dr. Kenyon's death or Disability (as defined in the Services Agreement), and (iv) Dr. Kenyon's employment being terminated either by the Company without Cause or by Dr. Kenyon for Good Reason (as defined in the Services Agreement). In the event of a Change of Control (as defined in the Services Agreement), 50% of any unvested portion of the Kenyon Options and the Kenyon RSUs shall vest immediately prior to such event.	The Kenyon Options have a term of 10 years from the date of grant. 1/3rd of the Kenyon Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Dr. Kenyon is employed by the Company and subject to the other provisions of the Services Agreement. The Initial Kenyon RSUs shall vest on the one-year anniversary of the Effective Date, subject to Dr. Kenyon's continued employment with the Company through such vesting date. The Additional Kenyon RSUs will vest as follows, subject to Dr. Kenyon's continued employment with the Company through the applicable vesting date: (i) 4,875 of the Additional Kenyon RSUs shall vest upon the Company submitting the CTA for PRP for the Study in an applicable jurisdiction to be selected by the Company, (ii) 4,875 of the Additional Kenyon RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iii) 4,875 of the Additional Kenyon RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (iv) the remaining 4,875 of the Additional Kenyon RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested Kenyon RSU shall be settled by delivery to Mr. Kenyon of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Services Agreement), (ii) the date that is ten business days following the vesting of such Kenyon RSU, (iii) the date of Dr. Kenyon's death or Disability (as defined in the Services Agreement), and (iv) Dr. Kenyon's employment being terminated either by the Company without Cause or by Dr. Kenyon for Good Reason (as defined in the Services Agreement). In the event of a Change of Control (as defined in the Services Agreement), 50% of any unvested portion of the Kenyon Options and the Kenyon RSUs shall vest immediately prior to such event.
Stock price | $ / shares	$ 4.25
Restricted stock value	$ 82,873
Exercise price | $ / shares	$ 4.25
Dividend yield	0.00%	0.00%
Years to maturity	10 years	10 years
Risk free rate	2.42%	2.42%
Expected volatility	268.00%	268.00%
Dr Kenyon [Member] | Restricted Stock [Member] | Services Agreement [Member]
Restricted stock shares of common stock | shares	39,000	39,000
Stock price | $ / shares	$ 4.25
Restricted stock value	$ 165,750
Fair value of restricted stock	$ 82,873

Related Party Transactions (D_2

Related Party Transactions (Details Narrative) (10-K)	May 14, 2019USD ($)$ / sharesshares	May 14, 2019AUD ($)shares	Mar. 14, 2019USD ($)	Mar. 16, 2018USD ($)	Mar. 16, 2018AUD ($)	Feb. 01, 2018USD ($)	May 05, 2016USD ($)	Apr. 14, 2016$ / shares	Feb. 25, 2016USD ($)	Feb. 25, 2016AUD ($)	Feb. 25, 2015AUD ($)	May 31, 2019shares	Dec. 31, 2019USD ($)$ / shares	Dec. 31, 2019AUD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2019AUD ($)	Jun. 30, 2019USD ($)$ / shares	Jun. 30, 2019AUD ($)	Jun. 30, 2018USD ($)$ / shares	Jun. 30, 2018AUD ($)	Dec. 31, 2019AUD ($)
Loans from related party													$ 52,022				$ 51,867		$ 54,753
Due to related parties													$ 31,257				$ 31,164		$ 32,898
Excercise price | $ / shares
Restricted stock shares of common stock | shares												78,000
Stock price | $ / shares													$ 0.38				$ 6
Board of Directors [Member]
Payments form related party																			$ 56,056
Chief Executive Officer [Member]
Payments form related party													$ 94,228				$ 64,377
Bonus payable amount																	137,120
Remaining bonus amount																	178,256
Granted exercise price | $ / shares								$ 3,750
Restricted stock shares of common stock | shares												39,000
Nathanielsz Employment Agreement [Member]
Expired date											Feb. 25, 2019
Annual salary													$ 205,680				$ 214,590
Percentage of pension of monthly salary													9.50%	9.50%			9.50%	9.50%
Percentage of bonus of annual base salary													200.00%	200.00%			200.00%	200.00%
Nathanielsz Employment Agreement [Member] | Minimum [Member]
Annual salary				$ 205,680
Nathanielsz Employment Agreement [Member] | Maximum [Member]
Annual salary				274,240
AUD Currency [Member] | Board of Directors [Member]
Payments form related party																				$ 80,046
AUD Currency [Member] | Chief Executive Officer [Member]
Payments form related party														$ 137,620				$ 90,000
Bonus payable amount																		200,000
Remaining bonus amount																		$ 260,000
AUD Currency [Member] | Nathanielsz Employment Agreement [Member]
Annual salary											$ 25,000			300,000			$ 300,000
AUD Currency [Member] | Nathanielsz Employment Agreement [Member] | Minimum [Member]
Annual salary					$ 300,000
AUD Currency [Member] | Nathanielsz Employment Agreement [Member] | Maximum [Member]
Annual salary					400,000
Initial Nathanielsz RSUs [Member] | Employment Agreement [Member]
Restricted stock shares of common stock | shares	39,000	39,000
Additional Nathanielsz RSUs [Member] | Employment Agreement [Member]
Restricted stock shares of common stock | shares	39,000	39,000
RSUS vest, shares | shares	7,800	7,800
Gross proceeds from equity financing	$ 4,000,000
Restricted Stock Units [Member] | Employment Agreement [Member]
Restricted stock shares of common stock | shares	78,000	78,000
Stock price | $ / shares	$ 4.25
Restricted stock value	$ 331,500
Fair value of restricted stock	$ 165,747
Initial Kenyon RSUs [Member] | Services Agreement [Member]
Restricted stock shares of common stock | shares	19,500	19,500
Additional Kenyon RSUs [Member] | Services Agreement [Member]
Restricted stock shares of common stock | shares	19,500	19,500
RSUS vest, shares | shares	4,875	4,875
Gross proceeds from equity financing	$ 4,000,000
North Horizon Pty Ltd [Member]
Lease term							5 years
Annual rental payments							$ 28,790
Goods and service tax							2,618
Future minimum payments due													$ 41,044				54,291
North Horizon Pty Ltd [Member] | AUD Currency [Member]
Annual rental payments							39,600
Goods and service tax							3,600
Future minimum payments due																	75,900				$ 59,943
Current and Former Director [Member]
Loans from related party													52,022				51,867		54,753
Former Director [Member]
Due to related parties													31,257				31,164		$ 32,898
Nathanielsz [Member] | North Horizon Pty Ltd [Member]
Future minimum payments due							143,953
Nathanielsz [Member] | North Horizon Pty Ltd [Member] | AUD Currency [Member]
Future minimum payments due							$ 210,242
Mr. Nathanielsz [Member]
Annual salary						$ 82,272
Payments form related party													$ 14,638				38,463
Mr. Nathanielsz [Member] | Board of Directors [Member]
Payments form related party															$ 154,100
Mr. Nathanielsz [Member] | AUD Currency [Member]
Annual salary						$ 75,000
Payments form related party														$ 21,378			53,772
Mr. Nathanielsz [Member] | AUD Currency [Member] | Board of Directors [Member]
Payments form related party																$ 219,954
James Nathanielsz [Member]
Payments form related party									$ 3,205
James Nathanielsz [Member] | AUD Currency [Member]
Payments form related party										$ 4,481
Mr. Nathanielsz [Member]
Paid in relation to bouns amount																	157,333
Mr. Nathanielsz [Member] | Board of Directors [Member]
Officers' compensation	$ 315,376		$ 329,038	$ 210,090
Mr. Nathanielsz [Member] | Employment Agreement [Member]
Agreement term	3 years	3 years
Agreement renewal term	1 year	1 year
Option purchase shares | shares	39,000	39,000
Excercise price | $ / shares	$ 4.675
Market price	110.00%	110.00%
Granted exercise price | $ / shares	$ 4.25
Restricted stock shares of common stock | shares	39,000	39,000
Option term	10 years	10 years
Options vested, description	The Nathanielsz Options have a term of 10 years from the date of grant. 1/3rd of the Nathanielsz Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Mr. Nathanielsz is employed by the Company and subject to the other provisions of the Employment Agreement. The Initial Nathanielsz RSUs shall vest on the one-year anniversary of the Effective Date, subject to Mr. Nathanielsz's continued employment with the Company through such vesting date. The Additional Nathanielsz RSUs will vest as follows, subject to Mr. Nathanielsz's continued employment with the Company through the applicable vesting date: (i) 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company submitting Clinical Trial Application (the "CTA") for PRP, the Company's lead product candidate ("PRP"), for a First-In-Human study for PRP (the "Study") in an applicable jurisdiction to be selected by the Company, (ii) 7,800 of the Additional Nathanielsz RSUs shall vest upon the CTA being approved in an applicable jurisdiction, (iii) 7,800 of the Additional RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iv) 7,800 of the Additional Nathanielsz RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (v) the remaining 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested restricted stock unit shall be settled by delivery to Mr. Nathanielsz of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the 2019 Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Employment Agreement), (ii) the date that is ten business days following the vesting of such restricted stock unit, (iii) the date of Mr. Nathanielsz's death or Disability (as defined in the Employment Agreement), and (iv) Mr. Nathanielsz's employment being terminated either by the Company without Cause or by Mr. Nathanielsz for Good Reason (each as defined in the Employment Agreement). In the event of a Change of Control, any unvested portion of the Nathanielsz Options and such restricted stock units shall vest immediately prior to such event.	The Nathanielsz Options have a term of 10 years from the date of grant. 1/3rd of the Nathanielsz Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Mr. Nathanielsz is employed by the Company and subject to the other provisions of the Employment Agreement. The Initial Nathanielsz RSUs shall vest on the one-year anniversary of the Effective Date, subject to Mr. Nathanielsz's continued employment with the Company through such vesting date. The Additional Nathanielsz RSUs will vest as follows, subject to Mr. Nathanielsz's continued employment with the Company through the applicable vesting date: (i) 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company submitting Clinical Trial Application (the "CTA") for PRP, the Company's lead product candidate ("PRP"), for a First-In-Human study for PRP (the "Study") in an applicable jurisdiction to be selected by the Company, (ii) 7,800 of the Additional Nathanielsz RSUs shall vest upon the CTA being approved in an applicable jurisdiction, (iii) 7,800 of the Additional RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iv) 7,800 of the Additional Nathanielsz RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (v) the remaining 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested restricted stock unit shall be settled by delivery to Mr. Nathanielsz of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the 2019 Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Employment Agreement), (ii) the date that is ten business days following the vesting of such restricted stock unit, (iii) the date of Mr. Nathanielsz's death or Disability (as defined in the Employment Agreement), and (iv) Mr. Nathanielsz's employment being terminated either by the Company without Cause or by Mr. Nathanielsz for Good Reason (each as defined in the Employment Agreement). In the event of a Change of Control, any unvested portion of the Nathanielsz Options and such restricted stock units shall vest immediately prior to such event.
Stock price | $ / shares	$ 4.25
Restricted stock value	$ 165,747
Exercise price | $ / shares	$ 4.65
Dividend yield	0.00%	0.00%
Years to maturity	10 years	10 years
Risk free rate	2.42%	2.42%
Expected volatility	268.00%	268.00%
Mr. Nathanielsz [Member] | AUD Currency [Member]
Paid in relation to bouns amount																	$ 219,954
Mr. Nathanielsz [Member] | AUD Currency [Member] | Board of Directors [Member]
Officers' compensation		$ 460,000	$ 460,000		$ 300,000
Mr. Nathanielsz [Member] | AUD Currency [Member] | Employment Agreement [Member]
Annual salary		400,000
Dr Kenyon [Member] | AUD Currency [Member] | Services Agreement [Member]
Annual salary		$ 54,000
Dr Kenyon [Member] | Services Agreement [Member]
Agreement term	3 years	3 years
Agreement renewal term	1 year	1 year
Option purchase shares | shares	19,500	19,500
Excercise price | $ / shares	$ 4.25
Market price	100.00%	100.00%
Granted exercise price | $ / shares	$ 19,500
Option term	10 years	10 years
Options vested, description	The Kenyon Options have a term of 10 years from the date of grant. 1/3rd of the Kenyon Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Dr. Kenyon is employed by the Company and subject to the other provisions of the Services Agreement. The Initial Kenyon RSUs shall vest on the one-year anniversary of the Effective Date, subject to Dr. Kenyon's continued employment with the Company through such vesting date. The Additional Kenyon RSUs will vest as follows, subject to Dr. Kenyon's continued employment with the Company through the applicable vesting date: (i) 4,875 of the Additional Kenyon RSUs shall vest upon the Company submitting the CTA for PRP for the Study in an applicable jurisdiction to be selected by the Company, (ii) 4,875 of the Additional Kenyon RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iii) 4,875 of the Additional Kenyon RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (iv) the remaining 4,875 of the Additional Kenyon RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested Kenyon RSU shall be settled by delivery to Mr. Kenyon of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Services Agreement), (ii) the date that is ten business days following the vesting of such Kenyon RSU, (iii) the date of Dr. Kenyon's death or Disability (as defined in the Services Agreement), and (iv) Dr. Kenyon's employment being terminated either by the Company without Cause or by Dr. Kenyon for Good Reason (as defined in the Services Agreement). In the event of a Change of Control (as defined in the Services Agreement), 50% of any unvested portion of the Kenyon Options and the Kenyon RSUs shall vest immediately prior to such event.	The Kenyon Options have a term of 10 years from the date of grant. 1/3rd of the Kenyon Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Dr. Kenyon is employed by the Company and subject to the other provisions of the Services Agreement. The Initial Kenyon RSUs shall vest on the one-year anniversary of the Effective Date, subject to Dr. Kenyon's continued employment with the Company through such vesting date. The Additional Kenyon RSUs will vest as follows, subject to Dr. Kenyon's continued employment with the Company through the applicable vesting date: (i) 4,875 of the Additional Kenyon RSUs shall vest upon the Company submitting the CTA for PRP for the Study in an applicable jurisdiction to be selected by the Company, (ii) 4,875 of the Additional Kenyon RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iii) 4,875 of the Additional Kenyon RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (iv) the remaining 4,875 of the Additional Kenyon RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested Kenyon RSU shall be settled by delivery to Mr. Kenyon of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Services Agreement), (ii) the date that is ten business days following the vesting of such Kenyon RSU, (iii) the date of Dr. Kenyon's death or Disability (as defined in the Services Agreement), and (iv) Dr. Kenyon's employment being terminated either by the Company without Cause or by Dr. Kenyon for Good Reason (as defined in the Services Agreement). In the event of a Change of Control (as defined in the Services Agreement), 50% of any unvested portion of the Kenyon Options and the Kenyon RSUs shall vest immediately prior to such event.
Stock price | $ / shares	$ 4.25
Restricted stock value	$ 82,873
Exercise price | $ / shares	$ 4.25
Dividend yield	0.00%	0.00%
Years to maturity	10 years	10 years
Risk free rate	2.42%	2.42%
Expected volatility	268.00%	268.00%
Dr Kenyon [Member] | Restricted Stock [Member] | Services Agreement [Member]
Restricted stock shares of common stock | shares	39,000	39,000
Stock price | $ / shares	$ 4.25
Restricted stock value	$ 165,750
Fair value of restricted stock	$ 82,873

Concentrations and Risks (Detai

Concentrations and Risks (Details Narrtive)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Risks and Uncertainties [Abstract]
Reimbursement on goods and service tax receivable percentage	100.00%	100.00%	100.00%

Concentrations and Risks (Det_2

Concentrations and Risks (Details Narrtive) (10-K) - USD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Proceeds from convertible debt	$ 1,130,000	$ 1,054,089	$ 1,369,000	$ 2,890,080
Reimbursement on goods and service tax receivable percentage	100.00%		100.00%	100.00%
Lender One [Member]
Proceeds from convertible debt			$ 621,000	$ 1,577,018
Convertible debt, percentage			45.00%	55.00%
Lender Two [Member]
Proceeds from convertible debt			$ 362,000	$ 951,900
Convertible debt, percentage			26.00%	33.00%
Lender Three [Member]
Proceeds from convertible debt			$ 200,000
Convertible debt, percentage			15.00%

Derivative Financial Instrume_3

Derivative Financial Instruments and Fair Value Measurements (Details Narrative) - USD ($)	Dec. 31, 2019	Jun. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Convertible debt	$ 216,400
Share price	$ 0.38	$ 6

Derivative Financial Instrume_4

Derivative Financial Instruments and Fair Value Measurements (Details Narrative) (10-K) - USD ($)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Convertible debt	$ 216,400
Share price	$ 0.38	$ 6
Convertible Debt [Member]
Convertible debt		$ 9,000	$ 429,000
Warrants [Member]
Convertible debt		$ 0	$ 12,000

Derivative Financial Instrume_5

Derivative Financial Instruments and Fair Value Measurements - Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques (Details)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Volatility [Member]
Derivative liability , measurement input, percentages	227.82
Volatility [Member] | Warrant [Member]
Derivative liability , measurement input, percentages		0	1.10
Volatility [Member] | Convertible Debt [Member]
Derivative liability , measurement input, percentages		3.55
Debt instrument, measurement input, percentages	227.82
Volatility [Member] | Convertible Debt [Member] | Initial Valuations [Member]
Derivative liability , measurement input, percentages		3.20
Volatility [Member] | Convertible Debt [Member] | Minimum [Member]
Derivative liability , measurement input, percentages			1.91
Volatility [Member] | Convertible Debt [Member] | Maximum [Member]
Derivative liability , measurement input, percentages			2.21
Expected Remaining Term [Member]
Derivative liability, measurement input, term	1 year
Expected Remaining Term [Member] | Warrant [Member]
Derivative liability, measurement input, term		0 years	2 months 30 days
Expected Remaining Term [Member] | Convertible Debt [Member] | Initial Valuations [Member]
Derivative liability, measurement input, term		1 year
Expected Remaining Term [Member] | Convertible Debt [Member] | Minimum [Member]
Derivative liability, measurement input, term		1 month 9 days	6 months 21 days
Debt instrument, measurement input, term	4 months 20 days
Expected Remaining Term [Member] | Convertible Debt [Member] | Maximum [Member]
Derivative liability, measurement input, term		10 months 25 days	1 year 1 month 6 days
Debt instrument, measurement input, term	10 months 28 days
Risk Free Interest Rate [Member]
Derivative liability , measurement input, percentages	1.59
Risk Free Interest Rate [Member] | Warrant [Member]
Derivative liability , measurement input, percentages		0	0.0193
Risk Free Interest Rate [Member] | Convertible Debt [Member] | Initial Valuations [Member]
Derivative liability , measurement input, percentages		0.0232
Risk Free Interest Rate [Member] | Convertible Debt [Member] | Minimum [Member]
Derivative liability , measurement input, percentages		0.0192	0.0211
Debt instrument, measurement input, percentages	1.48
Risk Free Interest Rate [Member] | Convertible Debt [Member] | Maximum [Member]
Derivative liability , measurement input, percentages		0.0215	0.0233
Debt instrument, measurement input, percentages	1.59
Expected Dividend Yield [Member]
Derivative liability , measurement input, percentages	0
Expected Dividend Yield [Member] | Warrant [Member]
Derivative liability , measurement input, percentages		0	0
Expected Dividend Yield [Member] | Convertible Debt [Member]
Derivative liability , measurement input, percentages		0	0
Debt instrument, measurement input, percentages	0
Expected Dividend Yield [Member] | Convertible Debt [Member] | Initial Valuations [Member]
Derivative liability , measurement input, percentages		0

Derivative Financial Instrume_6

Derivative Financial Instruments and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Embedded conversion option liabilities	$ 924,744	$ 698,264	$ 371,532
Total	924,744	698,264	371,532	$ 881,172
Fair Value, Inputs, Level 1 [Member]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 2 [Member]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 3 [Member]
Embedded conversion option liabilities	924,744	698,264	371,532
Total	$ 924,744	$ 698,264	$ 371,532

Derivative Financial Instrume_7

Derivative Financial Instruments and Fair Value Measurements - Schedule of Derivative Liabilities at Fair Value (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Balance at Beginning	$ 698,264	$ 371,532	$ 881,172
Effects of foreign currency exchange rate changes			38
Reductions due to repayment of debt		(936,650)	(199,339)
Initial fair value of embedded conversion option derivative liability recorded as debt discount	115,000	180,000	543,744
Initial fair value of embedded conversion option derivative liability recorded as expense	93,125	382,944	313,694
Reductions due to conversions	(44,588)	(1,388,764)	(861,695)
Change in fair value included in statements of operations	62,943	2,089,202	(306,082)
Balance at Ending	$ 924,744	$ 698,264	$ 371,532

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Feb. 04, 2020	Jan. 28, 2020	Jan. 22, 2020	Jan. 15, 2020	Jan. 13, 2020	Jan. 07, 2020	Jan. 02, 2020	Sep. 18, 2019	Sep. 09, 2019	Sep. 04, 2019	Jul. 19, 2019	Jul. 10, 2019	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Feb. 06, 2020	Jun. 24, 2019	Sep. 21, 2018	Sep. 20, 2018	Jan. 23, 2018	Jan. 22, 2018
Debt conversion shares							2,804,424
Debt conversion price per share							$ 0.165
Debt principal amount							$ 267,187
Bifurcated embedded conversion option derivatives							82,500
Fair value of derivative liability							228,863
Loss on extinguishment							146,367						$ 20,176		$ (20,355)	$ 20,176	$ 1,165,516	$ 1,204,242	$ 251,392
Additional paid in capital							$ 410,750						$ 47,766,162			$ 47,766,162		$ 45,713,322	$ 38,214,213
Common stock, shares authorized													100,000,000			100,000,000		100,000,000	100,000,000		100,000,000	4,000,000,000	400,000,000	400,000,000	100,000,000
Debt premium amount													$ 1,151,106			$ 1,151,106		$ 613,003	$ 1,731,167
Debt conversion threshold percentage																4.99%		4.99%
Sale of stock price per share											$ 1.99
Value of stock issued for the services														$ 39,800	$ 69,000			$ 169,000	130,000
Original debt discount													$ 415,712			$ 415,712		131,893	277,733
Proceeds from convertible debt																$ 1,130,000	$ 1,054,089	$ 1,369,000	$ 2,890,080
Subsequent Event [Member]
Debt conversion shares								45,547	13,360	36,049		20,454
Debt conversion price per share								$ 0.45	$ 0.63	$ 0.63		$ 0.91
Common stock, shares authorized	1,000,000,000																			1,000,000,000
Stock issued for the services, shares											20,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | January 13, 2020 Ader Alef Note [Member]
Debt principal amount					$ 110,250
Legal expenses					$ 5,000
Debt maturity date					Jan. 13, 2021
Debt interest rate					8.00%
Debt premium amount					$ 59,365
Debt conversion, description					The conversion price for the January 13, 2020 Ader Alef Note during the first 6 months the January 13, 2020 Ader Alef Note is in effect shall be fixed at $2.50 and thereafter shall be equal to a 35% discount of the lowest closing bid price ("Lowest Trading Price") of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, Ader Alef shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Ader Alef and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock which may be increased up to 9.99% upon 60 days prior written notice by the Ader Alef to the Company.
Debt conversion threshold percentage					35.00%
Outstanding common stock percentage					4.99%
Debt instrument effective interest rate					24.00%
Original debt discount					$ 5,250
Proceeds from convertible debt				$ 100,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Power Up Lending Group Ltd [Member] | January 7, 2020 Power Up Note [Member]
Debt principal amount					72,000	$ 75,000
Bifurcated embedded conversion option derivatives						$ 307,400
Legal expenses					2,500
Diligence fees					$ 500
Debt maturity date						Jan. 7, 2021
Debt interest rate						8.00%
Debt default amount percentage						150.00%
Debt conversion, description						The conversion price for the January 7, 2020 Power Up Note shall be $3.05, subject to certain Market Price (as defined below) adjustment. If the Market Price is greater than or equal to $5.00, the conversion price shall be the greater of 65% of the Market Price ("Variable Conversion Price") and $3.05. In the event Market Price is less than $5.00, the conversion price shall be the Variable Conversion Price. As defined in the January 7, 2020 Power Up Note, the "Market Price" shall be the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Power Up on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the "pink sheets" during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Power Up. Notwithstanding the foregoing, Power Up shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Power Up and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock.
Debt conversion threshold percentage						65.00%
Outstanding common stock percentage						4.99%
Debt instrument effective interest rate						22.00%
Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | January 22, 2020 GS Note [Member]
Debt principal amount			$ 58,000
Legal expenses			$ 2,500
Debt maturity date			Jan. 22, 2021
Debt interest rate			10.00%
Debt premium amount			$ 38,667
Debt conversion, description			The conversion price for the January 22, 2020 GS Capital Note shall be equal to a 40% discount of the lowest closing bid price ("Lowest Trading Price") of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, GS Capital shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by GS Capital and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock which may be increased up to 9.99% upon 60 days prior written notice by the GS Capital to the Company.
Debt conversion threshold percentage			40.00%
Outstanding common stock percentage			4.99%
Debt instrument effective interest rate			24.00%
Original debt discount			$ 3,500
Proceeds from convertible debt		$ 52,000
Subsequent Event [Member] | Consulting Services Agreement [Member] | January 7, 2020 Consulting Services Agreement [Member]
Stock issued for the services, shares	150,000
Sale of stock price per share	$ 0.14
Value of stock issued for the services	$ 21,000
Minimum [Member]
Debt conversion price per share							$ 0.0672
Minimum [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member] | January 13, 2020 Ader Alef Note [Member]
Debt default amount percentage					112.00%
Minimum [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | January 22, 2020 GS Note [Member]
Debt default amount percentage			112.00%
Maximum [Member]
Debt conversion price per share							$ 0.75
Maximum [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member] | January 13, 2020 Ader Alef Note [Member]
Debt default amount percentage					135.00%
Maximum [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | January 22, 2020 GS Note [Member]
Debt default amount percentage			130.00%

Subsequent Events (Details Na_2

Subsequent Events (Details Narrative) (10-K) - USD ($)	Jan. 02, 2020	Oct. 08, 2019	Oct. 03, 2019	Oct. 02, 2019	Sep. 18, 2019	Sep. 09, 2019	Sep. 04, 2019	Aug. 30, 2019	Aug. 08, 2019	Aug. 01, 2019	Jul. 30, 2019	Jul. 19, 2019	Jul. 10, 2019	Jul. 08, 2019	Jul. 03, 2019	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Sep. 10, 2019	Aug. 31, 2019
Debt conversion price per share	$ 0.165
Debt conversion shares	2,804,424
Debt principal amount	$ 267,187
Proceeds from convertible debt																$ 1,130,000	$ 1,054,089	$ 1,369,000	$ 2,890,080
Debt conversion threshold percentage																4.99%		4.99%
Original debt discount																$ 415,712		$ 131,893	$ 277,733
Warrants to purchase of common stock																				1,000,000
Warrants exercise price per share																				$ 2
Minimum [Member]
Debt conversion price per share	$ 0.0672
Maximum [Member]
Debt conversion price per share	$ 0.75
First Warrant [Member]
Warrants to purchase of common stock																					450,000
Warrants exercise price per share																					$ 2.25
Second Warrant [Member]
Warrants to purchase of common stock																					300,000
Warrants exercise price per share																					$ 3.33
Third Warrant [Member]
Warrants to purchase of common stock																					225,000
Warrants exercise price per share																					$ 4.50
Securities Purchase Agreement [Member] | Odyssey Capital Funding LLC [Member] | July 2019 Odyssey Note [Member]
Debt principal amount										$ 295,000	$ 320,000					320,000
Legal fees										10,000
Proceeds from convertible debt										285,000
Debt maturity date											Jul. 30, 2020
Debt interest rate											10.00%
Debt conversion threshold percentage											65.00%
Original debt discount											$ 25,000
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member]
Debt principal amount							$ 550,000	$ 550,000								550,000
Legal fees							5,000
Diligence fees							40,000
Proceeds from convertible debt							505,000
Debt maturity date								Aug. 30, 2020
Debt interest rate								10.00%
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Maximum [Member]
Debt principal amount								$ 15,000
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | First Warrant [Member]
Warrants to purchase of common stock								450,000
Warrants exercise price per share								$ 2.25
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Second Warrant [Member]
Warrants to purchase of common stock								300,000
Warrants exercise price per share								$ 3.33
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Third Warrant [Member]
Warrants to purchase of common stock								225,000
Warrants exercise price per share								$ 4.50
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member]
Original debt discount																$ 534,000
Subsequent Event [Member]
Stock issued for the services, shares												20,000
Debt principal conversion balance					$ 18,000	$ 7,820	20,000						$ 16,500
Debt interest conversion amount					$ 2,496	$ 574	$ 2,711						$ 2,031
Debt conversion price per share					$ 0.45	$ 0.63	$ 0.63						$ 0.91
Debt conversion shares					45,547	13,360	36,049						20,454
Subsequent Event [Member] | Common Stock One [Member]
Debt principal conversion balance									$ 21,000
Debt interest conversion amount									$ 2,721
Debt conversion price per share									$ 0.798
Debt conversion shares									29,725
Subsequent Event [Member] | Common Stock Two [Member]
Debt principal conversion balance									$ 28,000
Debt interest conversion amount									$ 1,860
Debt conversion price per share									$ 0.8113
Debt conversion shares									36,804
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Power Up Lending Group Ltd. [Member] | July 2019 Power Up Note [Member]
Debt conversion price per share															$ 3.25
Debt principal amount														$ 78,000	$ 78,000
Legal fees														2,500
Diligence fees														500
Proceeds from convertible debt														$ 75,000
Debt maturity date															Jul. 3, 2020
Debt interest rate															8.00%
Debt default amount percentage															150.00%
Debt conversion, description															The conversion price for the July 2019 Power Up Note shall be $3.25, subject to certain Market Price (as defined below) adjustment. If the Market Price is greater than or equal to $5.00, the conversion price shall be the greater of 65% of the Market Price ("Variable Conversion Price") and $3.25. In the event Market Price is less than $5.00, the conversion price shall be the Variable Conversion Price. As defined in the July 2019 Power Up Note, the "Market Price" shall be the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Power Up on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the "pink sheets" during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Power Up. Notwithstanding the foregoing, Power Up shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Power Up and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock.
Debt conversion threshold percentage															65.00%
Outstanding common stock percentage															4.99%
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Odyssey Capital Funding LLC [Member] | July 2019 Odyssey Note [Member]
Debt principal amount										295,000	$ 320,000
Legal fees										10,000
Proceeds from convertible debt										$ 285,000
Debt maturity date											Jul. 30, 2020
Debt interest rate											10.00%
Debt default amount percentage											120.00%
Debt conversion, description											The conversion price for the July 2019 Odyssey Note shall be equal to 65% of the lowest closing bid price of the Common Stock as reported on the OTC Markets on which the Company's shares are then traded or any exchange upon which the Common Stock may be traded in the future, for the ten prior trading days including the day upon which a Notice of Conversion is received by the Company. Common Stock beneficially owned by the Holder and its affiliates would exceed 4.99% of the outstanding shares of the Common Stock of the Company (which may be increased up to 9.9% upon 60 days prior written notice by the Holder to the Company).
Debt conversion threshold percentage											65.00%
Outstanding common stock percentage											4.99%
Original debt discount											$ 25,000
Debt default interest rate											24.00%
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member]
Debt principal amount							$ 550,000	$ 550,000
Legal fees							5,000
Diligence fees							40,000
Proceeds from convertible debt							$ 505,000
Debt maturity date								Aug. 30, 2020
Debt interest rate								10.00%
Debt default amount percentage								125.00%
Debt conversion, description								Auctus has the option to convert all or any amount of the principal face amount of the August 2019 Auctus Note, at any time following the issue date and ending on the later of the maturity date and the date the Default Amount, which is an amount equal to 125% of an amount equal to the then outstanding principal amount of the August 2019 Auctus Note (but not less than $15,000) plus any interest accrued from August 30, 2019 at the default interest rate of 24% per annum, is paid if an event of default occurs, for shares of the Company's common stock at the then-applicable conversion price. The conversion price for the August 2019 Auctus Note shall be the Variable Conversion Price, being 60% of the Market Price. Notwithstanding the foregoing, Auctus shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Auctus and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock.
Debt conversion threshold percentage								60.00%
Outstanding common stock percentage								4.99%
Debt default interest rate								24.00%
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | First Warrant [Member]
Warrants to purchase of common stock								450,000
Warrants exercise price per share								$ 2.25
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Second Warrant [Member]
Warrants to purchase of common stock								300,000
Warrants exercise price per share								$ 3.33
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Third Warrant [Member]
Warrants to purchase of common stock								225,000
Warrants exercise price per share								$ 4.50
Subsequent Event [Member] | Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | October 2019 GW Holdings Note [Member]
Debt principal amount			$ 131,000	$ 131,000
Legal fees			6,000
Proceeds from convertible debt			125,000
Debt maturity date				Oct. 1, 2020
Debt interest rate				8.00%
Debt conversion, description				The conversion price for the October 2019 GW Holdings Note shall be equal to a 40% discount of the lowest closing bid price ("Lowest Trading Price") of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, GW Holdings shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by GW Holdings and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock which may be increased up to 9.99% upon 60 days prior written notice by the GW Holdings to the Company.
Debt conversion threshold percentage				40.00%
Outstanding common stock percentage				4.99%
Subsequent Event [Member] | Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | October 2019 GW Holdings Note [Member] | Minimum [Member]
Debt default amount percentage				110.00%
Subsequent Event [Member] | Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | October 2019 GW Holdings Note [Member] | Maximum [Member]
Debt default amount percentage				150.00%
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 2019 Crown Bridge Note [Member]
Debt principal amount		$ 103,000	$ 108,000
Legal fees		3,000
Proceeds from convertible debt		$ 100,000
Debt maturity date			Oct. 3, 2020
Debt interest rate			10.00%
Debt default amount percentage			140.00%
Debt conversion, description			The conversion price for the October 2019 Crown Bridge Note shall be equal to a 40% discount of the lowest closing bid price ("Lowest Trading Price") of the Common Stock for the ten trading days immediately prior to the Conversion Date in accordance with the Notice of Conversion. Notwithstanding the foregoing, Crown Bridge shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Crown Bridge and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock which may be increased up to 9.99% upon 60 days prior written notice by the Crown Bridge to the Company.
Debt conversion threshold percentage			40.00%
Outstanding common stock percentage			4.99%
Original debt discount			$ 5,000